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Summary 
 
A study of substrate selectivity of aminoacyl-tRNA synthetases, from both bacterial and 
eukaryotic organisms, using unnatural amino acids is described and discussed in this 
thesis. 
 
The first part of this thesis involved an investigation of the substrate selectivity of 
bacterial (E. coli) aminoacyl-tRNA synthetases, by protein synthesis using unnatural 
amino acids via bacterial (E. coli) wild-type machinery. The levels of unnatural amino 
acid incorporation obtained are discussed in relation to the substrate selectivity of 
aminoacyl-tRNA synthetases. This work clearly shows that the E. coli TrpRS (Chapter 
One), the E. coli PheRS (Chapter Two) and the E. coli TyrRS (Chapter Three) display 
some degree of substrate promiscuity. 
 
An HPLC technique has been used to determine the relative rate of unnatural amino 
acid activation by E. coli TyrRS for a series of meta- and ortho-substituted tyrosines. 
This work, which is discussed in Chapter Four, shows that the reaction rate of 
aminoacylation is significantly affected by the substituent on the aromatic ring of 
tyrosine. 
 
The other part involved a study of the substrate selectivity of eukaryotic aminoacyl-
tRNA synthetase. Although the original work, which was conducted to investigate the 
substrate selectivity of eukaryotic PheRS and TyrRS by incorporating the unnatural 
amino acids into protein with a eukaryotic protein synthesis system and is discussed in 
Chapter Five, had been unsuccessful, an investigation of the human TyrRS with a series 
of meta- and ortho-substituted tyrosines using the ITC technique, which is discussed in 
	   vii 
Chapter Six, shows some degree of substrate promiscuity of human TyrRS. In addition, 
a selectivity comparison made between the bacterial (E. coli) and the eukaryotic 
(human) TyrRSs, which is also discussed in Chapter Six, shows that there is difference 
between these two enzymes regarding substrate selectivity, resulting in the discovery of 
two organic compounds that could potentially be developed as antimicrobial agents.  
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I. Unnatural Amino Acids 
 
Unnatural amino acids are considered to be ubiquitous. With over 140 unnatural amino 
acids found in proteins in nature,1 they have been involved in many aspects of 
pharmaceutical development.2!5 
 
In biochemistry, unnatural amino acids refer to the group of amino acids that are not 
encoded by the translational machinery of ribosomal synthesis of natural proteins. They 
are not members of the standard 20 proteinogenic amino acids. At present, there is no 
official, or generally accepted nomenclature for this group of organic compounds.6 
Other nomenclature widely used includes non-proteinogenic, noncanonical, non-coded 
and non-standard amino acid.6 
 
The unnatural amino acids are critical in living systems. While some of them are 
involved in many metabolic processes, the others display quite diverse physiological 
and pharmaceutical activity. For example, the unnatural amino acids citrulline (1) and 
ornithine (2) are important intermediates in the urea cycle in mammals, participating in 
the disposal of excess nitrogen.7 The non-proteinogenic amino acids "-
hydroxyisoleucine (3) and D-penicillamine (4) are used to treat non-insulin dependent 
diabetes and rheumatoid arthritis respectively, due to their pharmaceutical activities.8,9 
Some structural analogues of the proteinogenic amino acids, such as canavanine (5) and 
ethionine (7), can mimic their corresponding natural counterparts arginine (6) and 
methionine (8), thus are often mistakenly incorporated into proteins as substitutes for 
their natural counterparts. As a result, they are highly toxic.10,11 
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II. Applications of Unnatural Amino Acids 
 
One major application of unnatural amino acids is for protein engineering.2,4,6,7 This 
area has attracted a considerable amount of attention over the last decades, and has been 
a powerful tool in biochemistry in many regards, such as for the improvement of protein 
properties, the development of biotherapeutics, and the study of the structure and 
function relationship of biological macromolecules.4,12!14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein engineering using unnatural amino acids has been an effective way to produce 
proteins with enhanced stability or enzymes with novel catalytic activity.15!17 The 
fluorine-containing unnatural amino acids are particularly attractive due to the unique 
stereoelectronic properties of fluorine,18 and have been studied extensively.18!20 For 
example, a substitution of the four core residues of leucine (9) in a leucine zipper  
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peptide with a fluorinated leucine derivative, 5,5,5-trifluoroleucine (10), afforded a 
significant improvement in the thermal stability of the peptide. Meanwhile, the activity 
of the peptide modified with 10 remained unaffected as compared with its wild-type 
form.21 In later work,22 the same research group described a further enhancement of this 
improved thermal stability by introducing a more highly fluorinated derivative, 
5,5,5,5’,5’,5’-hexafluoroleucine (11) into the same peptide.22 
 
Another classic example of this type is the use of a structural analogue of tyrosine (12), 
7-hydroxycoumarinyl ethylglycine (13), to improve the catalytic activity of an 
enzyme.23 The bacterial phosphotriesterases are highly efficient enzymes, with their 
catalytic efficiencies being thought to be near evolutionary limits.24 However, by 
introducing the 7-hydroxycoumarinyl ethylglycine (13) into one of the bacterial 
phosphotriesterases as a substitute for tyrosine (12) at position 309 (Tyr309), the 
catalytic efficiency of a phosphotriesterase was increased by around 10 times.23 
 
Also, in a recent report,25 a tyrosine analogue, 3,4-dihydroxyphenylalanine (DOPA) 
(14) was introduced into mussel adhesive proteins, resulting in a significant 
improvement in surface adhesion and water resistance ability of the target proteins. 
Meanwhile, the underwater adhesive properties of the proteins engineered with 3,4-
dihydroxyphenylalanine (14) remained unchanged as compared with their wild-type 
counterparts. As a result, this study proposed potential underwater applications of 3,4-
dihydroxyphenylalanine (14)-containing mussel adhesive proteins as bioglues or 
adhesive hydrogels.25 
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Figure 1-1. Bioconjugation using unnatural amino acids: i) copper-catalyzed azide-alkyne cycloaddition 
(“click” chemistry or CuAAC), ii) Mizoroki-Heck reaction, iii) Sonogashira reaction, iv) reaction of keto 
with aminooxy or hydrazide groups.2 
 
Unnatural amino acids with side-chain functionalities have been introduced into 
proteins for posttranslational modifications. For example, using copper as a catalyst, 
proteins engineered with unnatural amino acids bearing azide or alkyne groups allow an 
azide-alkyne cycloaddition reaction to form an aromatic triazole linkage with organic 
molecules containing the corresponding functional group (Figure 1-1 i),26,27 where as 
proteins modified with iodide-containing non-proteinogenic amino acids enable  
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Mizoroki-Heck (Figure 1-1 ii) and Sonogashira reactions (Figure 1-1 iii) with molecules 
bearing alkene and alkyne group respectively,28!30 and proteins with keto-amino acids 
enable reactions with organic compounds containing an aminooxy or a hydrazide group 
(Figure 1-1 iv).31,32 These reactions have proved valuable for developing 
biopharmaceuticals and monitoring protein dynamics at molecular resolution in living 
cells.2 
 
 
 
 
 
 
 
 
 
 
Scheme 1-1. 3,5-Difluorotyrosine as a probe for 19F NMR spectroscopy: i) reversible tyrosine 
phosphorylation, ii) reversible 3,5-difluorotyrosine phosphorylation.33!35 
 
Unnatural amino acids have also been a useful tool for biophysical and mechanistic 
studies in biological systems. For example, due to the unique physical and chemical 
properties of fluorine, fluorinated amino acids have been used for the study of enzyme 
mechanisms and protein motions.18 Tyrosine phosphorylation (Scheme 1-1 i) is a 
posttranslational modification process, being important for the regulation of enzymatic 
activity, protein conformation and protein-protein interactions.33!35 However, due to 
technical difficulties such as hydrolysis of the phosphorylated tyrosine during protein  
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crystallization, the mechanism of this kind of posttranslational reaction remains unclear. 
In an earlier report,36 this problem was solved by using a fluorinated derivative of 
tyrosine (12), 3,5-difluorotyrosine. The 3,5-difluorotyrosine was introduced into protein 
tyrosine kinases as a substitute for tyrosine (12), and was used as a 19F NMR 
spectroscopy probe. As a result, the ways that the phosphorylated tyrosine interacts with 
other amino acid residues at the active sites of protein tyrosine kinases and the change 
of the conformation of the kinases upon the binding of a drug molecule were 
successfully elucidated using 19F NMR spectroscopy.36 
 
 
 
 
 
 
 
 
Scheme 1-2. Detection of conformational change using 4-biphenylphenylalanine (position 17) and 7-
hydroxycoumarinyl ethylglycine (position 115).37 
 
In another report,37 again by using unnatural amino acids, the conformational change of 
an enzyme upon the binding of its inhibitor was detected (Scheme 1-2). Two 
fluorescent amino acids, 4-biphenylphenylalanine and 7-hydroxycoumarinyl 
ethylglycine, which possess excitation and emission maxima at 280 and 345 nm, and at 
345 nm and 450 nm respectively, were site-specifically introduced at positions 17 and 
115 in a dihydrofolate reductase. The excitation and emission maxima of these amino 
acids allowed irradiation of 4-biphenylphenylalanine at 280 nm and an  
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observation of the emission of 7-hydroxycoumarinyl ethylglycine at 450 nm. As a 
result, the conformational change of dihydrofolate reductase upon the binding of one of 
its inhibitors was measured.37 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1-3. Use of 2-amino-3-(4-((3-(chloromethyl)phenyl)diazenyl)phenyl)propanoic acid for optically 
controlling protein conformation.38 
 
Not only can non-proteinogenic amino acids be used for measuring conformational 
change of biological macromolecules, but they can also be used to manipulate the 
conformation of the molecules directly, both in vitro and in vivo. For example, an 
earlier report described the use of an unnatural amino acid to control the conformation 
of a protein in whole cells (Scheme 1-3).38 A photoswitchable amino acid, 2-amino-3-
(4-((3-(chloromethyl)phenyl)diazenyl)phenyl)propanoic acid, which bears both a 
reversible azobenzene photoswitch and a benzyl chloride functional group, was 
introduced into a target protein, calmodulin, in both bacterial and mammalian cells.38 
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azobenzene switch with light, following the formation of a covalent protein bridge 
between the benzyl chloride group of the unnatural amino acid and the thiol of a nearby 
cysteine residue through proximity-enabled bioreactivity after they were incorporated 
into calmodulin (Scheme 1-3). This study opened up the avenue for investigation of 
biological processes in living cells.38 
 
 
III. Cell-free Protein Synthesis Using Unnatural Amino Acids 
 
Cell-free protein synthesis, or in vitro protein synthesis, is a technique that uses cell 
lysate, which contains cellular components required for protein biosynthesis such as 
ribosomes, aminoacyl-tRNA synthetases (aaRSs) and translational factors,39 instead of 
living cells as a medium for the production of proteins. Depending on the types of the 
cell lysate, there are prokaryotic and eukaryotic cell-free protein synthesis systems.  
 
 
III.A E. coli Cell-free System 
 
E. coli cell-free protein synthesis uses an E. coli S30 extract for protein expression.39 It 
has been useful for synthetic biology and has proven effective in overcoming many 
limitations inherent to traditional in vivo expression using living cells in regards to 
protein engineering using unnatural amino acids.40,41 
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E. coli cell-free protein synthesis has been useful for the study of relationships between 
structure and function of biological macromolecules. In an earlier report,42 an analogue 
of valine (15), (2R,3R)-2-amino-3-chlorobutyric acid (16), was investigated by 
introducing it into an enzyme as a substitute for 15 using an E. coli cell-free protein 
synthesis system, and it was found that the catalytic activity displayed by the enzyme 
modified with the unnatural analogue 16 was comparable to that of the wild-type form. 
In later work, with involvement of the E. coli cell-free system again, an X-ray 
crystallography study showed that this chlorinated analogue of valine 16 did not cause 
significant disturbance to the structure of the modified enzyme. These studies 
demonstrated that chlorinated aliphatic amino acids may potentially be functional and 
structural substitutes for their natural counterparts. E. coli cell-free protein synthesis 
significantly facilitates the study in this area.43 
 
 
 
 
 
 
In comparison with the traditional in vivo protein expression using living cells, E. coli 
cell-free synthesis has the advantage of being not affected by the issues associated with 
the cytotoxicity of the unnatural amino acids. For example, selenomethionine (18)- 
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containing proteins are often used for multi-wavelength anomalous diffraction phasing 
for X-ray crystallography studies.44 However, the efficiency of incorporating 
selenomethionine (18) into target proteins to replace the natural counterpart methionine 
(17) is limited by the cytotoxicity of 18 when in vivo expression approaches are used.45 
This problem was solved in an earlier report where a large quantity of protein modified 
with selenomethionine (18) was prepared with high incorporation level by using an E. 
coli cell-free protein synthesis system.46 X-ray crystallography studies showed that the 
three-dimensional structure of the protein produced by the cell-free method is 
comparable to that obtained by using in vivo expression approaches.46 
 
 
 
 
 
 
 
In another example,47 E. coli cell-free synthesis significantly improved the yields of 
protein using another unnatural amino acid. Due to poor water solubility, the cellular 
uptake of a tyrosine analogue, p-propargyloxyphenylalanine (19), was impaired,48 and 
protein synthesis using 19 needed improvement. An E. coli cell-free system was then 
used,47 and it successfully circumvented the issues caused by water solubility of 19. As 
a result, the yield of protein synthesis using p-propargyloxyphenylalanine (19) was 
increased by approximately 30 times above that of the highest reported previously.47 
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The open nature of the reaction environment is another factor contributing to E. coli 
cell-free synthesis being a compelling platform for study of incorporating unnatural 
amino acids, as it allows direct access to the reaction and, therefore an ease of control of 
the reaction conditions and manipulation of regulatory elements involved in protein 
biosynthetic machinery, as needed. For example, due to poor expression yields it can be 
challenging to incorporate unnatural amino acids into proteins or to incorporate at 
specific positions in proteins. Despite this, a successful case of incorporating a 
challenging unnatural amino acid at multiple difficult positions in a protein was 
described in an earlier report,49 because the yields of protein expression were increased 
by removing the release factor RF1, which recognizes the amber stop codon and 
therefore inhibits the production of full-length protein, from the E. coli cell extract.  
 
 
III.B Rabbit Reticulocyte Lysate Cell-free System 
 
Cell-free protein synthesis systems based on rabbit reticulocyte lysate are widely used 
for the study of eukaryotic genes.50 These in vitro protein expression systems use a 
lysate prepared from the blood of white rabbit as the source of cellular components 
required for protein biosynthesis.50 In the process of preparing the rabbit reticulocyte 
lysate, micrococcal nuclease is usually added to destroy the endogenous mRNA, which 
minimizes the expression of background proteins.51 Also, for effective protein 
expression, additional elements such as phosphocreatine and phosphocreatine kinase for 
generating energy, and hemin to prevent inhibition of protein expression initiation, are 
added to the lysate.51 
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There are rabbit reticulocyte lysate-based in vitro systems that translate proteins from 
RNA templates.50 This type of translation system requires exogenous supply of the 
mRNA transcripts of interest. There are also rabbit reticulocyte lysate-based in vitro 
systems available for DNA templates, requiring exogenous addition of the target 
plasmid DNA.50 The latter contain RNA polymerase and therefore allow transcription 
and translation from the gene constructs to occur in one reaction vessel.50 
 
The proteins produced using rabbit reticulocyte lysate cell-free systems can be detected 
radioactively.50 Radiolabelled amino acids, such as [35S]methionine, are commercially 
available. They can be added into the reaction and subsequently incorporated into 
proteins. The radioactive amino acid containing proteins can then be detected by 
autoradiography.50 There are also non-radioactive methods available for detection of the 
proteins. For example, the FluoroTech in vitro Translation System is a fluorescent 
approach for protein detection.52 This system involves the use of a lysine-specific tRNA 
(tRNALys) pre-charged with a lysine on which a fluorophore BODIPY-FL is attached at 
its #-position, allowing the product proteins to be incorporated with the fluorophore and 
therefore detectable by visualization using a fluorescent scanner.52 
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The use of rabbit reticulocyte lysate cell-free protein synthesis systems for 
incorporation of unnatural amino acid has been reported. In earlier work,53 protein 
synthesis using an unnatural amino acid, m-tyrosine (21), during a rabbit reticulocyte 
lysate cell-free system has been successful. In this case, the radiolabelled m-tyrosine 
(21), m-[14C]tyrosine was prepared and subsequently incorporated into a cellular protein 
as a substitute for the natural amino acid phenylalanine (20) using a TNT Coupled 
Reticulocyte Lysate Systems (Promega). The protein modified with the radioactive 
amino acid was detected using SDS-PAGE gel analysis and autoradiography.53 
 
 
IV. Aminoacyl-tRNA Synthetases and Their Unnatural Substrates 
 
IV.A Aminoacyl-tRNA Synthetase 
 
Aminoacyl-tRNA synthetases (aaRSs) are a family of enzymes that catalyze the 
reaction of a tRNA with its cognate amino acid in an aminoacylation reaction.54 They 
are of vital importance to protein synthesis as they are the primary factor governing 
fidelity in translation of genetic code.54!58 The catalysis of an aminoacylation by 
aminoacyl-tRNA synthetase is accomplished via two stages (Scheme 1-4).58 The amino 
acid is first activated by adenosine triphosphate (ATP) to form an aminoacyl-adenylate 
along with the release of pyrophosphate, followed by reacting to transfer the amino acid 
to the terminal adenosine of cognate tRNA (Scheme 1-4).58,59 
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Scheme 1-4. Aminoacylation of tRNA with the cognate amino acid by Class I aaRSs.59 
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The reaction catalyzed by an aminoacyl-tRNA synthetase can be described by the 
following model:60,61 
 
 
where E, S and P are enzyme, substrate and product respectively. 
 
The rate of an aminoacylation reaction can be determined using the Michaelis–Menten 
equation:62 
 
! ! !!"# !!!!! ! !!! 
 
where Vmax is the maximum rate, [S] is the concentration of the substrate, and KM is the 
Michaelis constant. 
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Scheme 1-5. Stabilization of the aminozyl-adenylate complex by aaRS.63 Proposed states for the amino 
acid activation reaction. State I: association; State II: dissociation; State III: Coordination.  
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Like other catalysts, aminoacyl-tRNA synthetases considerably increase the rate of 
reactions by lowering the activation energy, without changing the equilibrium constant 
of reaction. For aminoacyl-tRNA synthetases, this is achieved mainly by stabilizing the 
aminoacyl-adenylate,63 which is a highly reactive intermediate formed in the 
aminoacylation reaction,54!59 with its unique three-dimensional structure at the active 
site,58,59 through hydrophobic and electrostatic interactions.63 
 
Three possible states have been proposed for the aminoacyl-adenylate intermediate 
(States I, II and III, Scheme 1-5),63 involving a pentacoordinate transition state (State I: 
association) formed through nucleophilic attack on the $-phosphorus of adenosine 
triphosphate (ATP) by the $-carboxylate oxygen of the substrate amino acid, a 
metaphosphate transition state (State II: dissociation) where dissociation of the bond 
between the $- and %-phosphates occurs before bond formation between the carbonyl 
oxygen and $-phosphorus atom, and a coordinate state where bond formation and 
dissociation are simultaneous.63 
 
The enzyme family of aminoacyl-tRNA synthetases display remarkable specificity 
toward their cognate amino acids, with an error rate of aminoacylation being estimated 
to be around 1 in 104.64 For many of the aminoacyl-tRNA synthetases, this high level of 
substrate specificity is accomplished mainly at their active sites where aminoacyl-tRNA 
synthetases select the substrate amino acid following the “lock and key” principle,65 
discriminating the D-enantiomers of the amino acids and other structural analogues on 
steric grounds. They can distinguish slight structural differences among organic 
compounds and accurately select the substrate from a pool of analogues. For example, 
Bacillus stearothermophilus tyrosyl-tRNA synthetase (B. stearothermophilus TyrRS)  
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binds its cognate substrate tyrosine (12) at least 4&104 times greater than it does 
phenylalanine (20),66 yet the only structural difference between these amino acids is the 
additional para-hydroxyl group of tyrosine (12). Cysteinyl-tRNA synthetase (CysRS) 
binds its natural substrate cysteine (22) selectively over serine (23) and $-aminobutyric 
acid (24) with factors of 108 and 3&106 respectively,67 despite the only structural 
differences among these compounds being the moieties attached at the %-carbon. In 
addition, CysRS discriminates against alanine (25) with a factor of 2&107,67 solely via 
preferential binding, even though alanine (25) is smaller than cysteine (22) by one 
sulfur atom. 
 
In some cases, there is an additional proofreading mechanism assisting the selection of 
the amino acid.68,69 This editing process often occurs at a site independent of the active 
site, which is referred to as an “editing site”.69 IleRS, for example, activates both its 
cognate substrate isoleucine and a structural analogue of isoleucine, valine (15), at its 
active site to form isoleucyl- and valinyl-adenylate.70 However, the valinyl-adenylate is  
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subsequently hydrolyzed by IleRS.71 This mode of selecting the cognate amino acid by 
an aminoacyl-tRNA synthetase is known as “double-sieve amino acid selection”.68,69 
 
 
IV.B E. coli TrpRS and Trp Analogues 
 
The protonated nitrogen of the indole of tryptophan (26) is important for the substrate 
specificity of E. coli TrpRS.72 Earlier work has shown that replacement of this amino 
group with other heteroatoms such as selenium, sulfur or oxygen resulted in 
translationally inactive substrates.6,72 
 
 
 
 
 
 
 
The enzyme family of aminoacyl-tRNA synthetases display marked substrate 
specificity. However, protein synthesis using unnatural amino acids through E. coli 
wild-type translational machinery has been reported, suggesting a promiscuous 
substrate specificity of E. coli TrpRS.6 For example, the structural analogues of 
tryptophan (26), 4-fluorotryptophan (27), 5-fluorotryptophan (28), 6-fluorotryptophan 
(29), 4-hydroxytryptophan (30), 5-hydroxytryptophan (31), 4-aminotryptophan (32) and  
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5-aminotryptophan (33) have been incorporated into proteins as substitutes for 26 via  
E. coli TrpRS,6,73!75 indicating that the active site of E. coli TrpRS can accommodate an 
additional fluorine, hydroxy and amino group on the aromatic ring of 26. In addition, 
protein synthesis using 7-azatryptophan (34) has extensively been studied due to its 
unique fluorescent properties.74,76 
 
 
 
 
 
 
In the present study, a structural analogue of tryptophan (26), %-(1-azulenyl)-alanine 
(35), was studied, in an attempt to explore further the substrate promiscuity of E. coli 
TrpRS. Protein synthesis using %-(1-azulenyl)-alanine (35) as a substitute for 
tryptophan (26) using E. coli cell-free protein synthesis system was conducted. Also, 
owing to their particular spectroscopic properties, investigations on 5-
hydroxytryptophan (31) and 7-azatryptophan (34) were included.  
 
The results of protein synthesis using 5-hydroxytryptophan (31), 7-azatryptophan (34) 
and %-(1-azulenyl)-alanine (35) are presented and discussed in Chapter One of this 
thesis. While the synthesis of %-(1-azulenyl)-alanine (35) is discussed in Chapter One, 
5-hydroxytryptophan (31) and 7-azatryptophan (34) are commercially available. 
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IV.C E. coli PheRS and Phe Analogues 
 
Phenylalanyl-tRNA synthetase (PheRS) is known to be a complex and intriguing 
member of the aminoacyl-tRNA synthetase (aaRS) family.63 For example, the topology 
of E. coli PheRS is quite interesting due to its unusual $2%2 quaternary structure, which 
is constituted of two $% heterodimers (Figure 1-2), with each heterodimer consisting of 
11 structural domains.77 The N-terminal domain, A1 and A2 are three of the structural 
domains, belonging to the $-subunit, while the domains B1-B8 belong to the %-subunit 
(Figure 1-2).77 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Structure of E. coli PheRS.77 Diagram reproduced with the permission of John Wiley and 
Sons. 
 
The active site of E. coli PheRS is deep (Figure 1-3).77 While the bottom surface of the 
active site is parallel to the phenyl ring of the substrate,77 where one of the sides and the  
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top surface of the active site are covered with hydrophobic amino acid residues, the 
corresponding other side of the active site is built up entirely of hydrophilic residues 
(Figure 1-3).78 This manner of distributing the hydrophobic and hydrophilic amino acid 
residues within the active site of E. coli PheRS favors the binding of the amino and 
carbonyl groups of the cognate substrate phenylalanine (20).77 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Stereoview of the active site of E. coli PheRS.78 Diagram reproduced with the permission of 
John Wiley and Sons. 
 
Two phenylalanine residues, Phe248 and Phe250, are involved in recognizing the 
phenyl ring of the substrate phenylalanine (20). The phenyl rings of Phe248 and Phe250 
provide a system of aromatic-aromatic interactions with that of the substrate, with each 
aromatic pair arranging in an “edge-to-face” manner.77 This system of aromatic 
interactions highly favors a phenyl ring.77 
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Due to structural similarity between phenylalanine (20) and tyrosine (12), it is difficult 
for E. coli PheRS to discriminate against 12 if only relying on the aromatic interactions 
at the active site,63 despite the fact that the ring of phenylalanine (20) is more 
hydrophobic than that of tyrosine (12) and thus this interaction is more favourable.63 
Alanine (25) at position 294 (Ala294) is another factor contributing significantly to the 
substrate specificity of E. coli PheRS against tyrosine (12). The methyl group of Ala294 
is a determinant of the volume of the active site of E. coli PheRS, providing steric 
constraint to prevent the accommodation of the para-hydroxyl group of tyrosine 
(12).77!79  Replacing Ala294 with glycine (Ala294Gly) increases the volume of the 
active site, therefore relaxes the substrate specificity of E. coli PheRS. As a result, 
tyrosine (12) and phenylalanine analogues with para-substituents other than a hydroxyl 
group, such as chloro-, bromo-, iodo-, ethynyl-, cyano- and azido-groups, are accepted 
by the mutant E. coli PheRS.80!82 
 
Apart from the selection of the amino acid phenylalanine (20) that occurs at the active 
site of E. coli PheRS, there is an editing site, which is located about 35 Å from the 
active site, assisting in quality control in translation of genetic code.63,77,78 This 
proofreading process hydrolyses the tRNAPhe mischarged with tyrosine (12).77 Specific 
recognition of tyrosine (12) at the editing site is achieved mainly by recognizing the 
hydroxyl group of 12, through formation of hydrogen bonds with the amino group of 
Gly315 and the carboxyl group of Glu334.77 
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In analogy with E. coli TrpRS, there is evidence suggesting promiscuous substrate 
specificity of E. coli PheRS. Protein synthesis using fluorinated derivatives of 
phenylalanine (20), o-fluorophenylalanine (36), m-fluorophenylalanine (37) and p-
fluorophenylalanine (38) through E. coli wild-type machinery has been reported,83!88 
indicating that the active site of E. coli PheRS can accommodate an additional fluorine 
at all positions on the phenyl ring of 12. 
 
In the present work it was decided to investigate protein synthesis using related 
derivatives of phenylalanine (20) through E. coli wild-type machinery to evaluate 
further the nature of the substrate promiscuity of E. coli PheRS. An E. coli cell-free 
protein synthesis system was used in this study as it was expected to allow quick 
preparation of protein.39 
 
Therefore, E. coli cell-free protein synthesis using mono-substituted phenylalanines, 
including m-tyrosine (21), o-tyrosine (48), o-methylphenylalanine (49), m-
methylphenylalanine (50), p-methylphenylalanine (51), o-chlorophenylalanine (52), m-
chlorophenylalanine (53), p-chlorophenylalanine (54), o-nitrophenylalanine (55), m-
nitrophenylalanine (56), p-nitrophenylalanine (57), p-bromophenylalanine (73), p-
iodophenylalanine (74), p-trifluoromethylphenylalanine (75),  
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p-aminophenylalanine(76), and multi-substituted phenylalanines including 3,5-
difluorophenylalanine (58), 2,3,4,5,6-pentafluorophenylalanine (59), 3,5-
dihydroxyphenylalanine (63), 3,5-dimethylphenylalanine (67) and 3-hydroxy-5-
methylphenylalanine (71), as substitutes for their natural counterpart phenylalanine (20) 
was investigated. 
 
In these systems the volume of the substituent on the phenyl ring of the unnatural amino 
acids is varying, and so is the hydrophobicity. It was thought likely that the size and the 
hydrophobicity of the ring substituent were the two factors governing whether or not the 
unnatural amino acids would be activated by E. coli PheRS and subsequently 
incorporated into protein. 
 
In addition, competitive experiments between phenylalanine (5) and its analogues were 
conducted to determine the extent to which the unnatural amino acids can compete with 
the natural counterpart for protein incorporation. 
 
The results of E. coli cell-free protein synthesis using 21, 48!57, 58!59, 63, 67, 71, and 
73!76, as well as the competitive experiments between phenylalanine (20) and each of 
its analogues are presented and discussed in Chapter Two of this thesis. The synthesis 
of 3,5-dihydroxyphenylalanine (63), 3,5-dimethylphenylalanine (67) and 3-hydroxy-5-
methylphenylalanine (71) is also discussed in Chapter Two, whereas 21, 48!57, 58!59 
and 73!76 are commercially available.  
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IV.D E. coli TyrRS and Tyr Analogues 
 
E. coli TyrRS is a symmetric dimer (Figure 1-4),89 with each monomer having an 
independent active site. The two active sites of E. coli TyrRS are separated by over 33 
Å.89 Studies on E. coli TyrRS in solution have shown that the enzyme binds tightly only 
one mole of tyrosine or one mole of tyrosyl adenylate per mole of enzyme dimer.90 
 
 
 
 
 
 
 
 
 
 
Figure 1-4. Structure of E. coli TyrRS.89 a) Overall structure of the E. coli TyrRS-Tyr-AMP complex. A 
homodimer in the asymmetric unit is shown. b) Overall structure of the E. coli TyrRS-Tyr complex. One 
subunit in the asymmetric unit is shown. Diagrams reproduced with the permission of Elsevier.  
 
At the active site of E. coli TyrRS, there are two amino acid residues, Tyr37 and 
Asp182, interacting with the hydroxyl group of the substrate tyrosine (12) via hydrogen 
bonds.89 These interactions are fundamental for the biological specificity of E. coli 
TyrRS as they enable the enzyme to discriminate the most important competitor of 
tyrosine (12), phenylalanine (20), by preferentially binding the cognate substrate 12 
with a factor of 1.5 & 105, as measured in the aminoacylation reaction.91 This level of  
a) b) 
N 
C 
C 
N 
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selectivity is greater than the general error rate of the enzyme family of aminoacyl-
tRNA synthetases.91 
 
Overall, the active site of E. coli TyrRS is formed by side chains of polar amino acids.89 
For example, one of the walls of the active site is enclosed with side chains of Tyr175, 
Gln179, Thr76, Asp182, Gln179 and Gln201, where the other wall is surrounded by 
Gln195 and the amino group of Gln179.89 This polar environment may also contribute 
to the discrimination against phenylalanine (20) by interacting more favorably with the 
aromatic ring of the cognate amino acid, as the ring of tyrosine (12) is relatively more 
hydrophilic than that of 20.63, 89 
 
 
 
 
 
 
 
Although the active site of E. coli TyrRS is well defined for recognition of the aromatic 
ring of tyrosine (12), accommodation of tyrosines with substituents on the aromatic 
ring, particularly those that conserve a p-OH group, is known. From the crystal 
structure of E.coli TyrRS-Tyr complex,89 a small hydrophilic space is observed near 
one side of the ring of the substrate, where the ortho position at the other side of the 
ring appears to open to an empty space. In fact, the promiscuous substrate specificity of 
E. coli TyrRS has been demonstrated by protein synthesis using tyrosine analogues. 
Incorporation of 3,4-dihydroxyphenylalanine (14), m-fluorotyrosine (39) and  
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m-chlorotyrosine (40) into proteins through E. coli wild-type machinery as substitutes 
for their natural counterpart tyrosine (12) has been reported,92!94 which suggests that the 
active site of E. coli TyrRS can accommodate an additional fluorine, hydroxy group and 
a chlorine at the substrate meta position. In addition, incorporation of m-nitrotyrosine 
(41) through E. coli wild-type machinery has also been reported.95 In the case of m-
nitrotyrosine (41), considerably enhanced concentrations of the E. coli TyrRS and 41 
were required for incorporation, suggesting that 41 may not be effectively activated by 
E. coli TyrRS.  
 
In the present work it was decided to explore further the nature of substrate promiscuity 
of E. coli TyrRS, by protein synthesis using related structural analogues of tyrosine (12) 
through E. coli wild-type machinery. An E. coli cell-free protein synthesis system was 
used in this study as it was expected to allow quick preparation of protein.39 
 
Therefore, E. coli cell-free protein synthesis using para-substituted phenylalanines, 
including p-fluorophenylalanine (38), p-methylphenylalanine (51), p-
chlorophenylalanine (54), p-nitrophenylalanine (57), p-bromophenylalanine (73), p-
iodophenylalanine (74), p-trifluoromethylphenylalanine (75) and p-aminophenylalanine 
(76), and meta-substituted derivatives of tyrosine (12) including m-methyltyrosine (95), 
and ortho-substituted derivatives of tyrosine (12) including o-fluorotyrosine (83), 2,4-
dihydroxylphenylalanine (89), o-chlorotyrosine (92), o-methyltyrosine (99) and o-
nitrotyrosine (104), as substitutes for their natural counterpart tyrosine (12) was 
performed.  
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The para-modified phenylalanines were studied in an attempt to explore the possibility 
of other groups being incorporated in place of the hydroxy group. It was anticipated that 
moieties such as the amino group would likely form hydrogen bond interactions with 
the E. coli TyrRS. 
 
With meta- and ortho-substituted tyrosine species, the size of the substituents on the 
corresponding position varied. The aim was to investigate the flexibility of the space 
near both meta- and ortho-position at the active site of E. coli TyrRS. 
 
To evaluate the extent to which these structural analogues of tyrosine (12) can compete 
with their natural counterpart 12 for protein incorporation, a competition experiment 
between each of the analogues and tyrosine (12) was conducted. 
 
The results of E. coli cell-free protein synthesis using para-substituted phenylalanines 
38, 51, 54, 57 and 73!76, meta-substituted tyrosine 95, and ortho-substituted tyrosines 
83, 89, 92, 99 and 104, as well as the competitive experiments between tyrosine (12) 
and each of its analogues, are presented and discussed in Chapter Three of this thesis. 
The synthesis of o-fluorotyrosine (83), 2,4-dihydroxyphenylalanine (89), o-
chlorotyrosine (92), m-methyltyrosine (95), o-methyltyrosine (99) and o-nitrotyrosine 
(104) is discussed in Chapter Three, while m-nitrotyrosine (41) is commercially 
available. 
 
Protein synthesis using unnatural amino acids is an indirect measure of the substrate 
promiscuity of the aminoacyl-tRNA synthetases. Following Chapter Two and Chapter 
Three, work was also conducted to directly evaluate the substrate promiscuity of  
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aminoacyl-tRNA synthetases. A study of the interactions between structural analogues 
of tyrosine (12) and E. coli TyrRS in an aminoacylation reaction was therefore 
conducted, and the results of this work are presented and discussed in Chapter Four of 
this thesis.  
 
In the present work it was also decided to investigate misincorporation of unnatural 
amino acids into proteins via eukaryotic wild-type machinery, aiming to study the 
differences between bacterial and eukaryotic systems regarding protein synthesis using 
unnatural amino acids. However, due to technical difficulties, an attempt to develop a 
rabbit reticulocyte lysate in vitro expression system for the incorporation of unnatural 
amino acids was unsuccessful. This work is described in Chapter Five of this thesis.  
 
As a continuation of the study of the differences between bacterial and eukaryotic 
machineries regarding protein synthesis using unnatural amino acids, a representative 
enzyme from each organism was isolated, followed by a comparison of the substrate 
specificity of the enzymes by investigating interactions between the respective enzyme 
and unnatural amino acids. An ITC study of TyrRS from E. coli and human cytosolic 
(human TyrRS) with structural analogues of tyrosine (12) was performed, and the 
results are presented and discussed in Chapter Six of this thesis. 
 
Following Chapter Six, a conclusion is included in which the general relationships 
between the work described in Chapters Two-Six are discussed. 
 !
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1.1 Introduction 
 
Due largely to its particular spectroscopic properties amongst proteinogenic $-
amino acids, tryptophan (26) has been a useful intrinsic probe in the study of protein 
structure and dynamics.6 Also, the diverse chemistry of the indole group provides an 
opportunity to generate analogues with alternative optical properties that overcome the 
limitations with tryptophan (26) such as nonexponential fluorescence decay.74,76,96,97 
This has been demonstrated by the substitution of tryptophan (26) with its structural 
analogues 5-hydroxytryptophan (31) and 7-azatryptophan (34) in proteins as optical 
probes.96,97 
 
 
 
 
 
 
 
 
 
 
 
 
Proteins containing tryptophan (26) are naturally fluorescent.98 This intrinsic 
fluorescence has been advantageous for visualization of unstained protein on SDS- 
26 
31 34 35 
H
N
H2N
OH
O
H
N
H2N
OH
O
OH
N
H
N
H2N
OH
O
H2N
OH
O
Results and Discussion: Chapter One 
! 34 
 
polyacrylamide gels,98!101 as it avoids modification of proteins for downstream 
applications, such as mass spectral analysis,99 and is relatively economical compared to 
other labelling methods with fluorescent dyes.99 Since 5-hydroxytryptophan (31) and 7-
azatryptophan (34) have been incorporated into proteins,96-97 work was carried out in an 
attempt to detect proteins containing these two unnatural fluorescent amino acids on 
SDS-polyacrylamide gel. A cell-free protein synthesis system was chosen in this study 
as it was expected to allow quick preparation of protein.39 
 
%-(1-Azulenyl)-alanine (35) is also structurally similar to, but spectroscopically distinct 
from tryptophan (26), displaying comparable absorbance but with a spectral band 
shifted to 312 nm.74 Korendovych et al.74 demonstrated that its fluorescent properties in 
peptides are independent of the microenvironment, such as solvents and the presence of 
weak fluorescent quenchers, and suggested its potential application as a biological 
probe for the study of protein-protein interactions. It would be of great value to 
accomplish the biosynthetic incorporation of this amino acid. However, attempts made 
by Moroder et al.102 with the cell-based selective pressure incorporation (SPI) technique 
were unsuccessful. This failure led us to investigate the incorporation of this azulene 35 
using a cell-free synthesis approach. 
 
 
1.2 E. coli Cell-free Protein Synthesis with Tryptophan Analogues 
 
1.2.1 Amino Acid and Protein Synthesis 
 
Of the three tryptophan analogues, 5-hydroxytryptophan (31) and 7-azatryptophan (34) 
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are commercially available, while %-(1-azulenyl)-alanine (35) was prepared using 
literature methods.102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1-1. Synthesis of %-(1-azulenyl)-L-alanine (35).102 a) (CH3)2NCH2N(CH3)2, HCHO, AcOH, 
CH2Cl2 (62%); b) MeI, EtOH, 4 °C (83%); c) EtO2CCH(NHCOCH3)CO2Et, NaOEt, EtOH, reflux, 2 h 
(85%); d) 20% (w/v) KOH, EtOH, reflux, 3 h (91%); e) 0.2 M HCl, THF, reflux, 8 h (24%); f) Acylase I, 
0.1 M phosphate buffer, 37 °C, 16 h (39%).  
 
The method used in the synthesis of %-(1-azulenyl)-alanine (35) involves the classic 
malonic ester condensation pathway, and is outlined in Scheme 1-1.102 In the presence 
of para-formaldehyde, azulene (42) reacted with N,N,N’,N’- 
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tetramethyldiaminomethane in acetic acid to give 1-dimethylaminomethylazulene (43), 
which was converted to 1-azulenylmethyltrimethylammonium iodide (44) by treatment 
with methyl iodide. Alkylation of diethyl acetamidomalonate with the quaternary 
ammonium salt 44 in ethanol, in the presence of sodium ethoxide afforded diethyl 
acetamido-(1-azulenylmethyl)malonate (45), which gave the $-acetamido-%-(1-
azulenyl)propanoic  acid (47) as a racemic mixture through base hydrolysis, followed 
by decarboxylation with dilute acid. %-(1-Azulenyl)-alanine (35) was obtained as the L-
enantiomer by enantioselective deacetylation of 47 with acylase from Aspergillus 
melleus (A. melleus). 
 
E. coli peptidyl-Pro cis-trans isomerase B (PpiB) was expressed as a test protein using 
an E. coli S30 extract cell-free protein synthesis system, with a hexahistidine tag 
attached at the N-terminus (His6-PpiB) facilitating protein purification. The choice of 
PpiB was based on considerations that it has been extensively studied,174 and its activity 
is readily evaluated.42,43 
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Figure 1-1. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 26, D) no 26 but with the azulenyl derivative 35, E) no 26 but with the 5-
hydroxytryptophan (31), F) no 26 but with the 7-azatryptophan (34).  
 
The sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis 
of His6-PpiB synthesized in the presence of tryptophan (26) and the analogues 2!4 is 
illustrated in Figure 1-1. As shown in lane B, His6-PpiB (19.2 kDa) was produced when 
all components required for protein synthesis were supplied. A trace of protein was 
produced when tryptophan (26) was not added to the reaction mixture (lane C), which is 
probably due to traces of 26 in the S30 extract. No protein was obtained in the absence 
of plasmid DNA encoding His6-PpiB (lane A). 
 
Lanes E and F show efficient formation of His6-PpiB when tryptophan (26) was 
replaced with 5-hydroxytryptophan (31) or 7-azatryptophan (34), respectively, 
indicating that both analogues are incorporated into protein as substitutes for 26. 
However, only background protein was observed in lane D, where tryptophan (26) was 
replaced with %-(1-azulenyl)-alanine (35), suggesting that it does not incorporate instead 
of 26.  
 
A! B! C! D! E! F! A! B! C! D! E! F!
21.5 kDa!
14.4 kDa!
Marker!
a)! b)!
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Figure 1-2. Mass spectral analysis of native His6-PpiB. 
 
The incorporation of 5-hydroxytryptophan (31) and 7-azatryptophan (34) was 
confirmed by analysing the purified proteins using mass spectrometry. Native His6-
PpiB has a molecular weight of 19221.9 Da. Due to the low peptide deformylase 
activity in the E. coli S30 extract, the E. coli cell-free reaction usually retains a partner 
protein with an N-formyl group on the N-terminal methionine residue, having a 
molecular weight of 19249.6 Da.92 The pair of the predominant peaks observed at 
19221.9 Da and 19249.1 Da in Figure 1-2 corresponds to these two species of wild-type 
His6-PpiB.  
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Figure 1-3. Mass spectral analysis of His6-PpiB synthesised in the presence of 31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4. Mass spectral analysis of His6-PpiB synthesised in the presence of 34. 
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His6-PpiB contains one tryptophan residue in its amino acid sequence. Accordingly, the 
peaks at 19239.8 Da and 19265.3 Da in the mass spectrum of the protein produced in 
the presence of 5-hydroxytryptophan (31) show (Figure 1-3) substitution of tryptophan 
(26) with 31 in formylated and non-formylated His6-PpiB, respectively. However, mass 
spectral analysis of His6-PpiB produced using 7-azatryptophan (34) was unable to 
distinguish it as there is only a 1 Da mass difference from the wild-type protein. The 
most abundant peaks at 19222.8 Da and 19249.9 Da (Figure 1-4), in that case, are 
consistent with both the native His6-PpiB and His6-PpiB modified with 7-azatryptophan 
(34).  
 
 
1.2.2 Fluorescence Imaging of Proteins 
 
Due to insufficient analytical resolution to distinguish the small mass difference 
between native His6-PpiB and His6-PpiB modified with 7-azatryptophan (34), 
confirmation of incorporation of 34 was then attempted using fluorescence imaging. 
The intrinsic fluorescence of tryptophan (26) has been used as a tool for visualization of 
unstained proteins within SDS-polyacrylamide gels with a high sensitivity,98!101 and the 
fluorescent properties of 5-hydroxytryptophan (31) and 7-azatryptophan (34) are 
enhanced as compared to tryptophan (26).96-97 It was considered that this could be used 
to distinguish His6-PpiB containing tryptophan derivatives 31 and 34 from native His6-
PpiB. 
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Figure 1-5. SDS-PAGE analysis of His6-PpiB. Lanes: A) no DNA, B) all components, C) no 26, D) no 
26 but with the azulene derivative 35, E) no 26 but with 5-hydroxytryptophan (31), F) no 26 but with 7-
azatryptophan (34).  a) Fluorescence imaging of the gel excited at 312 nm using a UV transilluminator, b) 
Coomassie blue stain of the same gel after imaging. 
 
Figure 1-5 shows the detection of His6-PpiB containing 5-hydroxytryptophan (31) and 
7-azatryptophan (34) with a fluorescent gel scanner. Lanes E and F in Figure 1-5a show 
a substantially increased fluorescence of His6-PpiB containing 5-hydroxytryptophan 
(31) or 7-azatryptophan (34) as compared to that of the native protein (lane B), 
confirming the incorporation of the tryptophan derivative 31 and 34. The results 
observed here with 5-hydroxytryptophan (31) and 7-azatryptophan (34) are consistent 
with literature,96,97 demonstrating that the tryptophan analogues 31 and 34 are substrates 
of E. coli tryptophanyl-tRNA synthetase (E. coli TrpRS).  
 
Although %-(1-azulenyl)-alanine (35) is similar in structure to, and also can mimic 
tryptophan (26) in a biological environment such as peptides,102 to some extent, 
incorporation of 35 into proteins as a substitute for 26 occurred neither in a in vivo 
protein synthesis system using E. coli tryptophan auxotrophic cells, as demonstrated in  
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an earlier report,102 nor in a in vitro system using E. coli cell-free approach in the 
present work. The lack of incorporation of %-(1-azulenyl)-alanine (35) may be attributed 
to the absence of the N-H group, which has been found to be an important part of the 
substrate recognition process by E. coli TrpRS,6,72,75 and 35 can not provide such 
recognition machinery. On the other hand, it may be attributable to the expanded 
aromatic ring system of the azulene moiety. In an earlier report,176 incorporation of %-
(1-azulenyl)-alanine (35) into proteins as a substitute for tryptophan (26) with TrpRS 
from an organism other than E. coli, has been described. This was accomplished using 
tryptophan auxotrophic strains with Lactococcus lactis (L. lactis) TrpRS, which has 
been shown with a more relaxed substrate specificity towards tryptophan analogues as 
compared to E. coli TrpRS, being able to activate and incorporate tryptophan analogues 
bearing large substituents such as a chlorine or a bromine.177 This indicates that the 
azulene moiety of %-(1-azulenyl)-alanine (35) may be too large for the amino acid 
active site of E. coli TrpRS. 
 
 
1.3 Conclusion 
 
This study shows the translational incorporation of 5-hydroxytryptophan (31) and 7-
azatryptophan (34) into His6-PpiB as substitutes for tryptophan (26), with an E. coli 
cell-free protein synthesis system, and the detection of the resulting proteins through 
intrinsically fluorescent visualisation.  
 
This work also described an investigation of %-(1-azulenyl)-alanine (35). However, 
incorporation of %-(1-azulenyl)-alanine (35) into His6-PpiB instead of tryptophan (26)  
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did not occur, most probably due to discrimination by E. coli TrpRS. 
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2.1 Introduction 
 
Protein synthesis is a strictly regulated biosynthetic pathway.63 The high degree of 
accuracy is mainly attributed to the remarkable specificity exhibited by aminoacyl-
tRNA synthetases (aaRSs), a family of enzymes that catalyse the aminoacylation of 
tRNA with their cognate amino acids.58,63 Under physiological conditions, aaRSs 
catalyse the aminoacylation reaction with an average error rate of approximately 10!4.64 
 
This accurate mode of amino acid selection by an aaRS is accomplished primarily at the 
active site, a well-defined cavity that enables the enzyme to selectively activate the 
corresponding substrate from a pool of structural analogues.63 Phenylalanyl-tRNA 
synthetase (PheRS) and tyrosyl-tRNA synthetase (TyrRS), for example, exhibit marked 
specificity toward their cognate substrates phenylalanine (20) and tyrosine (12), 
respectively, despite the fact that there is only slight structural difference between the 
two amino acids.63,79,91,103,104 The reported crystal structure of the E. coli PheRS-Phe 
complex (Figure 2-1) indicates that the active site of E. coli PheRS is a mainly 
hydrophobic pocket with stringent steric requirements for the phenyl ring.77!79 The 
methyl group of Ala294 is a primary factor assuring the high degree of discrimination 
against tyrosine (12), as it provides a steric constraint at the para position preventing 
the accommodation of the phenolic hydroxyl group.77,79,103 Deletion of this methyl 
group by mutating alanine with glycine (Ala294Gly) relaxes the substrate specificity of 
E. coli PheRS and, as a consequence, tyrosine (12) and phenylalanine analogues with 
para-substituents larger than a hydroxyl group, such as chloro-, bromo-, iodo-, ethynyl-, 
cyano- and azido-groups, are accepted.77!82 
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Figure 2-1. Stereo view of the E. coli PheRS binding site with bound Phe (5).77 Substrate Phe (5) is 
shown in lines. 
 
While the ortho- and meta-positions on one side of the ring project toward a small 
hydrophobic space, surrounded by the side chains of Phe248 and Phe250 arranging in a 
“edge-to-face” manner for each aromatic pair (Figure 2-1), the corresponding positions 
on the other side of the ring are enclosed with the side chains of Gly296, Glu210, 
Gln174, Gln208 and Ser171, pointing to a hydrophilic area.77,78 These observations 
indicated that the active site of E. coli PheRS might be able to accommodate 
phenylalanine derivatives bearing small hydrophobic or hydrophilic substituents at the 
ortho- and meta-positions, and that the phenylalanine derivatives might therefore be 
activated and transferred to tRNAPhe for protein synthesis. 
 
To be incorporated into protein, these phenylalanine analogues will also need to survive 
the post-transfer proofreading possessed by E. coli PheRS at its editing site locating in 
the B3/4 domain of the %-subunit about 35 Å from the active site.77,78 The editing  
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mechanism is designed to assist the selection of substrate by hydrolysing tRNAPhe 
mischarged with non-cognate amino acid at the active site.77 This is known as a double-
sieve amino acid selection mechanism.63 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Binding of Tyr (6) at the editing site of E. coli PheRS.77 
 
However, this editing activity appears to have evolved to specifically hydrolyse Tyr-
tRNAPhe by recognising the side chain of tyrosine (12), primarily through hydrogen 
bond interactions between the phenolic hydroxyl group of 12 and the side chain of 
Glu334 and the main chain amide of Gly315 (Figure 2-2).63,77,78,80,103,104 Previous 
reports have shown that E. coli PheRS does not hydrolyse tRNAPhe bound para-
substituted (fluoro-, chloro-, bromo- and amino-) phenylalanine derivatives.77,80!82 
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2.2 E. coli Cell-free Protein Synthesis with Phenylalanine Analogues 
 
2.2.1 Oxidized Aromatic Amino Acids 
 
 
 
 
 
 
The initial aim was to examine the discrimination against m-tyrosine (21) and o-
tyrosine (48). While PheRS is highly selective for phenylalanine (20) over tyrosine 
(12), the tyrosine isomers 21 and 48 were shown to incorporate into eukaryotic proteins 
using a whole-cell based method with human mitochondrial PheRS (Hsmt PheRS).105 
This suggests that, although PheRS has evolved to distinguish between 12 and 20 
primarily through recognition of the para-hydroxyl group, it imparts far lower 
selectivity against ortho- and meta-hydroxyl groups. 
 
In this study, 3,4-dihydroxyphenylalanine (14) (3,4-DOPA) was also included, as 
together with 21 and 48 it is the most abundant modified amino acid found bound to 
proteins that are commonly detected in pathological tissues, such as atherosclerotic 
plaque and cataract lens.106!109 Also, 14 is the most commonly prescribed drug for the 
treatment of Parkinson’s disease.107 Elevated levels of 14-containing proteins are 
always found in patients treated with this drug.107 
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Although 3,4-dihydroxyphenylalanine (14) has been demonstrated to incorporate into 
protein as a substitute for tyrosine (12),92 its incorporation could in principle also occur 
as a replacement for phenylalanine (20). Mischarging of tRNAPhe with 14 by Hsmt 
PheRS, human cytoplasmic PheRS (Hsct PheRS) and thermus thermophilus PheRS (T. 
thermophilus PheRS) has been reported.106!108,110 
 
E. coli cell-free protein synthesis using m-tyrosine (21), o-tyrosine (48) and 3,4-
dihydroxyphenylalanine (14), which were commercially available, in place of 
phenylalanine (20) was therefore investigated. 
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Figure 2-3. SDS-PAGE analysis of His6-PpiB before (a and c) and after (b and d) purification. Lanes: A 
and F) no DNA, B and G) all components, C and H) no 20, D) no 20 but with o-Tyr (48), E) no 20 but 
with m-Tyr (21), I) no 20 but with 3,4-DOPA (14). 
 
SDS-PAGE analysis of the synthesized His6-PpiB (Figure 2-3) shows that protein was 
produced when all components required for protein synthesis were supplied (lanes B 
and G). Mass spectral analysis (Figure 2-4) confirmed that it is wild-type protein, with 
peaks at 19249.5 Da and 19222.3 Da, corresponding to formylated and deformylated 
His6-PpiB, respectively.  
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Figure 2-4. Mass spectral analysis of native His6-PpiB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5. Mass spectral analysis of His6-PpiB synthesised in the absence of Phe (20). 
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By comparison, only a trace of protein was produced when phenylalanine (20) was 
excluded from the reaction mixture (lanes C and H). Mass spectral analysis (Figure 2-5) 
showed this is wild-type His6-PpiB, suggesting that the production of background 
protein was due to the presence of traces of 20 during cell-free reaction. Phenylalanine 
(20) may be from the pool of endogenous amino acids in the S30 extract, or from 
degradation of peptides during the reaction.92 
 
No protein band corresponding to His6-PpiB was observed when the DNA plasmid was 
not added (lanes A and F). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6. Mass spectral analysis of His6-PpiB synthesised in the presence of 48.  
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Figure 2-7. Mass spectral analysis of His6-PpiB synthesised in the presence of 21. 
 
Efficient formation of protein was observed with o-tyrosine (48) and m-tyrosine (21) 
before protein purification (Figure 2-3a, lanes D and E), indicating that both isomers 
were incorporated into His6-PpiB as substitutes for phenylalanine (20). This was 
confirmed by mass spectrometry. His6-PpiB has 12 phenylalanine residues in its amino 
acid sequence and each substitution with either 48 or 21 increases the mass by 16 Da. 
Accordingly, the single dominating peak at 19441.3 Da in the spectrum of protein 
synthesised in the presence of o-tyrosine (48) (Figure 2-6) corresponds to total 
substitution of 20 with 48 in formylated His6-PpiB. Given the absence of peak 
corresponding to incompletely substituted protein species, the average level of 
substitution of 48 for 20 was concluded to be greater than 95%. The three of the 
strongest peaks at 19440.9 Da, 19426.1 Da and 19408.6 Da in the spectrum of protein 
synthesised in the presence of m-tyrosine (21) (Figure 2-7) match the substitutions of 12,  
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11, and 10 of 21 for phenylalanine residues in formylated His6-PpiB, respectively, 
giving approximately a 90% incorporation level for 21. This incorporation level was 
assessed semiquantitatively, by following a method described in an earlier report,92 
through a comparison of the height of the peaks corresponding to 12, 11 and 10 
substitutions in the mass spectrum (Figure 2-7). 
 
A substantially decreased intensity of the protein bands of isomers 48 and 21 (lanes D 
and E) was observed after purification (Figure 2-3b) compared to that before 
purification (Figure 2-3a). This is presumably due to loss of protein during protein 
purification, which may be associated with protein precipitation and aggregation 
resulting from the incorporation of oxidized amino acids. As a consequence, a low 
signal-to-noise ratio in the spectra of His6-PpiB containing o-tyrosine (48) (Figure 2-6) 
and m-tyrosine (21) (Figure 2-7) was observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-8. Mass spectral analysis of His6-PpiB synthesised in the presence of 14. 
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SDS-PAGE also shows that the amount of His6-PpiB produced with 3,4-
dihydroxyphenylalanine (14) (lane I, Figure 2-3 c and d) is comparable to that produced 
in the absence of phenylalanine (20) (lanes C and H), suggesting that 14 does not 
incorporate instead of 20. The mass spectrum of this protein (Figure 2-8) showed native 
His6-PpiB. 
 
The studies of protein synthesis with the oxidised aromatic amino acids showed a 
translational incorporation of o-tyrosine (48) and m-tyrosine (21) into protein as 
substitutes for phenylalanine (20), suggesting that both 48 and 21 can be activated by E. 
coli PheRS and transferred to tRNAPhe for protein synthesis. This demonstrates that the 
active site of E. coli PheRS is able to accommodate a hydrophilic group at both ortho- 
and meta-positions, which conforms to the spaces observed in structural analysis 
(Figure 2-1). In addition, the hydrophilic property of the side of the ring might have 
been another driving force behind the acceptance of the two isomers, by forming 
hydrogen bonds with the hydroxyl groups to stabilise the enzyme-substrate complex 
generated in the aminoacylation reaction.  
 
The results obtained with o-tyrosine (48) and m-tyrosine (21) also demonstrate that 
these isomers are not susceptible to the editing activity of E. coli PheRS, or at least, 
they are not efficient substrate for the editing site and the rate of hydrolysis is far lower 
than the rate of activation. This is most likely attributed to the lack of a hydroxyl group 
at the para-position to effectively interact with Gly315 and Glu334 (Figure 2-2). 
 
The studies of 3,4-dihydroxyphenylalanine (14) showed that it could not be 
incorporated into protein as a replacement for phenylalanine (20), which is presumably  
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owing to the presence of a hydroxyl group at the para-position. Activation of 14 would 
be expected to substantially decrease as a result of the steric hindrance from the methyl 
group of Ala294. Also, since the cleavage of the tRNAPhe misacylated with 3,4-
dihydroxyphenylalanine (14) by E. coli PheRS has been reported,110 it seems highly 
likely that the lack of incorporation of 14 is because the rate of hydrolysis at the editing 
site is greater than that of activation at the active site.  
 
 
2.2.2 Other Substituted Phenylalanines 
 
 
 
 
 
 
As mentioned above, the hydrophilic nature of the amino acid binding site of E. coli 
PheRS might have contributed to incorporating o-tyrosine (48) and m-tyrosine (21). To 
investigate this further, studies of the o-methylphenylalanine (49), m-
methylphenylalanine (50) and p-methylphenylalanine (51) in which a hydrophobic 
group is attached, were performed, as the other ring side was observed to project to a 
hydrophobic space (Figure 2-1). These phenylalanine analogues were commercially 
available. 
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Figure 2-9. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with o-Me-Phe (49), E) no 20 but with m-Me-Phe  
(50), F) no 20 but with p-Me-Phe (51). 
 
SDS-PAGE analysis of His6-PpiB synthesised in the presence of each of the methyl-
substituted phenylalanines 49!51 (Figure 2-9) shows that protein was produced 
efficiently only with m-methylphenylalanine (50) (lane E), indicating that only the 
meta-isomer 50 was incorporated into His6-PpiB as a substitute for phenylalanine (20) 
and that 49 and 51 did not incorporate. This was confirmed by mass spectrometry, with 
the incorporation level of m-methylphenylalanine (50) being greater than 95% (Figure 
II-1 in Appendix II). In consistent with SDS-PAGE analysis, mass spectrometry showed 
peaks corresponding to only wild-type protein synthesized in the presence of o-
methylphenylalanine (49) and p-methylphenylalanine (51). 
 
Protein synthesis using m-methylphenylalanine (50) in place of phenylalanine (20) 
demonstrates that 50 can be activated by E. coli PheRS. This shows that the active site 
of E. coli PheRS is able to accommodate an extra methyl group at the meta-position, in 
which the hydrophobic site (Figure 2-1), presumably, is responsible. 
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The lack of incorporation of o-methylphenylalanine (49) and p-methylphenylalanine 
(51) may be attributed to the selectivity of E. coli PheRS. It is highly likely that 51 was 
rejected at the active site of E. coli PheRS on steric grounds, from a consideration of the 
van der Waals radii of a methyl group (2.0 Å) being larger than that of a hydroxyl group 
(1.65 Å),111,112 while the factor leading to the rejection of 49 is ambiguous as it can be 
related to either the size or the hydrophilic nature of the space near the substrate ortho-
position. 
 
 
 
 
 
 
Due to the size of a methyl group (2.0 Å) being similar to that of chlorine (1.73 
Å),111,112 it was demonstrated that the methyl group of the side chains of aliphatic amino 
acids could be replaced by chlorine for protein synthesis.42 Incorporation of o-
chlorophenylalanine (52), m-chlorophenylalanine (53) and p-chlorophenylalanine (54) 
replacing phenylalanine (20) was subsequently studied, in order to investigate if the 
methyl group on the ring of aromatic amino acids could also be replaced by chlorine. 
The chlorinated phenylalanines 52!54 were commercially available. 
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Figure 2-10. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with o-Cl-Phe (52), E) no 20 but with m-Cl-Phe (53), F) no 20 
but with p-Cl-Phe (54). 
 
SDS-PAGE analysis of His6-PpiB synthesized in the presence of each of the isomers of 
chlorophenylalanine 52!54 (Figure 2-10) shows a pattern analogous to the isomers of 
methylphenylalanine (Figure 2-9), suggesting that only the meta-isomer 53 (lane E) was 
incorporated into His6-PpiB as a substitute for phenylalanine (20). This was confirmed 
by mass spectrometry, with the incorporation level of m-chlorophenylalanine (53) being 
greater than 95% (Figure II-2 in Appendix II). 
 
These results show that the methyl group of an aromatic amino acid is also replaceable 
by chlorine for protein synthesis. The study of m-chlorophenylalanine (53) 
demonstrates that the active site of E. coli PheRS is able to accept a chlorine at the 
meta-position, while the rejection of o-chlorophenylalanine (52) and p-
chlorophenylalanine (54) is most likely associated with the selection at the active site of 
E. coli PheRS. 
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To probe the size limit of the active site of E. coli PheRS, o-nitrophenylalanine (55), m-
nitrophenylalanine (56) and p-nitrophenylalanine (57) were also investigated. The three 
isomers of nitrophenylalanine 55!57 were purchased. 
 
 
 
 
 
 
 
 
Figure 2-11. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with o-NO2-Phe (55), E) no 20 but with m-NO2-Phe (56), F) 
no 20 but with p-NO2-Phe (57). 
 
SDS-PAGE analysis (Figure 2-11) of His6-PpiB synthesised using each of the three 
isomers shows the presence of only background protein (lanes D, E, and F), indicating 
that none of the nitrophenylalanines 55!57 was incorporated as a replacement for 
phenylalanine (20), which was confirmed by mass spectrometry where only native  
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His6-PpiB was observed. This is likely because the nitro group is too bulky to occupy 
the active site of E. coli PheRS. 
 
Contrary to the results obtained for the nitrophenylalanines 55!57, three isomers of 
fluorophenylalanine, the o-fluorophenylalanine (36), the m-fluorophenylalanine (37) 
and the p-fluorophenylalanine (38) were all shown to be substrates of E. coli 
PheRS.83!86 Translational incorporation of the fluorides 55!57 instead of phenylalanine 
(20) using whole-cell based approach was reported.83!86 The acceptance of the para-
fluoride 38 demonstrates a slight flexibility of the space near the para-position 
regardless of the stringent steric requirement imposed by Ala294, and therefore 
supports the size-exclusion manner of selecting non-cognate substrates by E. coli 
PheRS for incorporating unnatural amino acids. 
 
However, varied incorporation levels of the three isomers were obtained in previous 
studies, and no incorporation level greater than 90% was reported. This may be due to 
the presence of a high concentration of endogenous phenylalanine (20) or the 
cytotoxicity of the fluorides 36!38 to cells used in the whole-cell approach, which 
consequently prevents efficient substitution of 20 with each of the fluorides 36!38, or it 
may be a result of slow activation of the fluorides 36!38 by E. coli PheRS. If the latter 
was the case, these results would be insufficient to provide information about the nature 
of the active site of E. coli PheRS. 
 
Protein synthesis with o-fluorophenylalanine (36), m-fluorophenylalanine (37) and p-
fluorophenylalanine (38) instead of phenylalanine (20) was therefore investigated using 
the E. coli cell-free expression system. The issues associated with background natural  
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amino acids and cytotoxicity were therefore circumvented. The fluorinated 
phenylalanines 36!38 were obtained commercially. 
 
 
 
 
 
 
 
 
Figure 2-12. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with o-F-Phe (36), E) no 20 but with m-F-Phe (37), F) no 20 
but with p-F-Phe (38). 
 
SDS-PAGE analysis of His6-PpiB synthesised in the presence of each of the 
fluorophenylalanines 36!38 (Figure 2-12) shows efficient formation of protein with 
each of the isomers (lanes D, E, and F), demonstrating that all fluorides 36!38 are 
incorporated into His6-PpiB as substitutes for phenylalanine (20). Mass spectral analysis 
showed a greater than 95% incorporation level for each isomer (Figure II-3, Figure II-4 
and Figure II-5 in Appendix II). 
 
The results observed for o-fluorophenylalanine (36), m-fluorophenylalanine (37) and p-
fluorophenylalanine (38) are consistent with the earlier reports, supporting that all 
fluorides 36!38 are activated by E. coli PheRS.83!86 The higher degree of substitution 
emphasizes the advantages of cell-free systems over the whole cell-based techniques.  
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Studies of the monofluoro-substituted phenylalanines 36!38 showed that the active site 
of E. coli PheRS can accommodate a fluorine at any position of the substrate aromatic 
ring. Protein synthesis using the 3,5-difluorophenylalanine (58) and the 2,3,4,5,6-
pentafluorophenylalanine (59) in place of phenylalanine (20) was then studied, to 
investigate if the active site can accept aromatic rings with multiple fluorines. The 
fluorides 58 and 59 were obtained commercially. 
 
 
 
 
 
 
 
 
 
Figure 2-13. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with 3,5-F2-Phe (58), E) no 20 but with 2,3,4,5,6-F5-Phe (59). 
 
SDS-PAGE analysis of the synthesised His6-PpiB (Figure 2-13) showed efficient 
production of protein with the difluoride 58 (lane D), indicating that 58 is incorporated 
into His6-PpiB as a replacement for phenylalanine (20), while analysis of the  
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pentafluoride 59 (lane E) showed that no incorporation occurred. This was confirmed 
by mass spectral analysis, with the incorporation level of 58 being greater than 95% 
(Figure II-6 in Appendix II). The results observed for 3,5-difluorophenylalanine (58) 
demonstrate that the active site of E. coli PheRS can accept a fluorine at both meta-
positions. This might have been expected as the fluorine (1.4 Å) is similar in size to 
hydrogen (1.2 Å).111,112 
 
Based on the same concept, 2,3,4,5,6-pentafluorophenylalanine (59) might also have 
been expected to be a substrate of E. coli PheRS. The failure to incorporate 59 in place 
of phenylalanine (20) may be attributed to the significant change of the physical 
properties of the amino acid side chain. Substituting a hydrogen on the aromatic ring 
with a fluorine would affect the orientation of dipole moment.18,19 In an additive 
manner,178 a replacement of all hydrogens on the ring with fluorines would completely 
change the orientation of the benzene quadrupole moment to the opposite direction,178 
and at the same time, cause a significant addition to the hydrophobicity of the ring 
system.18,19 In addition, an apparent increase in the steric repulsion (molecular volumes 
of C6H6 and C6F5H are 106 Å and 141 Å, respectively) would also be expected.18 These 
alterations would make the aromatic ring of the pentafluoride 59 so different that it 
would be differentiated by E. coli PheRS. The rejection of the 2,3,4,5,6-
pentafluorophenylalanine (59) illustrates the tolerance of the degree of fluorination by E. 
coli PheRS. 
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To explore further the promiscuity of the active site of E. coli PheRS near both meta-
positions, 3,5-dihydroxyphenylalanine (63) and 3,5-dimethylphenylalanine (67), two 
amino acids bearing ring substituents larger than fluorine, were investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-1. Synthesis of 3,5-dihydroxy-DL-phenylalanine (63).113,114 a) EtONa, EtOH, 
EtO2CCH(NHCOCH3)CO2Et, reflux, 2 h (81%); b) 37% HCl, AcOH, reflux, 1.5 h (93%); c) 48% HBr, 
sealed tube, 150 °C, 2 h (63%). 
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Scheme 2-2. Synthesis of 3,5-dimethyl-DL-phenylalanine (67).115 a) NBS, AIBN, $,$,$-trifluorotoluene, 
reflux, 1 h (52%); b) EtONa, EtOH, EtO2CCH(NHCOCH3)CO2Et, reflux, 2 h (55%); c) 37% HCl, 
AcOH, reflux, 8 h (87%). 
 
The methods used in the syntheses of 3,5-dihydroxyphenylalanine (63) and 3,5-
dimethylphenylalanine (67), which were obtained as racemic mixtures, involve the 
malonic ester condensation pathway and are outlined in Scheme 2-1 and Scheme 2-2, 
respectively. Since protein biosynthesis involves only the L-enantiomer of amino 
acids,57 resolution of the racemic mixtures of 63 and 67 to obtain enantiomerically pure 
samples was not required. 
 
Treatment of 3,5-dimethoxybenzyl bromide (60) with diethyl acetamidomalonate in 
ethanol, in the presence of sodium ethoxide, yielded diethyl 3,5-
dimethoxylbenzylacetamidomalonate (61).114 Hydrolysis of the malonic ester 61 with 
concentrated hydrochloric acid gave 3,5-dimethoxyphenylalanine (62).114 3,5- 
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Dihydroxyphenylalanine (63) was obtained by demethylation of 62 with concentrated 
hydrobromic acid under vigorous conditions.116 
 
Side-chain monobromination of the mesitylene (64) with N-bromosuccinimide afforded 
3,5-dimethylbenzyl bromide (65),115 which was converted to diethyl 3,5-
dimethylbenzylacetamidomalonate (66) by reacting with diethyl acetamidomalonate in 
ethanol, in the presence of sodium ethoxide.115 3,5-Dimethylphenylalanine (67) was 
obtained by acid hydrolysis of the ester 66.115 
 
 
 
 
 
 
 
 
Figure 2-14. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with 3,5-di-OH-Phe (63), E) no 20 but with 3,5-di-Me-Phe 
(67). 
 
SDS-PAGE analysis of the crude His6-PpiB synthesised using 3,5-
dihydroxyphenylalanine (63) and 3,5-dimethylphenylalanine (67) (Figure 2-14a) shows 
efficient production of protein only with the dihydroxy derivative 63 (lane D), 
indicating that 63 is incorporated into His6-PpiB as a replacement for phenylalanine 
(20) while 67 is not (lane E). This was confirmed by mass spectrometry, with the 
incorporation level of 63 being greater than 95% (Figure II-7 in Appendix II). 
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A substantial decrease in intensity of the protein band with 3,5-dihydroxyphenylalanine 
(63) was observed after protein purification (lane D, Figure 2-14b). Again, this may be 
attributed to protein precipitation and aggregation associated with the incorporation of 
oxidised amino acids, as discussed previously. As a result, protein for mass spectral 
analysis was prepared by solubilising the insoluble part with buffer containing a high 
concentration of urea. The high ratio of signal-to-noise in the mass spectrum (Figure II-
7 in Appendix II) suggests that the insoluble part was mainly His6-PpiB containing 3,5-
dihydroxyphenylalanine (63).  
 
Protein synthesis using 3,5-dihydroxyphenylalanine (63) as a replacement for 
phenylalanine (20) demonstrates that it is activated by E. coli PheRS. Structural 
analysis (Figure 2-1) indicated that one meta-position of the substrate ring projects to a 
hydrophilic space and the other points to a hydrophobic space. The results obtained here 
with 3,5-dihydroxyphenylalanine (63) demonstrate that the active site of E. coli PheRS 
is able to accommodate a hydroxyl group at both meta positions, which suggests that 
the contribution of hydrophobicity to the selectivity of E. coli PheRS is minor. Together 
with the results obtained with the mono-methyl-substituted m-methylphenylalanine (50), 
it also suggests that the lack of incorporation of 3,5-dimethylphenylalanine (67) is most 
likely due to the space near one of the meta positions being inadequate for a methyl 
group. 
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Collective analysis of the results with m-methylphenylalanine (50), 3,5-
dihydroxyphenylalanine (63) and 3,5-dimethylphenylalanine (67) indicates that at the 
active site of E. coli PheRS the space near both the substrate meta positions is suitable 
for a hydroxyl group but only one is suitable for a methyl group. A study of 3-hydroxy-
5-methylphenylalanine (71) was then conducted. It was anticipated that one side would 
accommodate the methyl group and the other side the hydroxyl group, and that protein 
synthesis with 3-hydroxy-5-methylphenylalanine (71) in place of phenylalanine (20) 
would then occur. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-3. Synthesis of 3-hydroxy-5-methyl-DL-phenylalanine (71).114!118 a) NBS, benzoyl peroxide, 
CCl4, H2O (5 equiv, w/w), reflux, 1 h (82%); b) EtO2CCH(NHCOCH3)CO2Et, EtONa, EtOH, reflux, 2 h 
(74%); c) 48% HBr, sealed tube, 150 °C, 2 h (80%). 
 
The procedure used in the preparation of 3-hydroxy-5-methylphenylalanine (71) was 
based on the malonic ester condensation pathway and is outlined in Scheme 2-3.  
O O Br
HN
O
OO
O
O
O
a
b
c
68 69 
70 
71 
HO OH
O
NH2
Results and Discussion: Chapter Two 
 69 
 
The first step involves side-chain monobromination of 3,5-dimethylanisole (68) with N-
bromosuccinimide. Due to the para-directing effect of the methoxy group, and the two 
methyl groups at meta positions, the reaction of 68 with N-bromosuccinimide normally 
involves electrophilic aromatic substitution in preference to the side-chain radical 
reaction to give the ring-brominated product 72 (Scheme 2-4),118 even under conditions 
promoting the radical reaction.118 The selectivity of the reaction was reported with a 
ratio of 1:3.2 in favour of the electrophilic substitution reaction.118 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-4. Electrophilic aromatic substitution of 68 by NBS.118 
 
A small amount of H2O was therefore added to the reaction mixture. The presence of 
H2O is expected to suppress the substitution reaction by forming hydrogen bonds with 
the methoxy group of 68 to diminish mesomeric electron donation to the aromatic ring, 
and therefore favour the side-chain radical reaction.118 
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Reaction of 68 with N-bromosuccinimide in carbon tetrachloride, in the presence of 
H2O, gave 3-bromomethyl-5-methylanisole (69) in a ratio 1:4.6 in favour of the 
formation of 69. Alkylation of the benzyl bromide 69 with diethyl acetamidomalonate 
in ethanol, in the presence of sodium ethoxide, yielded diethyl 3-hydroxy-5-
methoxybenzylacetamidomalonate (70).115 The molecular structure of 70 was 
confirmed by X-ray crystallography (Figure 2-15, full details are provided in Appendix 
I). 3-Hydroxy-5-methylphenylalanine (71) was obtained as a racemic mixture by 
hydrolysis and demethylation of the ester 70 with concentrated hydrobromic acid under 
vigorous conditions.114,116 The molecular structure of 71 was confirmed by X-ray 
crystallography (Figure 2-16, full details are provided in Appendix I). 
 
 
 
 
 
 
 
 
 
 
Figure 2-15. X-Ray crystal structure of the malonate 70. 
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Figure 2-16. X-Ray crystal structure of the 3-OH-5-Me-Phe (71). 
 
 
 
 
 
 
 
 
 
 
Figure 2-17. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 20, D) no 20 but with 3-OH-5-Me-Phe (71). 
 
Initial studies of the incorporation of 3-hydroxy-5-methyl-phenylalanine (71) under 
standard conditions of cell-free protein synthesis only resulted in trace amounts of 
protein. Prolonged reaction times and enhanced concentrations of the amino acid 71 
were used to produce appreciable amounts of protein. SDS-PAGE analysis of the crude 
His6-PpiB synthesized under the modified conditions (Figure 2-17a) showed  
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incorporation of 71 (lane D) as a substitute for phenylalanine (20). Again, loss of 
protein during purification was observed by SDS-PAGE (lane D, Figure 2-17b). Protein 
for mass spectral analysis was prepared using a procedure identical to that with 3,5-
dihydroxyphenylalanine (63). A greater than 95% incorporation level was measured for 
71 (Figure II-8 in Appendix II). 
 
Incorporation of 3-hydroxy-5-methylphenylalanine (71) as a replacement for 
phenylalanine (20) demonstrates that the active site of E. coli PheRS can accept a 
methyl group at one meta-position and a hydroxyl group at the other. The prolonged 
reaction time and increased concentration of 3-hydroxy-5-methylphenylalanine (71) 
required for experiment suggests that it is activated only poorly by E. coli PheRS. 
 
 
2.2.3 para-Substituted Phenylalanines 
 
 
 
 
 
 
It was demonstrated that there is slight flexibility near the para position at the active 
site of E. coli PheRS, being able to accommodate a fluorine. To explore this further, the 
para-substituted phenylalanines, including p-bromophenylalanine (73), p-
iodophenylalanine (74), p-trifluoromethylphenylalanine (75) and p-aminophenylalanine 
(76), were studied.  
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Figure 2-18. SDS-PAGE analysis of His6-PpiB before (a, c) and after (b, d) purification. Lanes: A and F) 
no DNA, B and G) all components, C and H) no 20, D) no 20 but with p-Br-Phe (73), E) no 20 but with 
p-I-Phe (74), I) no 20 but with p-CF3-Phe (75), J) no 20 but with p-NH2-Phe (76).  
 
The presence of only background protein in lanes D and E (Figure 2-18 a and b), and 
lanes I and J (Figure 2-18 c and d) during SDS-PAGE analysis indicates that none of 
the para-substituted analogues 73!76 is incorporated into His6-PpiB as a surrogate for 
phenylalanine (20). This is most probably due to the stringent steric requirements at the 
para position, which was observed by analysis of the crystal structure (Figure 2-1). 
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2.3 Competition between Phenylalanine and Its Analogues 
 
The high levels of incorporation obtained in the present study showed that many 
phenylalanine derivatives are efficient substrates of E. coli PheRS. Competitive 
experiments between phenylalanine (20) and its analogues were conducted to determine 
the extent to which that the unnatural amino acids compete with the natural counterpart. 
 
The competition efficiencies, which were obtained by including 0.2 mM phenylalanine 
(20) and 2.0 mM of each analogue in a single reaction, are shown in Table 2-1. They 
are given as percentages based on the incorporation level obtained in the competition 
assay, and the concentrations of phenylalanine (20) and of the analogue used (Equation 
2-1).42,91,92 The concentration value is calculated for the L-enantiomer. The amino acid 
derivatives that did not incorporate were not investigated, except for the compounds 49, 
51, 52, 54!57 and 67, which were studied for the purpose of comparison. A 
representative mass spectrum of a competition assay is shown in Figure 2-19. The mass 
spectra for the rest of competitive experiments are included in Appendix II, from Figure 
II-9 to 11. 
 
 
 
 
 
 
Equation 2-1 
 
 
[Phe] is the concentration of phenylalanine (5); 
[Analogue] is the concentration of the phenylalanine analogue. 
Competition efficiency = Incorporation level (%) !! [Phe] 
[Analogue] 
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Table 2-1. Incorporation levels and competition efficiencies of phenylalanine analogues. 
Analogue 
(2.0 mM) 
Incorporation level, % Competition 
efficiency, % 0.0 mM 
Phe (5) 
0.2 mM 
Phe (5) 
12 <10 - - 
48 >95 21 2.1 
21 90 N.D. N.D. 
14 <10 N.D. N.D. 
49 <10 N.D. N.D. 
50 >95 N.D. N.D. 
51 <10 N.D. N.D. 
52 <10 N.D. N.D. 
53 >95 N.D. N.D. 
54 <10 N.D. N.D. 
55 <10 N.D. N.D. 
56 <10 N.D. N.D. 
57 <10 N.D. N.D. 
36 >95 14 1.4 
37 >95 21 2.1 
38 >95 36 3.6 
58 >95 N.D. N.D. 
59 <10 - - 
63 >95 N.D. N.D. 
67 <10 N.D. N.D. 
71 >95 N.D. N.D. 
73 <10 - - 
74 <10 - - 
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Table 2-1. !Continued 
75 <10 - - 
76 <10 - - 
 
N.D. = Not detectable. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-19. Mass spectral analysis of His6-PpiB synthesised in the presence of 0.2 mM Phe (20) and 2.0 
mM o-Tyr (48). 
 
The results of competition experiments clearly show that phenylalanine (20) is highly 
favoured among all substrates investigated. Inclusion of a small amount of 
phenylalanine (20) in the reaction mixture precludes the incorporation of most 
derivatives. The inefficient competition only for the o-tyrosine (48) (2.1%) and the 
fluorides, o-fluorophenylalanine (36), m-fluorophenylalanine (37) and p-
fluorophenylalanine (38) (1.4%, 2.1% and 3.6%, respectively) shows that the selectivity 
for phenylalanine (20) is at least two orders of magnitude higher than for all  
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phenylalanine surrogates, despite some being shown to be efficient substrates of E. coli 
PheRS. 
 
The KM value of E. coli PheRS for phenylalanine (20) (0.05 mM) is reported to be 
approximately 100-, 30- and 10-fold lower than for o-fluorophenylalanine (36) (5.0 
mM), m-fluorophenylalanine (37) (1.4 mM) and p-fluorophenylalanine (38) (0.56 mM), 
respectively.119 These ratios are similar to the competition efficiencies (Table 2-1) 
obtained.  
 
Complete substitution of phenylalanine residues in His6-PpiB was achieved with o-
tyrosine (48) (> 95%, Table 2-1) when phenylalanine (20) was not included in the 
reaction mixture. The competition assay, however, showed that this incorporation level 
decreased to 21% in the presence of 0.2 mM phenylalanine (20) (Figure 2-19). This 
provides evidence to support that His6-PpiB containing o-tyrosine (48) and m-tyrosine 
(21) is not necessarily a result of posttranslational chemical modification but may also 
be through translation of genetic code in protein synthesis. 
 
 
2.4 Conclusion 
 
This work demonstrates some degree of promiscuity of E. coli PheRS, although the 
enzyme family of aminoacyl-tRNA synthetase are remarkably specific 
catalysts.63,79,91,103,104 These results clearly show that the active site of E. coli PheRS is a 
determinant governing translational incorporation of unnatural amino acids. Due to a 
stringent steric requirement at the para-position most para-substituted phenylalanines  
Results and Discussion: Chapter Two 
! 78 
 
do not incorporate into protein. The only analogue allowed for incorporation is that with 
a fluorine attached. On the other hand, the spaces near the other ring positions are able 
to accommodate a variety of substituents. As a result, a number of ortho- and meta-
substituted phenylalanines are incorporated into protein. 
 
Although many phenylalanine analogues were found out to be efficient substrates of E. 
coli PheRS, the competitive experiments demonstrate that phenylalanine (20) is highly 
favoured.
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3.1 Introduction 
 
The work described in Chapter Two demonstrated that discrimination of E. coli PheRS 
against tyrosine (12) is based on the phenolic hydroxyl group, mainly through steric 
constraints preventing substrate binding at the active site. E. coli PheRS is highly 
selective for its cognate substrate phenylalanine (20) over tyrosine (12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Stereo view of the E. coli TyrRS binding site with bound Tyr (12).89 
 
It follows naturally that TyrRS requires a hydroxyl group at the para position to select 
for tyrosine (12) against phenylalanine (20). The reported crystal structure of the E. coli 
TyrRS-Tyr complex (Figure 3-1) shows that E. coli TyrRS forms hydrogen bonds 
between the para-hydroxyl group of tyrosine (12) and the side chains of Asp182 and 
Tyr37.89 The hydroxyl group leads tyrosine (12) to being favoured by E. coli TyrRS by  
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a factor of 105 over phenylalanine (20).91 Fidelity in translation of the genetic code is 
maintained at a high level despite E. coli TyrRS not possessing proofreading activity.91 
 
In a similar manner to the active site of E. coli PheRS (Figure 2-1), spaces near ring 
positions other than para in the active site of E. coli TyrRS (Figure 3-1) are observed. 
The ortho- and meta-positions on one side of the substrate ring, enclosed by the side 
chains of Tyr175, Thr76, and Gln179, project to a small hydrophilic space, whereas the 
corresponding positions on the other side point to an open area, in particular the ortho-
position.  
 
In earlier reports, translational incorporation of 3,4-dihydroxyphenylalanine (14) and m-
nitrotyrosine (41) into proteins as substitutes for tyrosine (12) using the E. coli cell-free 
approach,92,95 and of m-fluorotyrosine (39) and m-chlorotyrosine (40) using a whole cell 
technique with E. coli,93,94 have been observed. These indicate that the tyrosine 
analogues 14, 39, 40 and 41 are substrates of E. coli TyrRS and suggest promiscuous 
substrate specificity of this synthetase. 
 
Work in this Chapter was conducted to further explore the substrate promiscuity of E. 
coli TyrRS, by studying translational incorporation of related amino acids into protein 
in place of tyrosine (14) using the E. coli cell-free protein synthesis system. 
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3.2 E. coli Cell-free Protein Synthesis with Tyrosine Analogues 
 
3.2.1 para-Substituted Phenylalanines 
 
Studies of m-tyrosine (21) and o-tyrosine (48) as substitutes for phenylalanine (20) in 
Chapter Two showed that E. coli PheRS specifically discriminates against a hydroxyl 
group at the para position. The isomers 21 and 48 were also investigated in the present 
study as potential substitutes for tyrosine (12) to investigate if E. coli TyrRS shows a 
similar specificity for a para-hydroxyl group. Studies of the para-substituted 
phenylalanines p-fluorophenylalanine (38), p-methylphenylalanine (51), p-
chlorophenylalanine (54), p-nitrophenylalanine (57), p-bromophenylalanine (73), p-
iodophenylalanine (74), p-trifluoromethylphenylalanine (75) and p-aminophenylalanine 
(76) in place of tyrosine (12) were also performed to explore the possibility of other 
groups being incorporated as replacements for the hydroxyl group. 
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Figure 3-2. SDS-PAGE analysis of His6-PpiB before (a, c, e, and g) and after (b, d, f, and h) purification. 
Lanes: A, F, K, and P) no DNA; B, G, L, and Q) all components; C, H, M, and R) no 12; D) no 12 but 
with m-Tyr (21); E) no 12 but with o-Tyr (48); I) no 12 but with p-Me-Phe (51); J) no 12 but with p-Cl- 
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Phe (54); N) no 12 but with p-NO2-Phe (57); O) no 12 but with p-F-Phe (38); S) no 12 but with p-Br-Phe 
(73); T) no 12 but with p-I-Phe (74); U) no 12 but with p-CF3-Phe (75); and V) no 12 but with p-NH2-Phe 
(76).  
 
SDS-PAGE analysis of the His6-PpiB (Figure 3-2) synthesised in the presence of the 
isomers 21 and 48, and the para-substituted phenylalanines 38, 51, 54, 57 and 73!76, 
shows that protein was produced when all components required for protein synthesis 
were provided (lanes B, G, L and Q). In an analogous manner to Chapter Two where a 
trace of protein was produced when phenylalanine (20) was not added to the reaction 
mixture, a similar small amount of protein was also observed when tyrosine (12) was 
not added (lanes C, H, M and R). This background level of protein is presumably 
attributable to the presence of some tyrosine (12) as a result of the endogenous amino 
acid pool in the S30 extract or its biosynthesis during the cell-free reaction.92 No protein 
band corresponding to His6-PpiB was observed when the DNA plasmid was not added 
(lanes A, F, K and P). 
 
The amount of protein observed in lanes D and E (Figure 3-2 a and b), lanes I and J 
(Figure 3-2 c and d), lanes N and O (Figure 3-2 e and f), and lanes S, T, U and V 
(Figure 3-2 g and h) is comparable to that of the background, suggesting that neither the 
tyrosine isomers 21 and 48 nor any of the para-substituted phenylalanines 38, 51, 54, 
57 and 73!76 is incorporated into His6-PpiB instead of tyrosine (12). 
 
The lack of incorporation of m-tyrosine (21) and o-tyrosine (48) is presumably due to 
the absence of a para-hydroxyl group. The results obtained with the para-substituted 
phenylalanines 38, 51, 54, 57 and 73!76 demonstrate that the hydroxyl group of 
tyrosine (12) is irreplaceable by other moieties, including iodo-, trifluoromethyl- and  
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amino-groups that could potentially form halogen bonds or hydrogen bonds similar to 
the hydroxyl group.120 These studies highlight the crucial importance of the para-
hydroxyl group. 
 
 
3.2.2 Analogues with a para-Hydroxyl Group 
 
 
 
 
 
 
As mentioned above, m-fluorotyrosine (39) was incorporated into proteins with a whole 
cell technique.93 This implies that it is a substrate of E. coli TyrRS and that protein 
synthesis using the E. coli cell-free system would occur. To explore the space near the 
substrate ortho-position, o-fluorotyrosine (83) was also investigated. The m-
fluorotyrosine (39) was commercially available, while o-fluorotyrosine (83) was 
synthesised.  
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Scheme 3-1. Synthesis of o-fluoro-DL-tyrosine (83).121 a) SOCl2, reflux, 10 h (95%); b) LiAlH4, Et2O, 
RT, 20 min, c) SOCl2, RT, overnight (80% in two steps), d) EtO2CCH(NHCOCH3)CO2Et, NaOEt, EtOH, 
reflux, 4 h (69%); e) (i) 2.5 M NaOH, reflux, 6 h; (ii) 0.15 M HCl, 2 h (80%), f) 48% HBr, sealed tube, 
150 °C, 2 h (64%). 
 
The method used in the synthesis of o-fluorotyrosine (83), which was obtained as a 
racemic mixture, is outlined in Scheme 3-1, as described in an earlier report.121 
Reaction of 2-fluoro-4-methoxybenzoic acid (77) with thionyl chloride yielded 2-
fluoro-4-methoxybenzoyl chloride (78), which was subsequently reduced with lithium 
aluminum hydride to give 2-fluoro-4-methoxybenzyl alcohol (79).121 The benzyl  
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alcohol 79 was converted to 2-fluoro-4-methoxybenzyl chloride (80) with thionyl 
chloride.121 The important intermediate, diethyl 2-acetamido-2-(2-fluoro-4-
methoxybenzyl)malonate (81) was obtained by treating the benzyl chloride 80 with 
diethyl acetamidomalonate in ethanol, in the presence of sodium ethoxide.121 o-
Fluorotyrosine (83) was obtained by hydrolysis of the ester 81, followed by 
deprotection of the resulting N-acetyl-2-fluoro-4-methoxyphenylalanine (82) with 
concentrated hydrobromic acid under vigorous conditions.121 
 
 
 
 
 
 
 
 
 
Figure 3-3. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 12, D) no 12 but with m-F-Tyr (39), E) no 12 but with o-F-Tyr (83). 
 
SDS-PAGE analysis (Figure 3-3) of His6-PpiB synthesised in the presence of m-
fluorotyrosine (39) and o-fluorotyrosine (83) shows that protein was produced when all 
components required for protein synthesis were supplied (lane B). Mass spectral 
analysis (Figure 3-4) confirmed that it is native His6-PpiB. By comparison, only a trace 
of protein was produced when tyrosine (12) was not added to the reaction mixture (lane 
C). The amount of this protein is also comparable to that observed in Chapter Two 
when phenylalanine (20) was withheld. Mass spectral analysis (Figure 3-5) supported  
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that it is native His6-PpiB, which confirmed the presence of tyrosine (12) during the 
cell-free reaction. No protein band corresponding to His6-PpiB was observed when the 
DNA plasmid was not added (lane A). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Mass spectral analysis of native His6-PpiB. 
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Figure 3-5. Mass spectral analysis of His6-PpiB synthesised in the absence of Tyr (12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6. Mass spectral analysis of His6-PpiB synthesised in the presence of 39. 
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Figure 3-7. Mass spectral analysis of His6-PpiB synthesised in the presence of 83. 
 
Efficient formation of protein was observed with m-fluorotyrosine (39) and o-
fluorotyrosine (83) (lanes D and E), indicating that both are incorporated into His6-PpiB 
as substitutes for tyrosine (12). This was confirmed by mass spectrometry. His6-PpiB 
has three tyrosine residues in its amino acid sequence and each substitution with either 
amino acid 39 or 83 increases the mass by 18 Da. Accordingly, the peaks at 19275.6 Da 
and 19304.0 Da (Figure 3-6) in the spectrum of protein synthesised using m-
fluorotyrosine (39) correspond to complete substitution for all three tyrosine residues in 
the respective non-formylated and formylated His6-PpiB, giving an incorporation level 
of greater than 95%. Similarly, the peaks at 19277.6 Da and 19304.7 Da (Figure 3-7) in 
the spectrum of protein synthesised using o-fluorotyrosine (83) match a total 
substitution for all tyrosine residues in non-formylated and formylated His6-PpiB, 
respectively, affording an incorporation level of greater than 95%.  
 
The results observed with m-fluorotyrosine (39) are consistent with the literature,93  
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confirming that it is a substrate of E. coli TyrRS. The results with o-fluorotyrosine (83) 
show that it can also be activated by E. coli TyrRS and transferred to tRNATyr for 
protein synthesis. These studies demonstrate that the active site of E. coli TyrRS is able 
to accommodate a fluorine at both the substrate ortho- and meta-positions. 
 
 
 
 
 
 
To investigate if the active site of E. coli TyrRS can also accommodate a hydroxyl 
group at both the ortho- and meta-positions, 2,4-dihydroxyphenylalanine (89) (2,4-
DOPA) was studied. The 3,4-dihydroxylphenylalanine (14) had already been 
investigated.92 
 
 
 
 
 
 
 
 
 
 
 
H2N
OH
O
OHHO
89 
Results and Discussion: Chapter Three 
91 
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3-2. Synthesis of 2,4-dihydroxy-DL-phenylalanine (89).116,122 a) Cs2CO3, MeI, DMF, reflux, 2 h 
(95%); b) C6H5C(=O)NHCH2CO2H, NaOAc, Ac2O, 110 °C, 1 h (87%); c) 0.5 M NaOH, EtOH, 100 °C, 2 
h (94%); d) 0.3 M NaOH, Pd/C, H2, 60 p.s.i, 2 h (88%); e) 62% HBr, N2, 150 °C, 2 h (68%). 
 
The method used for the preparation of 2,4-dihydroxyphenylalanine (89) is outlined in 
Scheme 3-2, as described in an earlier report.116 The two hydroxyl groups of 2,4-
dihydroxybenzaldehyde (84) were protected by treatment with methyl iodide. The 
protected product benzaldehyde (85) reacted with benzoylglycine in acetic anhydride, in 
the presence of sodium acetate, to give 4-(2,4-dimethoxybenzyldiene)-2-phenyl-5- 
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oxazolone (86). The unsaturated oxazolone 86 was converted to 2-benzamido-3-(2,4-
dimethoxyphenyl)-acrylic acid (87) by nucleophilic opening of the heterocyclic ring 
with base. 2,4-Dihydroxyphenylalanine (89) was obtained as a racemic mixture through 
catalytic hydrogenation of the unsaturated carboxylic acid 87, followed by 
demethylation and acid hydrolysis of the resulting 2-benzamido-3-(2,4-
dimethoxyphenyl)-propionic acid (88) with 48% hydrobromic acid under an inert 
atmosphere, under vigorous conditions. 
 
 
 
 
 
 
 
 
Figure 3-8. SDS-PAGE analysis of His6-PpiB before (a) and after (b) purification. Lanes: A) no DNA, 
B) all components, C) no 12, D) no 12 but with 3,4-DOPA (14), E) no 12 but with 2,4-DOPA (89). 
 
Illustrated in Figure 3-8 is the SDS-PAGE analysis of His6-PpiB synthesized in the 
presence of 3,4-dihydroxyphenylalanine (14) and 2,4-dihydroxyphenylalanine (89). 
Lanes D and E show efficient formation of protein with each of the isomers, indicating 
that both were incorporated into His6-PpiB as substitutes for tyrosine (12). Mass 
spectral analysis confirmed a greater than 95% incorporation level for 3,4-
dihydroxyphenylalanine (14) (Figure II-12 in Appendix II), with peaks at 19268.0 Da 
and 19296.6 Da corresponding to complete substitution for all tyrosine residues in the 
respective non-formylated and formylated His6-PpiB, and a greater than 95%  
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incorporation level for 2,4-dihydroxyphenylalanine (89) (Figure II-13 in Appendix II) 
with peaks at 19271.7 Da and 19299.3 Da corresponding to a total replacement of for 
all tyrosine residues in non-formylated and formylated His6-PpiB, respectively.  
 
The results with 3,4-dihydroxyphenylalanine (14) are in complete agreement with the 
literature,92 confirming it is an efficient substrate of E. coli TyrRS, while the 
incorporation of 2,4-dihydroxyphenylalanine (89) shows that it is also activated by E. 
coli TyrRS. These results demonstrate that the active site of E. coli TyrRS can 
accommodate an extra hydroxyl group at both the ortho- and meta-positions. 
 
 
 
 
 
 
A previous report indicated that m-chlorotyrosine (40) is a substrate of E. coli TyrRS,94  
suggesting that the active site of E. coli TyrRS can accommodate a chlorine at the meta-
position. However, the degree of substitution of tyrosine (12) had not been determined. 
E. coli cell-free protein synthesis using m-chlorotyrosine (40) in place of tyrosine (6) 
was therefore performed. An isomer of m-chlorotyrosine (40), o-chlorotyrosine (92) 
was also studied, in an attempt to further explore the space near the substrate ortho-
position. m-Chlorotyrosine (40) was commercially available.  
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Scheme 3-3. Synthesis of o-chloro-DL-tyrosine (92).123 a) EtO2CCH(NHCOCH3)CO2Et, NaOEt, EtOH, 
RT, 3 h (92%); b) 48% HBr, sealed tube, 150 °C, 3 h (67%). 
 
The method chosen for the preparation of o-chlorotyrosine (92) is outlined in Scheme 3-
3.123 Treatment of 2-chloro-4-methoxybenzyl bromide (90) with diethyl 
acetamidomalonate in ethanol, in the presence of sodium ethoxide, yielded diethyl 2-
acetamido-2-(2-chloro-4-methoxybenzyl)malonate (91), which was converted to a 
racemic mixture of o-chlorotyrosine (92) by demethylation and hydrolysis with 
concentrated hydrobromic acid at high temperature and high pressure.123 
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Figure 3-9. SDS-PAGE analysis of His6-PpiB before (a) and (b) after purification. Lanes: A) no DNA, 
B) all components, C) no 12, D) no 12 but with m-Cl-Tyr (40), E) no 12 but with o-Cl-Tyr (92). 
 
SDS-PAGE analysis of His6-PpiB (Figure 3-9) synthesised in the presence of m-
chlorotyrosine (40) and o-chlorotyrosine (92) shows that the amount of protein 
produced in each case (lanes D and E) is comparable to that produced when all usual 
components required by protein synthesis were supplied (lane B), indicating that both 
m-chlorotyrosine (40) and o-chlorotyrosine (92) are incorporated into His6-PpiB as 
replacements for tyrosine (12). 
 
The pair of peaks at 19324.5 Da and 19352.6 Da (Figure II-14 in Appendix II) in the 
spectrum of His6-PpiB synthesised with m-chlorotyrosine (40) correspond to complete 
substitution for all tyrosine residues in non-formylated and formylated His6-PpiB, 
respectively, giving an incorporation level of greater than 95%, whereas the pair at 
19325.3 Da and 19353.1 Da (Figure II-15 in Appendix II) in the spectrum of His6-PpiB 
synthesised with o-chlorotyrosine (92) correspond to a total replacement for all tyrosine 
residues in the respective non-formylated and formylated His6-PpiB, indicating a 
greater than 95% incorporation level. 
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The results observed with m-chlorotyrosine (40) confirmed the literature that it is a 
substrate of E. coli TyrRS. The incorporation level estimated from the mass spectrum is 
quite high, suggesting that it is efficiently activated. The results with o-chlorotyrosine 
(92) demonstrate that it is also efficiently activated by E. coli TyrRS. These studies 
show that the active site of E. coli TyrRS can accommodate a chlorine at both the ortho- 
and meta-positions. 
 
 
 
 
 
 
 
In the previous Chapter, m-chlorophenylalanine (53) was studied on the basis that m-
methylphenylalanine (50) incorporated and that chlorine is similar in size to a methyl 
group.111,112 Protein synthesis using m-methyltyrosine (95) and o-methyltyrosine (99) 
was then investigated because the corresponding chlorides 40 and 92 incorporated. 
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Scheme 3-4. Synthesis of m-methyl-DL-tyrosine (95).124,125 a) EtO2CCH(NHCOCH3)CO2Et, NaOEt, 
EtOH, reflux, 1.5 h (73%); b) 48% HBr, sealed tube, 150 °C, 3 h (43%). 
 
The method used for the preparation of m-methyltyrosine (95) is outlined in Scheme 3-
4.124,125 Alkylation of the 3-methyl-4-methoxybenzyl chloride (93) with diethyl 
acetamidomalonate afforded diethyl 2-acetamido-2-(4-methoxy-3-
methylbenzyl)malonate (94),125 which was converted to m-methyltyrosine (95) by 
deprotection and hydrolysis with 48% hydrobromic acid, at high temperature and high 
pressure. 
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Scheme 3-5. Synthesis of o-methyl-DL-tyrosine (99).126,127 a) NBS, AIBN, $,$,$-trifluorotoluene, reflux,  
15 min; b) NaH, DCM, RT, 12 h (40% over two steps); c) 48% HBr, AcOH, 150 °C, 3 h (71%). 
 
The route chosen for the synthesis of o-methyltyrosine (99) is outlined in Scheme 3-
5.127 Side-chain bromination of 3,4-dimethylanisole (96) with N-bromosuccinimide 
afforded 4-methoxy-2-methylbenzyl bromide (97).126 Silica chromatography was 
unsuitable for the purification of the benzyl bromide 97 as decomposition via 
nucleophilic substitution always occurred. The dried crude product mixture was thus 
directly used for the alkylation step. 
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The crude bromination product mixture was mainly the bromide 97 but chromatography 
separated the bromide 100 in 2% yield, which was present in the mixture as only a 
minor product. The bromination probably favours formation of the bromide 97 because 
the intermediate radical is extensively stabilised (Scheme 3-6).128 
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Scheme 3-6. Radical bromination and intermediate resonance stabilisation. The reaction is catalysed by 
HBr, a trace of which is ususlly present in NBS. Stabilisation mechanism is derived from an earlier 
report.128 
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Treatment of the crude benzyl bromide 97 with diethyl acetamidomalonate gave diethyl 
2-acetamido-2-(4-methoxy-2-methylbenzyl)malonate (98),127 which was converted to o-
methyltyrosine (99) by deprotection and hydrolysis with 48% hydrobromic acid at 150 
°C in a sealed tube. 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. SDS-PAGE analysis of His6-PpiB before (a) and (b) after purification. Lanes: A) no DNA, 
B) all components, C) no 12, D) no 12 but with m-Me-Tyr (95), E) no 12 but with o-Me-Tyr (99). 
 
SDS-PAGE analysis of His6-PpiB synthesised in the presence of m-methyltyrosine (95) 
and o-methyltyrosine (99) (Figure 3-10) shows efficient formation of protein with both 
derivatives as substitutes for tyrosine (12) (lanes D and E). The incorporation was 
confirmed by mass spectral analysis. The two pairs of peaks (Figure II-16 in Appendix 
II) at 19251.4 Da and 19265.7 Da, and at 19279.5 Da and 19293.5 Da in the spectrum 
of His6-PpiB synthesised using m-methyltyrosine (95) correspond to 2 and 3 
replacements of tyrosine in non-formylated and formylated His6-PpiB, respectively, 
indicating an incorporation level of approximate 90%, whereas the pair of peaks (Figure 
II-17 in Appendix II) at 19264.3 Da and 19291.9 Da in the spectrum of His6-PpiB 
synthesised with o-methyltyrosine (99) correspond to complete substitution of all  
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tyrosine residues in the respective non-formylated and formylated His6-PpiB, 
corresponding to a greater than 95% incorporation level. 
 
The translational incorporation of o-methyltyrosine (95) and m-methyltyrosine (99) 
shows that both are activated by E. coli TyrRS, demonstrating that the active site of E. 
coli TyrRS can accommodate a methyl group at both the ortho- and meta-positions. The 
somehow lower incorporation level of the meta-isomer 95 (~90%) compared to that of 
the ortho-isomer 99 (>95%) may be the result of some steric hindrance near the meta-
position (Figure 3-1).  
 
 
 
 
 
 
To probe the steric limit of the active site of E. coli TyrRS, m-nitrotyrosine (41) and o-
nitrotyrosine (104) in which the relatively large nitro group is attached to the ring, were 
also investigated. m-Nitrotyrosine (41) was commercially available. 
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Scheme 3-7. Synthesis of o-nitro-DL-tyrosine (104).116,129,130 a) NBS, AIBN, $,$,$-trifluorotoluene, hv 
(400 W), reflux,  6 h (45%); b) EtO2CCH(NHCOCH3)CO2Et, NaOEt, EtOH, reflux, 3 h (66%); c) 48% 
HBr, sealed tube, 150 °C, 3 h (77%). 
 
The approach of malonic ester condensation was again chosen for the preparation of o-
nitrotyrosine (104), as outlined in Scheme 3-7.116,129,130 4-Methoxy-2-nitrobenzyl 
bromide (102) was obtained through bromination of 4-methyl-3-nitroanisole (101) with 
N-bromosuccinimide,129 and was converted to diethyl 2-acetamido-2-(4-methoxy-2-
nitrobenzyl)malonate (103) by reacting with diethyl acetamidomalonate in ethanol, in 
the presence of sodium ethoxide.130 m-Nitrotyrosine (104) was obtained as a racemic 
mixture by demethylation and hydrolysis of the ester 103 with 48% hydrobromic acid, 
at 150 °C in a sealed tube.116 
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Figure 3-11. SDS-PAGE analysis of His6-PpiB before (a) and (b) after purification. Lanes: A) no DNA, 
B) all components, C) no 12, D) no 12 but with o-NO2-Tyr (104), E) no 12 but with m-NO2-Tyr (41). 
 
Efficient production of protein was observed on SDS-PAGE analysis (Figure 3-11) of 
the synthesised His6-PpiB only with the o-nitrotyrosine (104) (Lane D), indicating that 
it is incorporated into His6-PpiB as a replacement for tyrosine (12), while the m-
nitrotyrosine (41) (lane E) is not. The peaks (Figure II-18 in Appendix II) at 19296.4 
Da, 19341.5 Da and 19386.4 Da in the spectrum of His6-PpiB synthesised with o-
nitrotyrosine (104) match 1, 2 and 3 replacements of tyrosine residues in formylated 
His6-PpiB, respectively, indicating an incorporation level of approximately 80%.  
 
An open space was observed near one ortho-position of the substrate during structural 
analysis of E. coli TyrRS (Figure 3-1). The results obtained with o-nitrotyrosine (104) 
demonstrate that space is able to accommodate a large nitro group. 
 
With a similar protein expression system, incorporation of m-nitrotyrosine (41) was 
described in an earlier report.95 It was accomplished by considerably enhancing the 
concentrations of E. coli TyrRS and the m-nitrotyrosine (41). E. coli TyrRS was  
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prepared separately and supplemented to the system exogenously.95 The necessity for 
this suggests a poor activation by E. coli TyrRS, which is most probably the cause of 
the lack of incorporation in the present study. 
 
m-Iodotyrosine, a derivative of tyrosine (12) with a large iodine substituent, is not 
recognised by E. coli TyrRS.131 However, mutation of Tyr37 to valine (25) (Tyr37Val) 
and of Gln195 to cysteine (Gln195Cys) expanded the space near the substrate meta-
position and, as a consequence, m-iodotyrosine was activated.131 It therefore seems 
likely that the ring of Tyr37 and the side chain of Gln195 (Figure 3-1) are the 
determinants governing the accommodation of substrate substituents. The poor 
translation of m-nitrotyrosine (41) and the somewhat low incorporation level of m-
methyltyrosine (95) are therefore likely a result of the steric constraints from Tyr37 and 
Gln195. 
 
 
3.3 Competition between Tyrosine and Its Analogues 
 
The high incorporation levels obtained in the present study clearly show that 
many structural analogues of tyrosine are efficient substrates of E. coli TyrRS. 
Competitive experiments between tyrosine (12) and its analogues were subsequently 
conducted, in an attempt to investigate the extent to which these unnatural amino acids 
compete with their natural counterpart 12. 
 
The competitive experiments were performed in a manner identical to those with 
phenylalanine (20), as described in Chapter Two, with 0.2 mM tyrosine (12) and 2.0  
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mM of each of the analogues. This concentration is that of the L-enantiomer. 
Competition efficiencies are given as percentages, which are calculated on the basis of 
the incorporation levels obtained in the assays and the concentrations of tyrosine (12) 
and each analogue used (Equation 2-1),42,91,92 and are summarised in Table 3-1. The 
amino acid derivatives that did not incorporate were excluded from this assay, except 
for m-nitrotyrosine (41), which was studied for the purpose of comparison. A 
representative mass spectrum of protein from the competition assay is shown in Figure 
3-19. The mass spectra of the rest of the competition assays are included in Appendix 
II, Figure II-19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19. Mass spectral analysis of His6-PpiB synthesised in the presence of 0.2 mM Tyr (12) and 2.0 
mM m-F-Tyr (39). 
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  Table 3-1. Incorporation levels and competition efficiencies of tyrosine analogues. 
Analogue 
(2.0 mM) 
Incorporation level, % Competition 
efficiency, % 0.0 mM 
Tyr (12) 
0.2 mM 
Tyr (12) 
20 <10 - - 
48 <10 - - 
21 <10 - - 
14 >95 N.D. N.D. 
51 <10 - - 
54 <10 - - 
57 <10 - - 
38 <10 - - 
73 <10 - - 
74 <10 - - 
75 <10 - - 
76 <10 - - 
39 >95 29 2.9 
83 >95 23 2.3 
89 >95 N.D. N.D. 
40 >95 N.D. N.D. 
92 >95 N.D. N.D. 
95 90 N.D. N.D. 
99 >95 N.D. N.D. 
41 <10 N.D. N.D. 
104 80 N.D. N.D. 
 
 N.D. = Not detectable. 
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From an examination of Table 3-1 it is clear that tyrosine (12) is highly favoured 
amongst all potential substrates. The inclusion of a small amount of tyrosine (12) in the 
reaction mixture precludes the incorporation of most derivatives. The inefficient 
competition of m-fluorotyrosine (39) and o-fluorotyrosine (83) suggests that the 
selectivity for tyrosine (12) is at least two orders of magnitude higher. 
 
By analogy with E. coli PheRS, as described in Chapter Two, these results suggest that 
recognition of unnatural amino acids by E. coli TyrRS also relies mainly on steric 
interactions at the amino acid active site. The similarity between the competition 
efficiency of m-fluorotyrosine (39) (2.9%, Table 3-1) and the ratio of its KM (0.13 
mM132) relative to that of tyrosine (12) (0.0061 mM132) is consistent with the correlation 
of binding affinity with the substrate selectivity of E. coli TyrRS. Also, due presumably 
to the high KM of 3,4-dihydroxyphenylalanine (14) (1.4 mM132), competition between 
3,4-dihydroxyphenylalanine (14) and tyrosine (12) was not detected. 
 
 
3.4 Conclusion 
 
The para-hydroxyl group of tyrosine (12) is a key element for the substrate specificity 
of E. coli TyrRS as it offers complementary hydrogen bonds to assist the recognition of 
the amino acid. The results of this work clearly demonstrate that the hydroxyl group 
must be located at the para-position of the substrate ring and may not be replaced by 
other moieties. 
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This work also shows promiscuous substrate specificity of E. coli TyrRS, even though 
the family of aminoacyl-tRNA synthetases in general display remarkable 
specificity.58,63 The results clearly show that the size of the amino acid active site of E. 
coli TyrRS is a determinant governing translational incorporation of unnatural amino 
acids. Due to the space near the substrate ortho- and meta-positions in the active site of 
E. coli TyrRS, which can accommodate a variety of substituents, a number of ortho- 
and meta-substituted tyrosines are incorporated into protein. 
 
The competition experiments show that tyrosine (12) is highly favoured, even though 
many tyrosine analogues were found to be efficient substrates of E. coli TyrRS. 

 !
Results and Discussion 
Chapter Four 
 
Interaction of E. coli TyrRS with Tyrosine Analogues 
 
 
 
Section                           Page 
 
    4.1   Introduction                110 
 
    4.2   Monitoring Activity of E. coli TyrRS Using HPLC           112 
4.2.1   Assay Using Tyrosine as Substrate 
4.2.2   Assay Using Tyrosine Analogues as Substrates 
 
    4.3   Conclusion                119

Results and Discussion: Chapter Four 
! 110 
 
4.1 Introduction 
 
The Results and Discussion in Chapter Two and Chapter Three showed incorporation of 
a broad range of derivatives of phenylalanine (20) and tyrosine (12) into His6-PpiB as 
substitutes for their corresponding usual substrates. In order to incorporate into proteins, 
these unusual amino acids must be misactivated and subsequently charged onto the 
corresponding tRNAs by the respective aminoacyl-tRNA synthetases (aaRSs) in an 
aminoacylation reaction. 
 
The aminoacylation reaction is the first step in translation of genetic code, being of vital 
importance for translational quality control in protein synthesis.55!61,63 The preliminary 
responsibility of the aminoacylation reaction is to accurately select the cognate amino 
acid substrate from a pool of structural analogues,55,57!59 which is accomplished via two 
stages, being amino acid activation and amino acid transfer (Figure 4-1).63 
 
 
 
 
 
 
 
 
 
Figure 4-1. Mechanism of aminoacylation reaction catalysed by aminoacyl-tRNA synthetase.63 
 
 
aaRS 
aaRS!AA 
AA 
aaRS!ATP ATP 
aaRS!AA!ATP 
AA 
ATP 
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The aminoacylation reaction follows Michaelis!Menten kinetics:60,61 
 
! ! !!"# !!!!! ! !!! 
 
Equation 4-1 
 
When [S] >> KM, v = Vmax,60,61,133 
 !!"# ! !!!!! 
 
Equation 4-2 
 
In the above equations, v is the reaction velocity, KM is the Michaelis!Menten constant, 
Vmax is the maximum reaction velocity, kcat is the reaction rate constant, [E]0 is the 
initial enzyme concentration, and [S] is the substrate concentration.61 
 
In enzymology, the catalytic rate constant or turnover number (kcat) refers to the 
maximum number of substrate molecules converted to product per enzyme molecule 
per second.133 
 
While protein synthesis using unusual amino acids conducted in previous chapters is an 
indirect measure of the aminoacyl-tRNA synthetase activity, work presented in this 
Chapter was aimed to investigate these enzymes in a more direct manner, by evaluating 
the interactions between the unusual amino acids and the aminoacyl-tRNA synthetases 
through an aminoacylation reaction. 
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Of the two aminoacyl-tRNA synthetases indirectly investigated in Chapter Two and 
Chapter Three, E. coli TyrRS was selected in this study as it does not have an editing 
mechanism to proofread tRNATyr mischarged with non-cognate substrates.89,132 
 
E. coli TyrRS with a polyhistidine tag at the N-terminus (E. coli His6-TyrRS) 
facilitating purification was prepared and characterised. The gene encoding E. coli 
TyrRS was kindly provided by the Dixon group at the University of Wollongong, and 
was reconstructed to express the recombinant enzyme E. coli His6-TyrRS. The gene 
encoding the E. coli His6-TyrRS was expressed using an E. coli BL21 (DE3) cell strain 
and the resulting enzyme was purified using metal affinity chromatography, followed 
by characterisation with 20% SDS-PAGE and mass spectrometry.  
 
 
4.2 Monitoring Activity of E. coli TyrRS Using HPLC 
 
4.2.1 Assay Using Tyrosine as Substrate 
 
The activity of the E. coli His6-TyrRS was determined using HPLC.134 This method 
determines the catalytic rate constant (kcat) by monitoring the production of AMP 
produced in the aminoacylation reaction (Equation 4-3).56,58,63 
 
 
 
Equation 4-3 
 
 
ATP + L-tyrosine + tRNATyr            L-tyrosine-tRNATyr + diphosphate + AMP 
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The KM of tyrosine (12) with E. coli TyrRS has been reported to be 0.0061 mM.132 
Therefore, a concentration of 0.2 mM, which is over 30 times greater than the KM, was 
used in this assay. After pre-incubation of 0.2 mM tyrosine (12) with 0.05 µM E. coli 
His6-TyrRS in tris buffer, in the presence of 1.0 mM ATP at 37 °C for one minute, 
reaction was initiated by adding E. coli tyrosine-specific tRNA (tRNATyr) to a total 
concentration of 60 µM. The reaction was allowed to proceed for 90 seconds. The rate 
of the aminoacylation reaction was determined by HPLC analysis of aliquots taken 
from the reaction mixture and quenched with 0.1% SDS every 15 seconds. At higher 
concentrations of E. coli His6-TyrRS, aminoacylation occurs too fast to be monitored.134 
A control experiment that contained no tRNATyr was conducted in parallel. 
 
In a representative HPLC trace (Figure 4-2), peaks corresponding to AMP and ATP are 
observed at 8.1 min and 25.8 min, respectively. 
 
 
Figure 4-2. Representative HPLC trace. Analysis of aliquot taken from the reaction of Tyr (6) after 
incubating for 90 seconds. 
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HPLC analysis of the reaction mixture shows that the level of AMP increases 
proportionally with time (Figure 4-3). By comparison, the amount of AMP in the 
control stayed unchanged throughout the assay (Figure 4-4). The low amount of AMP 
presenting in the control is presumably attributable to ATP hydrolysis during storage. A 
separate HPLC analysis of ATP alone showed a comparable amount of AMP. 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Partial HPLC traces of aliquots collected every 15 seconds from the reaction of Tyr (12). 
 
 
 
 
Figure 4-4. Partial HPLC traces of aliquots collected every 15 seconds from the control experiment. 
 
The plot of the concentration of AMP against time afforded a reaction rate of 0.56 
µM s!1 (Figure 4-5) for the aminoacylation of tyrosine (12). From this value the 
catalytic rate constant (kcat) of aminoacylation of tyrosine (12) catalysed by E. coli His6- 
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TyrRS was determined to be 11.3 s!1 using Equation 4-2. This value is in good 
agreement with the value of 12 s!1 reported in earlier literature.135 The catalytic rate in 
the literature was determined using an enzyme without a polyhistidine tag at the N-
terminus, so it is apparent from this work that the influence of the polyhistidine tag on 
the activity of E. coli TyrRS is minor. 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2 Assay Using Tyrosine Analogues as Substrates 
 
The kcat values for tyrosine analogues, which were obtained using a procedure 
analogous to that with tyrosine (12), are given in Table 4-1. While the assays for the 
amino acids 14, 20, 39, 83 and 89 were conducted under the same conditions as that for 
tyrosine (12), with 60 µM tRNATyr and 0.05 µM E. coli His6-TyrRS, sampled at 15-
second intervals over 90 seconds, for amino acids 40, 41, 92, 95, 99 and 104 assays 
were performed with 16.7 µM tRNATyr and 0.15 µM His6-TyrRS, at 40-second intervals  
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Figure 4-5. Plot of the concentration of AMP against time. 
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over 360 seconds, due to lower reaction rates of the latter substrates. For each of the 
amino acids the rates shown in Table 4-1 are the average values obtained from at least 
two experiments. All amino acids were purified by preparative HPLC prior to use. 
Assays were generally performed with racemic tyrosine analogues at a concentration of 
5.0 mM. For enantiopure amino acids, a concentration of 2.5 mM was utilised as 
aminoacyl-tRNA synthetases only process the L-enantiomers.57 Exceptions were made 
for the racemic mixtures of compounds 39 and 104, which were used at 2.5 mM 
concentration due to solubility issues. 
 
Table 4-1. kcat of Phe (20), Tyr (12) and tyrosine analogues catalysed by E. coli TyrRS. 
Compounds kcat, s!1 KM, mM132 kcat/KM, s
!1 M!1 
20 N.D. - - 
12 11.3 0.0061 1.85 & 106 
14 3.3 1.4 2.33 & 103 
39 6.5 0.13 5.02 & 104 
83 4.8 - - 
89 0.89 - - 
40 0.34 - - 
92 0.17 - - 
95 0.087 - - 
99 0.13 - - 
41 N.D. - - 
104 0.058 - - 
 
 N.D. = No detectable reaction. 
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From an examination of Table 4-1 it is clear that E. coli TyrRS distinguishes between 
the tyrosine analogues and catalyses their reactions at different rates. Among all 
substrates used in this study, a highest kcat value was obtained for tyrosine (12). A 
combination of the kcat for tyrosine (12) and its KM value affords a catalytic efficiency 
(kcat/KM) being the greatest among the three ligands with reported KM values (12, 14 and 
39, Table 4-1), suggesting that 12 is the most efficient substrate of E. coli TyrRS. This 
is not surprising as tyrosine (12) is the natural substrate.  
 
There was no detectable reaction when phenylalanine (20) was used in the 
aminoacylation assay, indicating that 20 is not a substrate of E. coli TyrRS. This is in 
agreement with the results described in Chapter Three that phenylalanine (20) did not 
incorporate into the test protein His6-PpiB as a substitute for tyrosine (12). TyrRS 
selects tyrosine (12) over phenylalanine (20) by forming hydrogen bonds with the para-
hydroxyl group of 12.89 Therefore, the activation of phenylalanine (20) by E. coli 
TyrRS would only be expected to be extremely slow due to the absence of a phenolic 
hydroxyl group at the para-position. In a previous report,91 the activation of 
phenylalanine (20) by E. coli TyrRS was determined to be five orders of magnitude 
slower than that of tyrosine (12) by the same enzyme, suggesting that 20 is a 
considerably worse substrate for E. coli TyrRS. This activation rate is below the limits 
of detection using the current method. 
 
There was also no reaction with m-nitrotyrosine (41), which suggests that 41 is not 
activated by E. coli TyrRS, or at least the activation rate is not sufficient enough to be 
detected, conforming to the results in Chapter Three that m-nitrotyrosine (41) did not 
incorporate into protein as a substitute for tyrosine (12). As discussed previously, an  
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earlier report described incorporation of m-nitrotyrosine (41) into protein as a 
replacement for tyrosine (12) using a protein expression system similar to that 
employed in Chapter Three, but by substantially increasing the concentrations of m-
nitrotyrosine (41) and E. coli TyrRS.95 However, attempts to apply the same 
methodology in the present study to measure the reaction rate were unsuccessful, due to 
the solubility limit of m-nitrotyrosine (41). Slow activation of m-nitrotyrosine (41) by E. 
coli TyrRS is probably due to the steric constraints from Tyr37 and Gln195 at the active 
site of the enzyme preventing the accommodation of the meta-nitro group,131 as 
discussed before. 
 
A comparison of the catalytic efficiency (kcat/KM) of tyrosine (12) with m-fluorotyrosine 
(39) (Table 4-1) shows that 39 is activated only 2.7% as efficiently as 12 by E. coli 
TyrRS. This ratio correlates with the 2.9% competition efficiency (Table 3-1) observed 
in Chapter Three, indicating that competing for incorporation is essentially a 
competition for the activation by E. coli TyrRS.  
 
m-Fluorotyrosine (39) and o-fluorotyrosine (83) were the only two analogues which 
competed for protein incorporation in Chapter Three. The degree of competition was 
2.3% for o-fluorotyrosine (83), being similar to the 2.7% for m-fluorotyrosine (39). In 
this study, similar kcat values were also obtained for these fluorides (6.5 s!1 and 4.8 s!1 
for 39 and 83, respectively, Table 4-1). This indicates that m-fluorotyrosine (39) and o-
fluorotyrosine (83) probably share similar binding affinities (KM) to E. coli TyrRS, 
which is reasonable because they are isomers and fluorine is a small substituent. More 
discussion will be provided in Chapter Six where KM values are described for m-
fluorotyrosine (39) and o-fluorotyrosine (83). 
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The catalytic efficiency (kcat/KM) of 3,4-dihydroxyphenylalanine (14) with E. coli 
TyrRS is about 0.13% of that of tyrosine (12) (Table 4-1), indicating a likely protein 
incorporation competition efficiency of 0.13%. No competition between 3,4-
dihydroxyphenylalanine (14) and tyrosine (12) was observed in Chapter Three, because 
it was not practical to observe such a low level under the conditions used. Increasing the 
concentration of 3,4-dihydroxyphenylalanine (14) to increase the possibility of protein 
incorporation was not possible due to solubility issues. 
 
In view of the kcat values of the meta-substituted tyrosines 14, 39, 40 and 95, it appears 
that the relative reaction rate decreases in a direct relation to an increase of van der 
Waals radius of the substituent on the aromatic ring of each analogue. The same pattern 
was also observed for the ortho-substituted species (83, 89, 92, 99 and 104). This 
apparent influence of the volume of the ring substituent on reaction rate correlates with 
the previous observation that unusual amino acids with large ring substituents, such as 
m-nitrotyrosine (41), had a relatively lower incorporation level than the derivatives with 
small ring substituents, and suggests that the unusual amino acids that did not 
incorporate into protein may be attributable to inadequate activation rate by aminoacyl-
tRNA synthetase. 
 
 
4.3 Conclusion 
 
This work describes a kinetic study of aminoacylation of tyrosine analogues catalysed 
by E. coli TyrRS. The results clearly show that E. coli TyrRS distinguishes each of the 
analogues and catalyses their reactions at different rates. This study demonstrates that  
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size of the ring substituent of unusual amino acids directly affects the aminoacylation 
reaction rate. 
  
 !
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5.1 Introduction 
 
The work described in Chapters One, Two and Three showed incorporation of a broad 
range of unusual amino acids into the test protein His6-PpiB through bacterial (E. coli) 
wild-type machinery. In this work, those unusual amino acids were used for protein 
synthesis in a eukaryotic protein expression system, to investigate if they can be 
misincorporated into protein via eukaryotic wild-type machinery. Since accumulation of 
proteins modified with unusual amino acids may interfere with the growth and 
reproduction of bacteria,136 the resulting bacteria-specific amino acid derivative(s) 
could be potentially developed as antimicrobial agent(s). 
 
Due to evolutionary pressure, there are differences that exist between the bacterial and 
eukaryotic machineries. For example, at the active site of TyrRS from Bacillus 
stearothermophilus (B. stearo TyrRS), 18 amino acid residues are involved in 
catalysing the formation of the tyrosyl-adenylate intermediate.63,137 However, 4 of those 
18 residues were found not conserved in the corresponding human enzyme.138,139 In B. 
stearo TyrRS the second lysine in the KMSKS motif has been shown to interact with 
the pyrophosphate moiety of the ATP substrate to stabilise the TyrRS-Tyr-ATP and 
TyrRS-[Tyr-ATP] complexes.63,137 However, this second lysine is absent from all 
known eukaryotic TyrRSs’ sequences.63 In human TyrRS this lysine is functionally 
replaced by potassium.63,140 Human TyrRS is potassium-dependent in catalysing the 
activation of tyrosine, while B. stearo TyrRS is not.63 The differences in machinery 
between the two organisms such as these may result in misincorporating different 
unusual amino acids. 
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5.2 Expression of Luciferase 
 
Rabbit Reticulocyte Lysate (RRL) in vitro expression system, which was purchased 
from Promega, was chosen for this investigation as its mammalian environment more 
closely mimics human cells than other eukaryotic protein synthesis systems.50 Since the 
reaction conditions in manufacturer’s protocol (Promega, TB127) are optimized for the 
translation of luciferase mRNA, which was supplied with the system, expression of 
luciferase was then considered as a starting point. 
  
The use of radiolabelled amino acids, such as [35S]methionine, is recommended by the 
manufacturer (Promega, TB127) to detect the translation products. However, this was 
considered unsuitable for the present study, as the objective was to incorporate the 
derivatives of phenylalanine (20) and tyrosine (12) and most of these derivatives were 
not radioactively available. An alternative method for the detection of the translation 
product must be developed and validated. As a technique widely used in detecting 
biological macromolecules, SDS-PAGE was first attempted.  
 
Luciferase was then expressed in accordance to the manufacturer’s protocol (Promega, 
TB127), with slight modifications. In brief, reaction components including the rabbit 
reticulocyte lysate, ribonuclease inhibitor, amino acid mixture containing all natural 
amino acids, and luciferase mRNA, were assembled in a 0.5 mL polypropylene 
microcentrifuge tube, with the reaction volume being adjusted to a total of 50 µL using 
ribonuclease-free water. The assembled mixture was then incubated at 30 °C for 90 
minutes with gentle shaking. A control experiment containing no luciferase mRNA was 
performed in parallel. 
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Figure 5-1. SDS-PAGE analysis of luciferase crude mixture. Lanes: A) no RNA, B) with RNA. 
 
Shown in Figure 5-1 is the SDS-PAGE analysis of the crude luciferase expressed in 
rabbit reticulocyte lysate. It is seen from the gel that the lane of experiment (lane B) 
containing the luciferase mRNA is identical to that of the control experiment (lane A) in 
which no luciferase mRNA transcripts were added. This indicates that either there is no 
production of luciferase (61 kDa141) or the newly synthesised luciferase might not have 
stood out from the background of other proteins in the lysate. Given that nanogram 
amounts of luciferase were expected from the reaction,142 the latter is probably the case. 
 
 
5.3 Introduction of An In Vitro Protein Labelling System 
 
A more sensitive technique was required for the detection of the expressed luciferase. 
Considering the cost of experiment and instrumentation, the FluoroTechTM GreenLys  
in vitro Translation Labelling System was introduced.  
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Figure 5-2. Schematic representation of FluoroTechTM GreenLys tRNA.
142 
 
This labelling system involves the use of a lysine-specific tRNA (tRNALys) pre-charged 
with lysine on which a fluorophore BODIPY-FL is attached at its #-amino group 
(Figure 5-2).142 The fluorophore-labelled lysine is delivered to the growing polypeptide 
chain during translation of genetic code. Since the fluorophore BODIPY-FL has an 
absorbance maximum of 502 nm and an emission maximum of 510 nm,142 the newly 
synthesised luciferase can be detected fluorescently. This technique also allows “in gel” 
detection of protein using a fluorescent gel scanner. The sensitivity of this technique is 
in the range of 0.5!5 ng,142 which was expected to be sufficient for the detection of the 
newly synthesised luciferase.142 
 
The expression of luciferase was repeated with the labelling system, and the resulting 
product mixture was resolved by the conventional SDS-polyacrylamide gel, followed 
by fluorescent gel imaging. 
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Figure 5-3. SDS-PAGE analysis of BODIPY-FL labelled luciferase. Lanes: A) no RNA, B) with RNA.  
a) Fluorescent imaging of the gel excited at 532 nm, b) Coomassie blue stain of the same gel after 
imaging. 
 
Figure 5-3a shows the visualization of SDS-PAGE analysis of the luciferase expressed 
in conjugation with the fluorophore labelling system using a fluorescent gel scanner. 
Two fluorescent protein bands are observed when luciferase mRNA was added in the 
reaction mixture (lane B), with luciferase (61 kDa) present at the higher molecular 
weight. The band at lower molecular weight is presumably from an endogenously 
biotinylated protein,50,142 being likely the %-enolase.143,144 In comparison, no protein 
band near 61 kDa was observed in the control experiment in which no luciferase mRNA 
transcripts were added (lane A). This shows a successful detection of luciferase 
produced in rabbit reticulocyte lysate expression system without the use of radioactive 
amino acids. 
 
Subsequently, an evaluation of background protein expression was conducted, by 
excluding one of the proteinogenic amino acids in reaction mixture. Since an amino  
a)! b)!
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acid mixture minus leucine was supplied with the rabbit expression system, it was 
decided to first express luciferase without exogenous addition of leucine. Fluorescent 
gel (Figure 5-4a) of the product mixture showed that there is not much difference 
between the band obtained without exogenous leucine (lane A) and the one with all 
proteinogenic amino acids externally added (lane B). This suggests a high level of 
background leucine in the lysate, which is not surprising as its concentration is 
estimated to be approximately 5 µM by the manufacturer (Promega). 
 
Efforts were then directed toward reducing the levels of endogenous amino acids to 
inhibit background protein expression. An initial attempt was made by dialysing the 
lysate using a membrane with a molecular weight cut-off of 3,000 Da, at 4 °C for 16 
hours. Luciferase was again expressed with the treated lysate. Components with low 
molecular weight, such as spermidine, ATP, GTP and glucose that might be lost during 
dialysis, were supplemented exogenously. Fluorescent gel showed that the intensity of 
protein band of luciferase had decreased but again not much difference between the two 
bands was observed. Attempted extending the dialysis time to 30 hours to drive the 
dialysis further resulted in a substantial decrease in protein production (Figure 5-4b). 
Loss of components in lysate, such as enzymes in the procedure of dialysis might have 
been responsible for the decrease in yield of luciferase. 
 
To accelerate the progress of dialysis, the lysate was treated with filtration using a 
centrifugal filter unit. Fluorescent gel (Figure 5-4c) showed that background expression 
of luciferase was significantly inhibited (lane A) when the lysate was filtered with 2.0 
mL buffer (5 & 400 µL) at 4 °C. The difference between lane A and lane B was 
considered adequate to draw conclusions on misincorporation of unusual amino acids. 
Results and Discussion: Chapter Five 
 127 
 
 
 
 
 
 
 
 
 
 
Figure 5-4. SDS-PAGE analysis of luciferase expressed with no exogenous leucine. Lanes: A) no Leu 
(9), B) all components.  a) Untreated lysate, b) dialysed lysate, c) filtered lysate. 
 
 
 
 
 
 
 
 
 
 
Figure 5-5. SDS-PAGE analysis of luciferase expressed using filtered lysate with no exogenous Tyr (12) 
or Phe (20). Lanes: A) no Tyr (12), B) no Phe (20), C) all components. 
 
The filtration strategy was subsequently applied to remove the endogenous 
phenylalanine tyrosine (12) and (20) in rabbit reticulocyte lysate. The amino acid  
a)! b)! c)!
A! B! A! B! A! B!
A B C 
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mixtures minus tyrosine (12) and minus phenylalanine (20) were prepared and the 
expression was repeated. Gel analysis (Figure 5-5) showed that the levels of luciferase 
produced when either tyrosine (12) (lane A) or phenylalanine (20) (lane B) was 
externally withheld in the reaction mixture were similar to that of when all proteingenic 
amino acids (lane C) were added in, indicating high concentrations of tyrosine (12) and 
phenylalanine (20) in the lysate, which is in agreement with the manufacturer’s protocol 
(Promega) where 3 µM and 4 µM are recommended for phenylalanine tyrosine (12) and 
(20), respectively. 
 
Also, it may be possible that this high level of background expression was because of 
cross contamination of aromatic amino acids, as the purity of the commercial amino 
acids is around 99%. Purification of tyrosine (12), phenylalanine (20) and tryptophan 
(26) with preparative HPLC was then conducted, and the amino acid mixtures minus 12 
and minus 20 were reprepared. However, the level of background expression was not 
significantly inhibited as an SDS-PAGE analogous to Figure 5-5 was obtained. Other 
attempts, such as increasing the amount of buffer to drive the filtration further, were 
also unsuccessful. 
 
It is apparent that the filtration method, which is effective to remove leucine (9), is 
applicable to neither tyrosine (12) nor phenylalanine (20), although the manufacturer- 
recommended concentrations of these three amino acids in rabbit reticulocyte lysate are 
similar. It is then likely because that the KM values of tyrosine (12) and phenylalanine 
(20) are much lower than that of leucine (9) in eukaryotic organisms and the filtration 
was not sufficient to reduce the concentrations of 12 and 20 to a level where 
background protein expression would significantly be supressed. For example, at  
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30 °C, under similar conditions, the KM of leucine (9) (0.024 mM145) in homo sapiens is 
7.5- and 80-fold greater than that of phenylalanine (20) (0.0032 mM110) and tyrosine 
(12) (0.0003 mM146), respectively. 
 
Decreasing the levels of endogenous amino acids is a prerequisite for the present study 
as otherwise it would be impossible to draw conclusion from the fluorescent gel on 
whether or not the unusual amino acids are misincorporated. It is also a prior 
requirement for other methods such as mass spectrometry, as the competition arising 
from the corresponding usual counterparts would always interfere with the 
characterisation of protein modified with unnatural amino acids. However, in view of 
the difficulties experienced in attempting removal of the endogenous usual amino acids, 
suppression of background protein expression would be expected to be challenging in 
the rabbit reticulocyte lysate system. Protein synthesis using unusual amino acids in 
rabbit reticulocyte lysate in vitro expression system was therefore not pursued further. 
 
 
5.4 Conclusion 
 
This work described an attempt to develop a eukaryotic protein expression system for 
the translational incorporation of the unusual amino acids. Luciferase was expressed in 
rabbit reticulocyte lysate in vitro expression system and was detected “in gel” 
fluorescently. However, due to the difficulties to reduce the concentration of the 
background usual amino acids, it was decided to not pursue this work further.
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6.1 Introduction 
 
As described in Chapter Five, due to the difficulties in reducing the concentration of 
endogenous usual amino acids in rabbit reticulocyte lysate, attempted incorporation of 
unusual amino acids in a eukaryotic protein expression system was unsuccessful. Since 
aminoacyl-tRNA synthetases are a family of enzymes that catalyse aminoacylation of 
tRNA with cognate amino acids, being the principal component assuring fidelity in 
translation of genetic code,55!60,63 investigation of the difference in protein synthesis 
between bacterial and eukaryotic machineries was then attempted by comparing the 
substrate specificities of aminoacyl-tRNA synthetases from the respective systems. 
 
E. coli TyrRS was prepared previously as described in Chapter Four and is a 
representative of the bacterial organism, whereas the choice of human cytosolic TyrRS 
(human TyrRS) as a representative of eukaryotes was made based on the consideration 
that its crystal structure has been reported and that there are structural differences at the 
amino acid active sites of the two enzymes.58,63 
 
There are six amino acid residues conserved (Figure 6-1) at the amino acid active sites 
of E. coli TyrRS and human TyrRS.89,138,139 Four of the conserved amino acids 
participate in binding of the natural substrate tyrosine (6).89,138,139 At the active site of E. 
coli TyrRS one side of the substrate ortho position was shown to project to an open 
area,89 as discussed in Chapter Three (Figure 3-1), while the other side of the 
corresponding position is enclosed with polar side chains (Figure 6-2a): the phenolic 
group of Tyr175, carboxyl group of Asp41, hydroxyl group of Thr76 and carbonyl 
group of Gln179.89 In structural analysis of the active site of human TyrRS (Figure 6- 
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2b), one side of the substrate ortho position was also observed pointing to an empty 
space.138 However, the other side of that position appears to be surrounded mainly by 
hydrophobic side chains: the methyl groups of Ala43 and Ala74, backbone of His77, 
and possibly the phenyl ring of Tyr166.138 
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Figure 6-1. Conserved residues (coloured red) in the active sites of (a) E. coli TyrRS and (b) human 
TyrRS.89,138 Substrate Tyr (12) is coloured blue. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2. (a) Hydrophilic side of the ortho position of E. coli TyrRS,89 (b) hydrophobic side of the 
ortho position of human TyrRS.138 Substrate Tyr (12) is coloured blue. 
a) E. coli TyrRS b) Human TyrRS 
a) E. coli TyrRS b) Human TyrRS 
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These structural differences in the amino acid active sites might be a primary factor in 
human TyrRS catalysing aminoacylation of its natural substrate tyrosine (12) over 20 
times more efficiently than E. coli TyrRS does (kcat/KM of human TyrRS and E. coli 
TyrRS for tyrosine (12) at 30 °C are 4.97 & 106 s!1M!1 and 2.24 & 105 s!1M!1,146,147 
respectively), and therefore, the enzymes might also be expected to display catalytic 
differences towards unusual substrates. 
 
 
6.2 Study of Human TyrRS Using HPLC 
 
Human TyrRS was prepared in accordance to literature,146,148 with a hexahistidine tag 
attached at the N-terminus (human His6-TyrRS) facilitating purification. The gene 
encoding human TyrRS was purchased from Invitrogen, and was reconstructed to 
express the recombinant enzyme human His6-TyrRS. The reconstructed gene was 
expressed using an E. coli star BL21(DE3) cell strain and the resulting enzyme was 
purified using metal affinity chromatography, followed by characterisation with 20% 
SDS-PAGE and mass spectrometry.  
 
It was considered desirable to use the HPLC methodology described in Chapter Four to 
determine the relative aminoacylation rate by human TyrRS for each of the tyrosine 
analogues, as it would allow a direct comparison of substrate specificity between the 
two enzymes. However, a purified tyrosine-specific tRNA (tRNATyr) was required for 
that HPLC method.134 In this case, the purified mammalian tRNATyr is not readily 
available, and because mammalian TyrRSs do not cross-charge with bacterial  
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tRNATyr,147,149 the purified tRNATyr from E. coli used previously is not applicable to the 
reaction catalysed by human TyrRS. 
 
The above obstacles did not prevent an attempt using a mixture of tRNAs from bovine 
liver, which is commercially available. Aminoacylation of tyrosine (12) catalysed by 
human TyrRS was conducted in a procedure following that described in Chapter Four, 
and the rate of aminoacylation was measured by monitoring the amount of AMP in 
aliquots taken every 15 seconds. The concentration of the tRNA mixture used was 
based on an estimation of the pure tRNATyr being approximately 60 µM, which is the 
concentration of bacterial tRNATyr used in Chapter Four, by comparing the AMP 
produced using 60 µM pure tRNATyr in Chapter Four with a series of reactions 
conducted with bovine liver tRNAs. 
 
Analysis of the control experiment (containing no bovine liver tRNA) showed a 
negligible level of AMP throughout the assay, indicating that there was no reaction. The 
presence of the small amount of AMP was presumably due to the hydrolysis of ATP in 
storage, as discussed previously. 
 
HPLC analysis of aliquots taken from the reaction mixture that contained the bovine 
liver tRNA mixture showed formation of a significant amount of AMP for each of the 
aliquots, with the size and height of each peak being comparable to that (Figure 4-3) 
obtained in Chapter Four from the aliquot taken after 90 seconds. This indicates that the 
tRNATyr contained in the bovine liver tRNA mixture used in the present assay is similar 
to that used in Chapter Four. Unfortunately, the AMP level was not accurately 
quantifiable as many other unknown peaks were present interfering with the target  
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AMP peak. Even so, it was still quite clear that the shape of the AMP peak remained 
unchanged throughout the assay, which suggests that the level of AMP did not change 
after the initial 15 seconds when the first aliquot was taken. This is probably because 
the aminoacylation reaction has reached completion before the collection of the first 
sample (15 seconds), which is logical, because as mentioned before, even at 30 °C, the 
catalytic efficiency (kcat/KM) of human TyrRS is over 20 times greater than that of E. 
coli TyrRS.146!147 
 
With such a short reaction time, the concept of detecting AMP would not be practically 
applicable to human TyrRS, even if purified mammalian tRNA were available.  
Reducing the reaction rate by using less enzyme was not optional because the human 
TyrRS had been used at a minimal concentration. Instead an alternative assay was 
developed. 
 
 
6.3 Study of E. coli TyrRS and Human TyrRS Using ITC 
 
As discussed above, at 30 °C, human TyrRS catalyses the reaction of tyrosine (12) more 
efficiently than E. coli TyrRS.146,147 Part of the contribution comes from the binding 
interactions. At that temperature, human TyrRS displays a greater binding affinity 
toward tyrosine (12) than E. coli TyrRS does, with its KM being over 10 times lower 
than that of E. coli TyrRS (at 30 °C, the KM of human TyrRS and E. coli TyrRS with 
tyrosine (12) is 0.0003 mM and 0.0033 mM,146,147 respectively). This shows different  
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substrate specificity between human TyrRS and E. coli TyrRS, and the two enzymes 
may therefore exhibit different binding affinities toward unusual substrates. 
 
Isothermal Titration Calorimetry (ITC) was then used to continue the investigation into 
substrate specificity of E. coli TyrRS and human TyrRS. ITC is a physical technique 
that detects the enthalpy changes ('H) involved in titration.171 It is commonly used for 
the study of binding of small molecules to larger ones, such as the initial binding 
interactions between enzyme and its ligands (Equation 6-1).171 This technique was 
expected to be sensitive enough to detect the 10-fold binding differences between 
human TyrRS and E. coli TyrRS toward tyrosine (12), and may also be applicable to 
tyrosine analogues. 
 
 
 
 
Equation 6-1. Binding equilibrium between the enzyme and the substrate. 
 
 
6.3.1 Interaction of E. coli TyrRS and Human TyrRS with Tyrpsine 
 
E. coli TyrRS was first characterized using ITC. Integration of the titration of 0.05 mM 
E. coli TyrRS with 2.5 mM tyrosine (12) (L-enantiomer) performed at 25 °C using data 
plotting software gave a Ka (binding constant) value of 44,400 M!1 (Figure 6-3). Taking 
the reciprocal of Ka afforded a Kd (dissociation constant) of 0.0225 mM. Although this 
Kd value is different from the KM (30 °C, 0.0033mM), as measured in  
 
Enzyme  + Substrate Enzyme !  Substrate 
Ka 
Kd 
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aminoacylation,147 by a factor of 10, it is in good agreement with the reported Kd value 
of 0.024 mM determined at 4 °C using equilibrium dialysis.90 The differences are likely 
to arise from experimental variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3. ITC of E. coli TyrRS with Tyr (12). 
 
For comparison, titration of E. coli TyrRS (0.05 mM) with the non-cognate amino acid 
phenylalanine (20) (2.5 mM, L-enantiomer) gave only background signals (Figure 6-4), 
indicating that the interactions between phenylalanine (20) and E. coli TyrRS are very  
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weak. Control experiments for both tyrosine (12) and phenylalanine (20), where no E. 
coli TyrRS was used also gave only background signals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4. Titration of E. coli TyrRS with Phe (20). 
 
The human TyrRS was also characterised using ITC. Under identical conditions of the 
assay for E. coli TyrRS, titration of 0.05 mM human TyrRS with 2.5 mM tyrosine (12) 
(L-enantiomer) afforded a Kd of 0.0317 mM (Figure 6-5). Similar to the E. coli TyrRS, 
there is significant variation between the reported KM value of 0.0003 mM, which was 
measured in aminoacylation at 30 °C,146 and the Kd of 0.034 mM as determined using  
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equilibrium dialysis.150 The Kd value obtained in the present study is in agreement with 
the latter. Again, the differences are likely to arise from experimental variables.  
 
Only background signals were obtained for the comparative experiment conducted with 
phenylalanine (20) and for the control experiments where no enzyme was used, for both 
tyrosine (12) and phenylalanine (20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-5. ITC of human TyrRS with Tyr (12). 
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The titration of E. coli TyrRS with tyrosine (12) gave a negative change in entropy 
(Figure 6-3), whereas under identical conditions, study of human TyrRS with the same 
substrate 12 yielded a positive change in entropy (Figure 6-5). This is presumably an 
artifact of the calculation as, in each case, the entropy component is quite minor. 
 
 
6.3.2 Interaction of E. coli TyrRS with Tyrosine Analogues 
 
Having developed the method for the characterisation of E. coli TyrRS and human 
TyrRS, determination of the Kd of tyrosine analogues toward these enzymes was 
attempted. 
 
The Kd values of tyrosine analogues with E. coli TyrRS, determined under the same 
condition as that for tyrosine (12), are given in Table 6-1. The original titration curves 
are included in Appendix III. All substrates were purified by preparative HPLC prior to 
use. Assays were mostly performed at the concentrations of 0.05 mM for E. coli TyrRS 
and 2.5 mM for enantiopure tyrosine analogues, and 5.0 mM for racemic analogues. 
The Kd values of analogues 92 and 99 were determined at 10.0 mM with 0.1 mM E. coli 
TyrRS, as these compounds are soluble at that concentration. For each compound the 
value shown in Table 6-1 is the average obtained from at least two experiments. A 
blank titration for each analogue into the buffer that contained no enzyme was also 
performed in parallel. !!
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Table 6-3. Kd values of Tyr (12) and its analogues with E. coli TyrRS. 
Compounds Kd, mM kcat, s!1 B kcat/Kd, s!1 M!1 
   20 A N.D. N.D. - 
   12 A 0.0225 11.3 5.02 & 105 
14 N.D. 3.3 - 
39 0.216 6.5 2.97 & 104 
83 0.262 4.8 1.85 & 104 
89 0.11 0.89 8.09 & 103 
40 N.D. 0.34 - 
92   0.901 C 0.17 1.89 & 102 
95 N.D. 0.087 - 
99   1.076 C 0.13 1.2 & 102 
41 N.D. N.D. - 
104 N.D. 0.058 - 
 
 N.D. = No detectable interaction. 
 A.    Kd values are from 6.3.1.  
 B.    kcat values are taken from Chapter Four. 
 C.    Titration was conducted with 10.0 mM substrate and 0.1 mM E. coli TyrRS. 
 
It can be seen from Table 6-1 that each tyrosine analogue binds to E. coli TyrRS with 
varying ability. It would only have been expected that tyrosine (12) has the lowest Kd 
among all substrates used in this study as the natural substrate should be highly 
favoured. This correlates with the observation in Chapter Four that tyrosine reaction is 
catalysed by E. coli TyrRS most efficiently. 
 
Results and Discussion: Chapter Six 
! 142 
 
As shown above, the study of E. coli TyrRS with phenylalanine (20) indicates weak 
interactions. The unfavourable binding of phenylalanine (20) by E. coli TyrRS might 
also have been expected, as hydrogen bonding between the para-hydroxyl group of 
tyrosine (12) and TyrRS is one of the two main determinants of biological specificity.91 
E. coli TyrRS discriminates against phenylalanine (20) with a specificity factor of 105 
by simple preferential binding of the para-hydroxyl group of tyrosine (12).91 This 
indicates that the observation in Chapter Four where no reaction occurs for 
phenylalanine (20) with E. coli TyrRS is most likely due to weak binding interactions. 
 
At the amino acid active site of B. stearo TyrRS, the phenolic hydroxyl groups of Tyr34 
and Tyr169 form hydrogen bonds with the phenolic hydroxyl group and $-amino group 
of the ligand tyrosine (12),58,137 respectively. These two residues are conserved in E. coli 
TyrRS (Tyr37 and Tyr175).89 Mutagenesis studies showed that mutation of Tyr34 to 
phenylalanine (20) (Tyr34Phe) increased the KM of tyrosine (12) by only 2-fold while 
with the mutant Tyr169Phe by approximately 500-fold,151 suggesting that the para-
hydroxyl group of the ligand may contribute little to the binding affinity, but is instead 
important to the biological specificity of TyrRS for tyrosine (12) over phenylalanine 
(20). However, the results in this study clearly show that the interactions of E. coli 
TyrRS with phenylalanine (20) are substantially less as compared to those with tyrosine 
(12). Since hydrophilic exclusion is another of the two main determinants of biological 
specificity,152 this specificity is probably because that hydroxyl group makes the 
aromatic ring of tyrosine (12) more hydrophilic than that of phenylalanine (20), thus 
makes more favourable interactions with the hydrophilic active site of E. coli TyrRS. 
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The results with m-nitrotyrosine (41) (Table 6-1) suggest that it does not bind to E. coli 
TyrRS, or the interactions are too weak to be detected by ITC. According to the 
previous discussion it is most likely the latter. The present results provide evidence to 
support that aminoacylation did not occur in Chapter Four is attributable to inadequate 
interactions between m-nitrotyrosine (41) and E. coli TyrRS.  
 
As discussed before, due most likely to poor activation of m-nitrotyrosine (41) by E. 
coli TyrRS, as seen in Chapter Four, protein synthesis using m-nitrotyrosine (41) to 
replace tyrosine (12) was not observed in Chapter Three. However, by considerably 
increasing the concentrations of m-nitrotyrosine (41) and E. coli TyrRS, incorporation 
of m-nitrotyrosine (41) into protein as a substitute for tyrosine (12) using a protein 
expression system similar to that used in Chapter Three was described in an earlier 
report.95 Again, attempts to apply the same methodology in the present study were 
unsuccessful, due to the same reason as that in Chapter Four, the solubility limit of m-
nitrotyrosine (41) was reached. Also, an attempted increase in the concentration of the 
E. coli TyrRS was unsuccessful as precipitation of the enzyme always occurred during 
titration. 
 
In combination with the kcat values obtained in Chapter Four, the kcat/Kd of m-
fluorotyrosine (39) is found to be 5.9% of that of tyrosine (12), (Table 6-1) which is 
comparable to the competition efficiency observed in Chapter Three (2.9%, Table 3-1) 
and to the ratio of catalytic efficiency (kcat/KM) relative to tyrosine (12) obtained in 
Chapter Four (2.7% Table 4-1). A similar trend is also seen for o-fluorotyrosine (83), 
where the ratio of kcat/Kd relative to that of tyrosine (12) (3.7%, Table 6-1) is 
comparable to its competition efficiency against 12 (2.3%, Table 3-1). These data  
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provide further evidence to support the hypothesis that competing for protein 
incorporation is essentially a competition for activation by aminoacyl-tRNA synthetase, 
as discussed previously. 
 
The results with 2,4-dihydroxyphenylalanine (89), o-chlorotyrosine (92) and o-
methyltyrosine (99) suggest strong binding interactions between each of the compounds 
and E. coli TyrRS, which is consistent with the results in Chapter Four where 
aminoacylation reactions occurred for all these analogues. In Chapter Three, the 
competition against tyrosine (12) was not observed for either 89, 92 or 99. A collective 
analysis of the results obtained in the present study and that from Chapter Four suggests 
that it is most likely due to their competition efficiencies being below the detection limit 
of the method in Chapter Three. For example, the kcat/Kd of o-methyltyrosine (99) is 
found to be only 0.024% of that of tyrosine (12) (Table 6-1), indicating a likely 
competition efficiency of 0.024%, which is not practical to be detected. This may also 
apply to the compounds m-chlorotyrosine (40), m-methyltyrosine (95) and o-
nitrotyrosine (104), as the ratios of their kcat/Kd values (Table 6-1) relative to tyrosine 
(12) (Table 6-1) are lower than that of o-methyltyrosine (99), therefore indicating a 
lower chance of being detected. 
 
The Kd values of the ortho-substituted tyrosine derivatives 83, 89, 92 and 99 display 
detectable levels of binding interactions with E. coli TyrRS, which is consistent with the 
results in Chapter Four where aminoacylation occurred for each of them. By 
comparison, attempted determination of Kd of most of the meta-substituted species 14, 
40 and 95 was unsuccessful. This is likely associated with the volume of the active site 
of E. coli TyrRS. As discussed previously, one side of the ortho-position is observed  
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opening to an empty space (Figure 3-1), therefore being able to accommodate most of 
the ortho ring substituents, whereas there is steric hindrance at the meta-position 
coming from Tyr37 and Gln195 limiting the accommodation of meta-substituents. This 
suggests that the influence of the size of ring substituents on the aminoacylation rate, 
which was discussed in Chapter Four, is probably determined through initial binding 
interactions between the enzyme and ligand. 
 
The larger the substituent, the weaker the binding interactions would be expected to be, 
as it would involve more unfavourable steric repulsion.152 For example, it appears that 
the Kd values of the ortho-substituted tyrosine analogues 83, 92, 99 and 104 increase in 
a direct relation to an increase of van der Waals radius of the ring substituent (Table 6-
1). Also, due to the large volume of the nitro group, the binding interactions between o-
nitrotyrosine (104) and E. coli TyrRS are too weak to be detected although it was 
demonstrated in Chapter Three that at the active site of E. coli TyrRS the space near one 
of the ortho-positions is sufficient to accommodate a nitro group. However, 2,4-
dihydroxyphenylalalanine (89) exhibits greater binding affinity with the enzyme than o-
fluorotyrosine (83) (Table 6-1), despite the van der Waals radius of a hydroxyl group 
being larger than that of fluorine. This may be attributed to the hydrophilic property of 
one side of the ortho position at the active site of E. coli TyrRS (Figure 6-2), as it may 
be able to stabilise the enzyme-ligand complex by forming hydrogen bonds with the 
ortho-hydroxyl group of 89. 
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6.3.3 Interaction of Human TyrRS with Tyrosine Analogues 
 
The Kd values of tyrosine analogues with human TyrRS, determined under the same 
conditions as for E. coli TyrRS, are given in Table 6-2. The original titration curves are 
provided in Appendix III. 
 
Table 6-4. Kd values of Tyr (12) and its analogues with human TyrRS. 
Compounds Kd, mM 
   20 A N.D. 
   12 A 0.0317 
14 N.D. 
39   1.32 B  
83 0.14 
89   1.47 C 
40 N.D. 
92   0.71 C 
95 N.D. 
99   0.93 C 
41 N.D. 
104 N.D. 
 
 N.D. = Not detectable 
 A.    Kd values are taken from 6.3.1. 
 B.    Titration was conducted with 7.0 mM substrate and 0.15 mM human TyrRS. 
 C.    Titration was conducted with 10.0 mM substrate with 0.1 mM human TyrRS. 
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The varying Kd values obtained (Table 6-2) demonstrate different abilities of tyrosine 
analogues to bind to human TyrRS. Again, it would only have been expected that 
tyrosine (12) has the lowest Kd among all substrates tested as the cognate amino acid 
should be highly favoured. 
 
As with E. coli TyrRS, the ortho-substituted tyrosine derivatives 83, 89, 92 and 99 
display detectable levels of interactions with human TyrRS, which may be associated 
with the large space near one side of the ortho-position (Figure 6-2b). Attempted 
determination of Kd of the meta-substituted species 14, 40, 95 and 41 with human 
TyrRS was unsuccessful, conforming to the observation that the space near the meta-
position (Figure 6-2b) in the amino acid active site of human TyrRS is limited. 
 
From a collective analysis of Table 6-1 and Table 6-2 it is clear that E. coli TyrRS and 
human TyrRS display a similar manner of interaction to most of the unusual amino 
acids, as they showed an analogous degree of binding affinity to each tyrosine analogue. 
However, m-fluorotyrosine (39) and 2,4-dihydroxyphenylalanine (89) are exceptions, 
exhibiting a preferential binding to the bacterial enzyme. Initial titrations of human 
TyrRS with m-fluorotyrosine (39) and 2,4-dihydroxyphenylalanine (89) under the same 
conditions as for E. coli TyrRS gave only background signal (Figure III-6 and Figure 
III-9 in Appendix III, respectively), which was then improved by optimising the 
concentrations of enzyme and the two ligands (Figure III-7 and Figure III-10 in 
Appendix III, respectively), to measure a 6- and 13-fold greater Kd for 39 and 89 (Table 
6-2) respectively, than E. coli TyrRS. 
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Several experiments were conducted to preclude any external factors that could lead to 
this mode of selectivity. E. coli TyrRS and human TyrRS were re-titrated with the 
cognate amino acid tyrosine (12), and were found to be as active as when they were just 
prepared. This excludes the possibility of enzyme drying out during storage. The 
basicity of the buffer used for titration was carefully measured, and the pH was found to 
be constant to a variation of ± 0.12 throughout the assay, ruling out the chance of 
enzyme being denatured or deactivated by changing of the pH of buffer. Apart from 
these, the results were also successfully reproduced with freshly prepared E. coli TyrRS 
and human TyrRS. 
 
It is unlikely that the relatively weaker binding interaction of m-fluorotyrosine (39) with 
human TyrRS than that with E. coli TyrRS is due to a steric factor, given the fact that 
fluorine is similar in size to hydrogen.111,112 It is possible that the substantially decreased 
pKa value of the phenolic hydroxyl group (the pKa values of the para-hydroxyl group of 
tyrosine (12) and m-fluorotyrosine (39) are 10.05 and 8.54,173 respectively), resulting 
from fluorine at the meta-position, is responsible, as it may affect the hydrogen bond 
interactions more with human TyrRS than it does with E. coli TyrRS, as demonstrated 
in a similar system.153 
 
Alternatively, it may be associated with the pKa change of the carboxyl group of m-
fluorotyrosine (39),173 also a result of fluorine substitution. In the amino acid active site 
of E. coli TyrRS there is no covalent interaction with the carboxyl group of tyrosine 
(12),89 whereas in human TyrRS the carboxyl group of Glu188 interacts with the 
carboxyl group of tyrosine (12) via hydrogen bonds.138 A decrease in pKa of the 
carboxyl group of the ligand would not be expected to affect the binding interactions  
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between m-fluorotyrosine (39) and E. coli TyrRS but it may impair the binding to 
human TyrRS. 
 
The crystal structure of E. coli TyrRS (Figure 3-1) showed that one side of the ligand 
ortho-position projects to an empty space, and the other ortho-position is enclosed with 
side chains of polar amino acids, being hydrophilic. Although cell-free experiments 
showed that large ring-substituents, such as a nitro group, are likely to be 
accommodated on the empty side, binding interaction assays in this study suggested that 
the hydrophilic side is probably the one that accepted the ortho-hydroxyl group of 2,4-
dihydroxyphenylalanine (89), as it may provide additional hydrogen bond interactions 
to stabilise the enzyme-ligand complex, as discussed before. By comparison, at the 
amino acid active site of human TyrRS, one side of the ortho-position points to an 
empty space while the other is enclosed by hydrophobic side chains (Figure 6-2b). 
There would be no non-covalent bonds expected to interact with the ortho-hydroxyl 
group of 2,4-dihydroxyphenylalanine (89). It therefore seems likely that the preferential 
binding of E. coli TyrRS with regards to human TyrRS by 2,4-dihydroxyphenylalanine 
(89) is attributable to the stabilising force provided by the hydrophilic side of ortho-
position in the amino acid active site of the bacterial enzyme. 
 
 
6.4 Conclusion 
 
Work described in this study involved the development of a suitable method for 
characterization of E. coli TyrRS and human TyrRS, followed by an investigation of  
 
Results and Discussion: Chapter Six 
! 150 
 
initial binding interactions between tyrosine analogues and E. coli TyrRS, and human 
TyrRS. 
 
The study of E. coli TyrRS clarifies the mechanism that E. coli TyrRS uses to recognise 
the unusual substrates. Also, two tyrosine analogues were found exhibiting greater 
binding affinities to the enzyme from the bacterial organism than that from human. 
Although the difference in binding affinities is not sufficient for a drug, it shows that 
selectivity is possible. More importantly, these compounds are leads for structural 
modification to generate more compounds that selectively bind to the bacterial 
organism and a new generation of antibiotic(s) may then be discovered.
 !
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Conclusions 
 
The work described in this thesis shows inherent substrate promiscuity of aminoacyl-
tRNA synthetases, from both bacterial and eukaryotic organisms.  
 
The PheRS and the TyrRS from bacterial (E. coli) are promiscuous, as they can activate 
a broad range of structural analogues of phenylalanine (Chapter Two) and tyrosine 
(Chapter Three) and subsequently charge them onto the cognate tRNA for protein 
expression. However, most of the structural analogues are not incorporated in the 
presence of their corresponding natural counterpart, as the reaction rate of 
aminoacylation is significantly decreased by the substituent on the phenyl ring of 
substrate (Chapter Four). The TyrRS from the human cytosol is also promiscuous, as it 
selectively binds the analogues of tyrosine (Chapter Six).  
 
This work also describes a development of a methodology for drug discovery. By 
comparing the substrate specificities of aminoacyl-tRNA synthetase (TyrRS) from both 
bacterial (E. coli) and eukaryotic (human cytosol) organisms through the use of cell-free 
protein synthesis and ITC techniques, two organic compounds were found having the 
potential to be lead structures for chemical alteration for development of antimicrobial 
agents. 
 
Three avenues for the continuation of this work would seem to be worthwhile. It would 
be valuable to investigate the antimicrobial effect of the two resulting bacteria-specific 
compounds. Another logical continuation would be to use these two organic compounds 
as structural leads for chemical modification. A third would be to apply the 
methodology developed in this thesis, from E. coli cell-free synthesis to ITC assay, to  
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aminoacyl-tRNA synthetases other than TyrRS. LeuRS and MetRS, for example, are 
worthwhile to attempt as many analogues of these amino acids are known to incorporate 
into proteins via bacterial (E. coli) wild-type machinery but studies with eukaryotic 
organism have not been conducted. 
 !
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I General  
 
1H nuclear magnetic resonance (NMR) spectra were recorded on either a Varian 
MR400 spectrometer operating at 400 MHz or a Varian Mercury 300 spectrometer 
operating at 300 MHz. They were determined in chloroform-D (99.8% D), DMSO-D6 
(99.9% D), acetone-D6 (99.9% D), methanol-D4 (99.8% D) or D2O (99.8% D), which 
were purchased from Cambridge Isotope Laboratories Inc. or Sigma-Aldrich Co. The 
peak of the residual solvent was used as reference.154 The characteristics of the spectra 
are expressed in the text as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet of doublet. Chemical shifts (() are reported in parts per million 
(ppm) and coupling constants (J) are reported in Hertz (Hz). 
 
13C nuclear magnetic resonance (NMR) spectra were recorded on either a Varian 
MR400 spectrometer operating at 100 MHz or a Varian Mercury 300 spectrometer 
operating at 75 MHz. The peak of the residual solvent was used as reference, except 
D2O in which 3-(trimethylsilyl)-3,3,2,2-tetradeuteropropionic acid sodium salt-D4 
(TSPA) was used as an external reference. 
 
Melting points were measured using a Kofler hot-stage melting point apparatus under a 
Riechert microscope and are uncorrected.  
 
Microanalyses were conducted using a Eurovector EA3000 Elemental Analyser by the 
Australian National University Microanalytical Service, Canberra. 
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Electrospray ionisation (ESI) mass spectra were recorded using a Micromass VG 
AutoSpec M mass spectrometer and are reported as mass-to-charge ratio (m/z). Mass 
spectra of biological macromolecules were recorded on an Agilent 1100 series LC/MSD 
TOF instrument and are reported in Daltons (Da) after reconstruction. 
 
Gene sequencing was conducted using the ABI 3730 Genetic Analyser in conjunction 
with BigDye 3.1 at The Australian National University, Canberra. Aspergillus melleus 
Acylase I was purchased from Sigma-Aldrich Co. Fluorescent gel imaging was 
conducted using a Gel Documentation System with UV Transilluminator 
(UVT254/312) running on UVIProMW, operating at 312 nm with a filter of viewing 
dimension of 21 & 21 cm (8.27" & 8.27") detecting at 560 nm. 
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II E. coli Cell-free Protein Synthesis 
 
Structural analogues of tyrosine (12), phenylalanine (20) and tryptophan (26), and 
chemicals for synthesis were purchased from Sigma-Aldrich Co., PepTech Co., Alfa 
Aesar, Manchester Organics, Matrix Scientific, Oakwood Products and Toronto 
Research Chemicals. 
 
T7 RNA polymerase was purchased from New England BioLabs® Inc. Spectra/Por® 
dialysis membrane (#2, MWCO: 12-14 000) was purchased from Spectrum 
Laboratories Inc. Mini-PROTEAN® Tetra Electrophoresis System, acrylamide, 
bis-acrylamide, SDS-PAGE molecular weight standards and Bio-Safe® Coomassie Blue 
were purchased from Bio-Rad. HisGraviTrap® Kit was purchased from GE Healthcare. 
Amicon Ultracel YM-3 membrane microcon centrifugal filter devices were purchased 
from Millipore. 
 
All protein synthesis experiments were conducted on His6-PpiB. The amino acid 
sequence of His6-PpiB is:155 
 
MHHHHHHMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR 
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS 
ATAQFFINVV DNDFLNFSGE SLQGWGYCVF AEVVDGMDVV DKIKGVATGR 
SGMHQDVPKE   DVIIESVTVS  EN 
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II. A Preparation of the E. coli S30 Extract 
 
The E. coli S30 extract was prepared from E. coli star BL21(DE3) by following a 
protocol established earlier.39 It was prepared in 20 litres cell culture, which resulted in 
approximately 100 mL of the concentrated extract. The E. coli S30 extract was 
distributed into 1.5 mL Eppendorf tubes, with 1.0 mL each aliquot, which were snap 
frozen using liquid nitrogen and stored at !80°C. It has been shown that the E. coli S30 
extract can be stored for two years without significant decrease in activity for protein 
synthesis. For those aliquots that have been stored for three years, a reduction of 20% in 
the yield of the product protein, as compared to that of using the freshly prepared E. coli 
S30 extract, may be seen in some cases. This was observed form the present work. 
 
 
II. B Preparation of the Gene Encoding His6-PpiB 
 
The plasmid DNA in vector pND1098 encoding His6-PpiB with expression under 
control of the phage T7 promoter was a kind gift from Professor Nick Dixon at the 
University of Wollongong, and was transformed into the E. coli DH5$ for 
amplification. The plasmid DNA was isolated using Qiagen® Maxi or Mega kits. The 
concentration of the DNA was measured using a NanoDrop 1000 spectrophotometer.  
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II. C E. coli Cell-free Reaction Assembly 
 
The E. coli cell-free protein synthesis was conducted by following a procedure, as 
described in earlier reports,42,92,156!158 with the exception that the amino acid L-alanine 
and RNasin were not used and that T7 RNA polymerase was added to the reaction as a 
substitute for the plasmid DNA encoding for the polymerase itself.  
 
The apparatus for the cell-free reaction is constituted of two containers, with one being 
planted within another and separated by the Spectra/Por® dialysis membrane. The inner 
reaction mixture, with a total volume of 0.5 mL, contains all cellular components 
required for protein translation such as the E. coli S30 extract, expression vector and T7 
RNA polymerase, where the outer mixture that is with a volume of 5.0 mL includes 
biochemicals such as ATP, folinic acid and cyclic AMP.  
 
The natural amino acids were used at 1.0 mM (L-enantiomer). The unnatural amino 
acids were used at 2.0 mM (L-enantiomer) and the corresponding natural amino acid 
was not added.  
 
The reactions were proceeded for 6 h at 30°C, with shaking at 200 rpm, unless 
otherwise stated. 
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II. D Protein Analysis 
 
The crude contents of the inner reaction was analysed by SDS-PAGE containing 20% 
acrylamide, to confirm the production of soluble protein. 
 
The inner reaction contents were then purified using the HisGraviTrap® Kit following 
the native conditions recommended by the manufacturer,172 and the resulting elution 
fraction was concentrated using Amicon Ultra-4 (YM-3, 000) centrifugal filter devices. 
Protein concentrations were measured using a NanoDrop ND-1000 spectrophotometer. 
 
The mass of the protein produced was confirmed by the Agilent 1100 series LC/MSD 
TOF instrument (direct injection) operating a positive ionization mode, with the liquid 
chromatography running a mobile phase of a 50:50 (v/v) solution of 0.1% formic acid 
in acetonitrile: 0.1% aqueous formic acid, after purification. The mass spectra were 
recorded and then deconvoluted using the Agilent TOF Protein Confirmation Software. 
All mass spectra for His6-PpiB presented in this thesis were those after deconvolution. 
 
 
II. E Competitive Experiments 
 
The competitive experiments between unnatural amino acids and their corresponding 
natural counterparts were conducted in a manner similar to that used for usual cell-free 
protein synthesis. The concentrations of the natural amino acid and the corresponding 
structural analogues were used at 0.2 mM and 2.0 mM respectively. The concentrations 
are those of the L-enantiomers. The levels of unnatural amino acid incorporation in  
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competitive experiments were concluded from the mass spectra. The competition 
efficiencies were calculated based on the ratio of the concentrations between the natural 
amino acid and its corresponding competitor, and the level of unnatural amino acid 
incorporation (Equation 2-1). 
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III Aminoacylation Assay 
 
The ammonium phosphate, tetrabutylammonium phosphate in methanol and E. coli 
tRNATyr were purchased from Sigma-Aldrich Co.  
 
 
III. A Preparation of the E. coli His6-TyrRS 
 
The gene in pND706 vector encoding the E. coli TyrRS was kindly provided by Dr Xu 
in the Dixon group at the University of Wollongong. It was transformed into the E. coli 
AN1459 for amplification and was isolated using Qiagen® Mini kit following 
procedures recommended by the manufacturer. The gene encoding the E. coli TyrRS 
was then cloned in pETMCSIII vector within the Ndel-HindIII sites to generate the 
plasmid pET-TyrRS-His. The sequence of pET-TyrRS-His was confirmed using ABI 
3730 Genetic Analyser operating in conjunction with BigDye 3.1.  
 
The E. coli TyrRS with a polyhistidine tag at the C-terminus (E. coli His6-TyrRS) was 
overproduced from pET-TyrRS-His in E. coli BL21 (DE3) by following procedures 
described in earlier reports.90,91,132,135 The resulting enzyme was purified using 
HisGraviTrap® Kit following the conditions recommended by the manufacturer, and 
was concentrated using Amicon Ultra-4 (YM-3, 000) centrifugal filter devices. The 
enzyme concentration was measured using a NanoDrop ND 1000 spectrophotometer.  
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The amino acid sequence of E. coli His6-TyrRS is:89 
 
MHHHHHHMAS SNLIKQLQER GLVAQVTDEE ALAERLAQGP IALYCGFDPT 
ADSLHLGHLV PLLCLKRFQQ AGHKPVALVG GATGLIGDPS FKAAERKLNT 
EETVQEWVDK IRKQVAPFLD FDCGENSAIA ANNYDWFGNM NVLTFLRDIG 
KHFSVNQMIN KEAVKQRLNR EDQGISFTEF SYNLLQGYDF ACLNKQYGVV 
LQIGGSDQWG NITSGIDLTR RLHQNQVFGL TVPLITKADG TKFGKTEGGA 
VWLDPKKTSP YKFYQFWINT ADADVYRFLK FFTFMSIEEI NALEEEDKNS 
GKAPRAQYVL AEQVTRLVHG EEGLQAAKRI TECLFSGSLS ALSEADFEQL 
AQDGVPMVEM EKGADLMQAL VDSELQPSRG QARKTIASNA ITINGEKQSD 
PEYFFKEEDR   LFGRFTLLRR  GKKNYCLICW  K 
 
The prepared enzyme was analysed by SDS-PAGE containing 20% acrylamide:  
 
 
 
 
 
 
 
 
 
 
From the SDS-PAGE analysis it is apparent that the E. coli His6-TyrRS is of high 
purity. 
 
Marker!
42.7 kDa!
55.6 kDa!
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The enzyme was also analysed by the Agilent 1100 series LC/MSD TOF instrument 
(direct injection) operating a positive ionization mode:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass reconstruction of  +TOF MS: 0.068 to 0.321 min from Sample 2 (ZQW Ecoli) of 040214ZQW.wiff A... Max. 4.6e4 cps.
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The molecular weight of E. coli His6-TyrRS estimated by the Expert Protein Analysis 
System (ExPASy) is 48481.0 Da. The single dominating peak at 48476.3048 Da is 
different from this estimated value by 4.7 Da, which gives an error of 0.0097%. The 
peak at 96952.4786 Da is presumably the structural dimer of E. coli His6-TyrRS. 
 
 
III. B Reaction Assembly 
 
The aminoacylation was conducted based on previous work.134 Stock solutions were 
prepared in Tris-HCl buffer containing 100.0 mM Tris, 15.0 mM MgCl2, 40.0 mM KCl 
and 1.0 mM DTT, at pH7.6. 
 
The reaction was performed at 37 °C in a 0.5 mL microcentrifuge, with a total volume 
of 60 µL containing 0.05 or 0.15 µM E. coli His6-TyrRS, 1.0 mM ATP, 16.7 or 60.0 µM 
tRNATyr, and 0.1 mg/mL bovine serum albumin (BSA). After pre-incubation for one 
minute, the reaction was initiated by adding in the E. coli His6-TyrRS. A 10 µL sample 
was taken out by hand from the proceeding reaction every 15 or 40 seconds and 
quenched into 5.0 µL 0.3% (w/v) aqueous sodium dodecylsulfate (SDS). The SDS-
treated samples were either immediately analysed by HPLC or stored at -20 °C for later 
analysis. In the latter case, the storage was never longer than 12 hours. 
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III. C HPLC Analysis 
 
The aliquots taken from the reaction mixture were analysed using Agilent Hewlett 
Packard series 1100 separation system operating on Chemstation, in conjugation with 
the Alltech Alltima HP C18 5 mM (4.6 x 250 mm) column attached with an Alltech 
Allguard HP C18 guard cartridge, at a flow rate of 1.0 mL/min. The solvent system 
used for analysis was as follows:  
 
Time, min Buffer A, % Buffer B, % 
0 87 13 
18 87 13 
19 70 30 
23 70 30 
24 87 13 
 
In this solvent system, Buffer A contains 60.0 mM ammonium phosphate and 5.0 mM 
tetrabutylammonium phosphate, at pH5.0, while Buffer B contains 5.0 mM 
tetrabutylammonium phosphate in methanol. Both buffers were filtered and degased 
before use. 
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IV ITC Assay 
 
IV. A Preparation of the Human His6-TyrRS 
 
The gene in pMK vector encoding human TyrRS was purchased from Invitrogen. The 
gene in pETMCSIII vector encoding human His6-TyrRS was constructed in a manner 
similar to that used for the E. coli His6-TyrRS. The human His6-TyrRS was expressed 
from the gene using E. coli BL21 star (DE3) following procedures reported 
before.138,146 The resulting enzyme was purified with HisGraviTrap® Kit following the 
conditions recommended by the manufacturer, and was concentrated using Amicon 
Ultra-4 (YM-3, 000) centrifugal filter devices. The concentration of the enzyme was 
measured using a NanoDrop ND 1000 spectrophotometer.  
 
The amino acid sequence of human His6-TyrRS is: 
 
MHHHHHHMGD APSPEEKLHL ITRNLQEVLG EEKLKEILKE RELKIYWGTA 
TTGKPHVAYF VPMSKIADFL KAGCEVTILF ADLHAYLDNM KAPWELLELR 
VSYYENVIKA MLESIGVPLE KLKFIKGTDY QLSKEYTLDV YRLSSVVTQH 
DSKKAGAEVV KQVEHPLLSG LLYPGLQALD EEYLKVDAQF GGIDQRKIFT 
FAEKYLPALG YSKRVHLMNP MVPGLTGSKM SSSEEESKID LLDRKEDVKK 
KLKKAFCEPG NVENNGVLSF IKHVLFPLKS EFVILRDEKW GGNKTYTAYV 
DLEKDFAAEV VHPGDLKNSV EVALNKLLDP IREKFNTPAL KKLASAAYPD 
PSKQKPMAKG PAKNSEPEEV IPSRLDIRVG KIITVEKHPD ADSLYVEKID 
VGEAEPRTVV SGLVQFVPKE ELQDRLVVVL CNLKPQKMRG VESQGMLLCA 
SIEGINRQVE PLDPPAGSAP GEHVFVKGYE KGQPDEELKP KKKVFEKLQA 
DFKISEECIA   QWKQTNFMTK  LGSISCKSLK  GGNIS 
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The prepared enzyme was analysed by SDS-PAGE containing 20% acrylamide:  
 
 
 
 
 
 
 
 
 
 
The SDS-PAGE analysis shows that the enzyme is present between 55.6 and 66 kDa, 
which is in agreement with the literature in which a value of 58 kDa was reported.138 It 
is apparent from the SDS-PAGE that human His6-TyrRS was obtained at high purity. 
 
 
 
 
 
 
 
 
 
 
 
Marker!
42.7 kDa!
55.6 kDa!
66 kDa!
Experimental 
 167 
 
The enzyme was also analysed by the Agilent 1100 series LC/MSD TOF instrument 
(direct injection) operating a positive ionization mode:  
 
 
 
 
 
 
 
 
 
 
 
 
The molecular weight of human His6-TyrRS estimated by the Expert Protein Analysis 
System (ExPASy) is 60097.5 Da. There is a 8.6 Da difference between this estimated 
value and the dominating peak at 60088.8756 Da in the mass spectrum, giving an error 
of 0.014%. 
 
 
IV. B Reaction Assembly 
 
Stock solutions were prepared in Tris-HCl buffer containing 40.0 mM Tris, 0.8 mM 
magnesium chloride and 3.2 mM potassium chloride, at pH 7.6.  
 
Mass reconstruction of  +TOF MS: 0.046 to 0.336 min from Sample 1 (ZQW Human) of 040214ZQW.wiff... Max. 1.7e5 cps.
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Isothermal titration calorimetry (ITC) was conducted using a MicroCal VP-ITC 
MicroCalorimeter operating on VPViewer software. The enzyme and the substrate that 
were prepared in tris buffer and degased using ThermoVac, were loaded into the cell 
and the injection syringe respectively, as instructed by the manufacturer’s protocol.  
 
All assays were performed at 25 °C, by injecting 6 µL in 12 seconds, with a space of 
200 seconds, except for the first injection where a volume of 3 µL was made with an 
initial delay of 120 seconds. The heat generated from dilution was measured by titrating 
the substrate into buffer that involved no enzyme. 
 
 
IV. C Data Process 
 
The results of the titration for all substrates were recorded and then processed using 
Origin 7 software. The curve fitting was conducted with the Origin v setting to be 1.0, 
as E. coli TyrRS in solution binds only one mole of tyrosine or one mole of tyrosyl-
adenylate per mole of enzyme dimer, as reported previously.90 The heat of dilution was 
subtracted from the titration data before curve fitting. 
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V. Synthesis 
 
1-Dimethylaminomethylazulene (43): 
 
 
 
 
1-Dimethylaminomethylazulene (43) was prepared from azulene (42) by the method of 
Moroder.102 To an ice-cooled solution of azulene (0.99 g, 0.0077 mol) in 
dichloromethane (20.0 mL), a solution of para-formaldehyde (0.111 g, 0.0037 mol) and 
N,N,N’,N’-tetramethyldiaminomethane (0.395 g, 0.0039 mol) in 8.0 mL glacial acetic 
acid that had been heated until a clear solution persisted and was subsequently cooled to 
0 °C, was added dropwise while the temperature was kept at 0 °C. The resultant mixture 
was stirred on ice for 30 minutes, followed by 90 minutes at room temperature. Then 
water (40.0 mL) was added, followed by 5% HCl (20.0 mL), and the mixture was 
washed with dichloromethane (3 & 30 mL). The combined organic layers were extracted 
with water (3 & 30 mL). The aqueous layers were combined, adjusted to pH 12.0 using 
2.0 M aqueous sodium hydroxide, extracted with diethyl ether (3 & 30 mL). The 
combined ether extracts were washed with water (3 & 10 mL), dried (sodium sulphate) 
and concentrated, giving 1-dimethylaminomethylazulene (43) as a blue oil. 
 
Yield 0.898 g, 62%; 
 
1H NMR (CDCl3, (): 8.49 (d, J = 9.6 Hz, 1H, Ar H3), 8.30 (d, J = 9.2 Hz, 1H, Ar H7), 
7.88 (d, J = 4 Hz, 1H, Ar H9), 7.58 (dd, 1H, J = 10.4, 10 Hz, Ar H5), 7.35 (d, J = 4 Hz,  
N
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1H, Ar H10), 7.17 (dd, J = 9.6, 10 Hz, 1H, Ar H4), 7.13 (dd, J = 9.6, 10 Hz, 1H, Ar H6), 
3.91 (s, 2H, !CH2), and 2.28 (s, 6H, !N(CH3)2); 
 
Mass Spectrum (ESI): m/z 186 ([M + H]+) (100%). 
 
The spectral properties of this compound were identical with those previously reported 
for 1-dimethylaminomethylazulene (43).102 
 
 
1-Azulenylmethyltrimethylammonium iodide (44): 
 
 
 
 
 
1-Azulenylmethyltrimethylammonium iodide (44) was prepared from 1-
dimethylaminomethylazulene (43) by the method of Moroder.102 To a solution of 1-
dimethylaminomethylazulene (43) (0.887 g, 0.0048 mol) in dry ethanol (20.0 mL), 
methyl iodide (0.683 g, 0.0048 mol) was added. The resulting mixture was cooled to 
4 °C and maintained at this temperature during stirring overnight. The blue precipitate 
formed was collected and dried to give 1-azulenylmethyltrimethylammonium iodide 
(44) as a blue solid. 
 
Yield 1.67g, 83%; 
 
N
I
44!
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1H NMR (CD3OD, (): 8.78 (d, J = 9.6 Hz, 1H, Ar H3), 8.57 (d, J = 10 Hz, 1H, Ar H7), 
8.10 (d, J = 4 Hz, 1H, Ar H9), 7.87 (dd, J = 9.6, 10 Hz, 1H, Ar H5), 7.53 (dd, J = 9.6, 
9.6 Hz, 1H, Ar H4), 7.51 (d, J = 4 Hz, 1H, Ar H10), 7.47 (dd, J = 10, 9.6 Hz, 1H, Ar 
H6), 5.09 (s, 2H, !CH2), and 3.15 (s, 9H, !N(CH3)3);  
 
Mass Spectrum (ESI): m/z 200 (M+) (100%). 
 
The spectral properties of this compound were identical with those previously reported 
for 1-azulenylmethyltrimethylammonium iodide (44).102 
 
 
Diethyl acetamido-(1-azulenylmethyl)malonate (45): 
 
 
 
 
 
Diethyl acetamido-(1-azulenylmethyl)malonate (45) was prepared from 1-
azulenylmethyltrimethylammonium iodide (44) by the method of Moroder.102 To a 
solution of metallic sodium (0.35 g, 0.0152 mol) in dry ethanol (40.0 mL), diethyl 
acetaminomalonate (3.26 g, 0.015 mol) was added and stirred for 15 minutes. To the 
resultant mixture, 1-azulenylmethyltrimethylammonium iodide (44) (1.32 g, 0.004 mol) 
was added and refluxed for three hours. The reaction mixture was diluted with water 
(150.0 mL), adjusted to pH 7.0 using 2.0 M aqueous hydrochloric acid and extracted 
with diethyl ether (3 & 60 mL). The combined ether extracts were washed with water (3 
& 60 mL), dried (sodium sulphate) and concentrated, yielding a blue slurry which was  
 
HN
O
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O
O
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recrystallized from dichloromethane and ethyl acetate to give diethyl acetamido-(1-
azulenylmethyl)malonate (45) as a blue solid.  
 
Yield 1.21 g, 85%; 
 
1H NMR (CDCl3, (): 8.13 (d, J = 9.2 Hz, 1H, Ar H7), 8.15 (d, J = 9.6 Hz, 1H, Ar H3), 
7.49 (broad absorption, 1H, unresolved), 7.48 (dd, J = 9.8 Hz, 1H, unresolved), 7.23 (d, 
J = 4 Hz, 1H, Ar H10), 7.05 (d, J = 9.6 Hz, 1H, Ar H6), 7.04 (dd, J = 10, 9.6 Hz, 1H, 
Ar H6), 6.4 (broad absorption, 1H, !CNH), 4.19 (m, 4H, (!OCH2CH3)2), 4.08 (s, 2H, 
!CCH2), 1.86 (s, 3H, !(C=O)CH3), and 1.18 (m, 6H, (!OCH2CH3)2); 
 
Mass Spectrum (EI): m/z M+ 357 (60). 
 
The spectral properties of this compound were identical with those previously reported 
for diethyl acetamido-(1-azulenylmethyl)malonate (45).102 
 
 
Acetamino-(1-azulenylmethyl)malonic acid (46): 
 
 
 
 
 
Acetamino-(1-azulenylmethyl)malonic acid (46) was prepared from diethyl acetamido-
(1-azulenylmethyl)malonate (45) by the method of Moroder.102 To a solution of diethyl 
acetamido-(1-azulenylmethyl)malonate (45) (1.2 g, 0.0034 mol) in ethanol (27.0 mL), 
20% aqueous potassium hydroxide (27.0 mL) was added. The resultant mixture was  
HN
OH
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refluxed for three hours, diluted with water (120.0 mL), acidified to pH 2.0 using 2.0 M 
aqueous hydrochloric acid and extracted with diethyl ether (3 & 60 mL). The combined 
ether extracts were washed with brine (3 & 60 mL), dried (sodium sulphate) and 
concentrated to give acetamino-(1-azulenylmethyl)malonic acid (46) as a blue solid, 
which was used on next step without further purification. 
 
Yield 0.94 g, 91%; 
 
1H NMR (CD3OD, (): 8.26 (d, J = 10 Hz, 2H, Ar H3 and H7), 7.67 (d, J = 4 Hz, 1H, Ar 
H9), 7.57 (t, J = 10 Hz, 1H, Ar H5), 7.29 (d, J = 4 Hz, 1H, Ar H10), 7.12 (t, J = 9.6 Hz, 
2H, Ar H4), 7.11 (t, J = 9.6 Hz, 2H, Ar H6), 4.10 (s, 2H, !CCH2), and 1.90 (s, 3H, 
!(C=O)CH3); 
 
Mass Spectrum (ESI): m/z 300 ([M ! 1]-) (100%). 
 
The spectral properties of this compound were identical with those previously reported 
for acetamino-(1-azulenylmethyl)malonic acid (46).102 
 
 
$-Acetamido-%-(1-azulenyl)propanoic  acid (47): 
 
 
 
 
 
$-Acetamido-%-(1-azulenyl)propanoic  acid (47) was prepared from acetamino-(1-
azulenylmethyl)malonic acid (46) by the method of Moroder.102 To a solution of  
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acetamino-(1-azulenylmethyl)malonic acid (46) (0.83 g, 0.0028 mol) in tetrahydrofuran 
(12.0 mL), 0.2 M aqueous hydrochloric acid (60.0 mL) was added. The resultant 
mixture was heated under reflux for 8 hours, then cooled and extracted with diethyl 
ether (3 & 20 mL). The combined ether extracts were washed with water (3 & 20 mL), 
dried (sodium sulphate) and concentrated. The residue was recrystallized from diethyl 
ether to give $-acetamido-%-(1-azulenyl)propanoic  acid (47) as blue powder.  
 
Yield 0.211 g, 29%; 
 
1H NMR (CD3OD, (): 8.34 (d, J = 9.6 Hz, 1H, Ar H3), 8.26 (d, J = 9.6 Hz, 1H, Ar H7), 
7.78 (d, J = 4 Hz, 1H, Ar H9), 7.58 (t, J = 9.6 Hz, 1H, Ar H5), 7.30 (d, J = 4 Hz, 1H, Ar 
H10), 7.15 (t, J = 9.6 Hz, 1H, Ar H6), 7.11 (t, J = 9.6 Hz, 1H, Ar H4), 4.79 (dd, J = 8, 
5.6 Hz, 1H, !CH2CH), 3.67 (dd, J = 5.6, 14.4 Hz, 1H, !CHHCH), 3.48 (dd, J = 8, 14.4 
Hz, 1H, !CHHCH), and 1.86 (s, 3H, !(C=O)CH3); 
 
Mass Spectrum (ESI): m/z 256 ([M ! 1]-) (100%). 
 
The spectral properties of this compound were identical with those previously reported 
for $-acetamido-%-(1-azulenyl)propanoic  acid (47).102 
 
 
%-(1-Azulenyl)-L-alanine (35): 
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%-(1-Azulenyl)-L-alanine (35) was prepared from $-acetamido-%-(1-azulenyl)propanoic  
acid (47) by the method of Moroder.102 To a solution of $-acetamido-%-(1-
azulenyl)propanoic  acid (47) (0.199 g, 0.0008 mol) in 0.1 M phosphate buffer (15.0 
mL, pH 7.5), 4.0 M aqueous potassium hydroxide (4.0 mL) was added, followed by 
Acylase I from Aspergillus melleus (0.13 g). The resultant mixture was incubated for 18 
hours at 37 °C, then filtered through membrane (Amicon Ultra-4, YM-3, 000). The 
filtrate was acidified to pH 2.5 using 1.0 M aqueous hydrochloric acid, washed with 
diethyl ether (3 & 5 mL), neutralized to pH 7.0 using 1.0 M aqueous  sodium hydroxide, 
concentrated, and was recrystallized from water to give %-(1-azulenyl)-L-alanine (35) as 
a blue solid. 
 
Yield 0.067 g, 39%; 
 
1H NMR (D2O, (): 8.43 (d, J = 9.6 Hz, 2H, Ar H3 and H7), 7.85 (d, J = 4 Hz, 1H, Ar 
H9), 7.72 (t, J = 9.6 Hz, 1H, Ar H5), 7.43 (d, J = 10 Hz, 1H, Ar H10), 7.29 (t, J = 9.6 
Hz, 1H, Ar H6), 7.25 (t, J = 9.6 Hz, 1H, Ar H4), 4.06 (dd, J = 7.2, 5.2 Hz, 1H, 
!CH2CH), 3.74 (dd, J = 15.2, 5.2 Hz, 1H, !CHHCH), and 3.58 (dd, J = 15.2, 8 Hz, 1H, 
!CHHCH); 
 
Mass Spectrum (ESI): m/z 216 ([M + H]+) (100%). 
 
The spectral properties of this compound were identical with those previously reported 
for %-(1-azulenyl)-alanine (35).102 
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Diethyl 2-acetamido-2-(3,5-dimethoxybenzyl)malonate (61): 
 
 
 
 
 
Diethyl 2-acetamido-2-(3,5-dimethoxybenzyl)malonate (61) was prepared from 3,5-
dimethoxybenzyl bromide (60) by the method of Warne.113 To a solution of metallic 
sodium (0.624 g, 0.0271 mol) in dry ethanol (40.0 mL), diethyl acetaminomalonate 
(2.82 g, 0.013 mol) was added. The resultant mixture was stirred at room temperature 
for 30 minutes, mixed with 3,5-dimethoxybenzyl bromide (60) (3.0 g, 0.013 mol), 
heated under reflux for 1.5 hours, concentrated and extracted with ethyl acetate (3 & 15 
mL). The combined acetate extracts were washed with saturated brine, dried (sodium 
sulfate), filtered and concentrated, yielding a residue which was recrystallized from 
ethyl acetate and hexane to give diethyl 2-acetamido-2-(3,5-dimethoxybenzyl)malonate 
(61) as a white solid. 
 
Yield 1.138 g, 81%; 
 
mp 113.3!114.9 °C (lit.113 mp 114 °C); 
 
1H NMR (CDCl3, (): 6.59 (s, 1H, !NH), 6.32!6.13 (m, 3H, Ar H), 4.27!4.24 (m, 4H, 
(!OCH2CH3)2), 3.71 (s, 6H, (!OCH3)2), 3.56 (s, 2H, !CCH2), 2.02 (s, 3H, 
!(C=O)CH3), and 1.28 (t, J = 7.2 Hz, 6H, (!OCH2CH3)2); 
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Found: C, 58.85; H, 6.99; N, 3.91. C18H25NO7 requires C, 58.85; H, 6.86; N, 3.81%. 
 
The spectral properties of this compound were identical with those previously reported 
for diethyl 2-acetamido-2-(3,5-dimethoxybenzyl)malonate (61).114 
 
 
3,5-Dimethoxy-DL-phenylalanine (62): 
 
 
 
 
3,5-Dimethoxy-DL-phenylalanine (62) was prepared from diethyl 2-acetamido-2-(3,5-
dimethoxybenzyl)malonate (61) by the method of Warne.113 A solution of 2-acetamido-
2-(3,5-dimethoxybenzyl)malonate (61) (1.0 g, 0.0027 mol) in 37% aqueous 
hydrochloric acid (10.0 mL) and acetic acid (10.0 mL) was heated under reflux for 1.5 
hours and then concentrated. Recrystallization of the residue from ethanol gave 3,5-
dimethoxy-DL-phenylalanine (62) as a white solid. 
 
Yield 0.57 g, 93%; 
 
mp 227.8!231.2 °C; 
 
1H NMR (CD3OD, (): 6.44!6.38 (m, 3H, Ar H), 4.23 (m, 1H, !CH2CH), 3.74 (s, 6H, 
(!OCH3)2), and 3.21!3.08 (m, 2H, !CH2CH); 
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Found: C, 50.45; H, 6.25; N, 5.30. C11H16NO4Cl requires C, 50.48; H, 6.16; N, 5.35%. 
 
 
3,5-Dihydroxy-DL-phenylalanine (63): 
 
 
 
 
3,5-Dihydroxy-DL-phenylalanine (63) was prepared from 3,5-dimethoxy-DL-
phenylalanine (62) by the method reported previously.114,116 A solution of 3,5-
dimethoxy-DL-phenylalanine (62) (0.5 g, 0.0022 mol) in 62% aqueous hydrobromic 
acid (11.5 mL) and acetic acid (7.0 mL) was heated in a sealed tube at 150 °C for two 
hours. The mixture was diluted with water (10.0 mL), decolorized with charcoal and 
concentrated, affording a light brown residue which was recrystallized from ethanol to 
gave 3,5-dihydroxy-DL-phenylalanine (63) as a white solid. 
 
Yield 0.28 g, 63%; 
 
mp 307.4!309.6 °C decomp. (lit.116 mp 312 °C decomp.); 
 
1H NMR (D2O, (): 6.32!6.31 (m, 3H, Ar H), 4.28 (dd, J = 6.0, 5.2 Hz, 1H, !CH2CH), 
3.20 (dd, J = 14.4, 8 Hz, 1H, !CHHCH), and 3.01 (dd, J = 14.4, 6 Hz, 1H, !CHHCH); 
 
Found: C, 54.47; H, 6.02; N, 6.98. C9H11NO4 requires C, 54.82; H, 5.62; N, 7.10%. 
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3,5-Dimethylbenzyl bromide (65): 
 
 
 
 
3,5-Dimethylbenzyl bromide (65) was prepared from mesitylene (64) by the method of 
Dailey.115 The choice of $,$,$-trifluorotoluene instead of carbon tetrachloride as the 
solvent for bromination is for environmental reasons and is based on the work of 
Golding.159 
 
To a solution of mesitylene (64) (2.0 g, 0.017 mol) in anhydrous $,$,$-trifluorotoluene 
(30.0 mL), N-bromosuccinimide (2.94 g, 0.017) and azobisisobutyronitrile (0.09 g, 
0.00055 mol) were added. The resultant mixture was heated under reflux for one hour, 
then filtered and concentrated, yielding a residue which was purified with 
chromatography from chloroform and hexane to give 3,5-dimethylbenzyl bromide (65) 
as a pale yellow semi-solid at room temperature (lit.160 mp 37.5!38 °C). 
 
Yield 1.72 g, 52%; 
 
1H NMR (CDCl3, (): 7.07 (s, 2H, Ar H), 6.99 (s, 1H, Ar H), 4.49 (s, 2H, !CH2Br), and 
2.37 (s, 6H, (!CH3)2). 
 
The spectral properties of this compound were identical with those previously reported 
for 3,5-dimethyllbenzyl bromide (65).161 
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Diethyl 2-acetamido-2-(3,5-dimethylbenzyl)malonate (66): 
 
 
 
 
 
Diethyl 2-acetamido-2-(3,5-dimethylbenzyl)malonate (66) was prepared from 3,5-
dimethyllbenzyl bromide (65) by the method used for alkylation of 3,5-
dimethoxybenzyl bromide (60).113 A solution of metallic sodium (0.17 g, 0.0075 mol) 
and diethyl acetaminomalonate (1.627 g, 0.0075 mol) in dry ethanol (20.0 mL) was 
stirred at room temperature for 15 minutes. To the resultant mixture, 3,5-
dimethyllbenzyl bromide (65) (1.5 g, 0.0075 mol) was added, followed by heating 
under reflux for three hours, and filtered. Then water (70.0 mL) was added to the filtrate, 
affording a separation of an oil which crystallized upon cooling, giving diethyl 2-
acetamido-2-(3,5-dimethylbenzyl)malonate (66) as white powder. 
 
Yield 2.51 g, 55%; 
 
mp 149.6!152.3 °C (lit.115 mp 149!150 °C); 
 
1H NMR (CDCl3, (): 6.85 (s, 1H, !CNH), 6.59 (s, 2H, Ar H), 6.54 (s, 1H, Ar H), 4.25 
(q, J = 7.2 Hz, 4H, (!OCH2CH3)2), 3.55 (s, 2H, !CCH2), 2.23 (s, 6H, (!CH3)2), 2.01 (s, 
3H, !(C=O)CH3), and 1.28 (t, J = 7.2 Hz, 6H, (!OCH2CH3)2); 
 
Found: C, 64.57; H, 7.70; N, 4.31. C18H25NO5 requires C, 64.46; H, 7.51; N, 4.18%. 
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3,5-Dimethyl-DL-phenylalanine (67): 
 
 
 
 
3,5-Dimethyl-DL-phenylalanine (67) was prepared from diethyl 2-acetamido-2-(3,5-
dimethylbenzyl)malonate (66) by the method of Dailey.115 A suspension of diethyl 2-
acetamido-2-(3,5-dimethylbenzyl)malonate (66) (0.5 g, 0.0015 mol) in 37% aqueous 
hydrochloric acid (6.0 mL) was heated under reflux for eight hours and then filtered. 
The filtrate was diluted with water (25.0 mL), concentrated and cooled in an ice-bath, 
giving 3,5-dimethyl-DL-phenylalanine (67) as colourless crystals.  
 
Yield 0.81 g, 87%; 
 
mp 224.1!231.1 °C decomp. (lit. 229!231 °C115 and 212!214 °C175); 
 
1H NMR (D2O, (): 6.84 (s, 1H, Ar H), 6.79 (s, 2H, Ar H), 3.35!3.31 (m, 1H, !CH2CH), 
2.83!2.57 (m, 2H, !CH2CH), and 2.15 (s, 6H, (!CH3)2); 
 
Found: C, 57.48; H, 7.10; N, 6.01. C11H16NO2Cl requires C, 57.52; H, 7.02; N, 6.10%. 
 
The spectral properties of this compound were identical with those previously reported 
for 3,5-dimethyl-DL-phenylalanine (67).162 
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3-Bromomethyl-5-methylanisole (69): 
 
 
 
 
3-Bromomethyl-5-methylanisole (69) was prepared from 3,5-dimethylanisole (68) by 
the method of Bickelhaupt.118 The choice of solvent for bromination was based on the 
work of Golding.159 
 
To a solution of 3,5-dimethylanisole (68) (2.0 g, 0.015 mol) and N-bromosuccinimide 
(2.655 g, 0.015 mol) in $,$,$-trifluorotoluene (160.0 mL) and water (1.32 g, 0.073 mol), 
benzoyl peroxide (0.363 g, 0.01 mol) was added. The resultant mixture was heated 
under reflux for one hour, then filtered. The filtrate was washed with 3.0 M aqueous 
hydrochloric acid (3 & 50 mL), saturated sodium bicarbonate (3 & 50 mL), water (3 & 50 
mL), brine (3 & 50 mL), and then dried (sodium sulphate) and concentrated, yielding a 
residue which, upon purification with chromatography from dichloromethane and 
hexane, gave 3-bromomethyl-5-methylanisole (69) as a semi-solid at room temperature 
(lit.163 mp 38 °C). 
 
Yield 2.64 g, 82%; 
 
1H NMR (CDCl3, (): 6.68!6.57 (m, 3H, Ar H), 4.46 (s, 2H, !CH2Br), 3.82 (s, 3H, 
!OCH3), and 2.42 (s, 3H, !CH3); 
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The spectral properties of this compound were identical with those previously reported 
for 3-bromomethyl-5-methylanisole (69).163,164 
 
 
Diethyl 2-acetamido-2-(3-methoxy-5-methylbenzyl)malonate (70): 
 
 
 
 
 
Diethyl 2-acetamido-2-(3-methoxy-5-methylbenzyl)malonate (70) was prepared from 
3-bromomethyl-5-methylanisole (69) by the method used for the preparation of diethyl 
2-acetamido-2-(3,5-dimethoxybenzyl)malonate (61) from 3,5-dimethoxybenzyl 
bromide (60), as described in an earlier report.113 To a solution of metallic sodium 
(0.235 g, 0.01 mol) in dry ethanol (20.0 mL), diethyl acetaminomalonate (2.17 g, 0.01 
mol) was added. The resultant mixture was stirred at room temperature for 30 minutes, 
mixed with 3-bromomethyl-5-methylanisole (69)  (2.0 g, 0.0093 mol), heated under 
reflux for two hours, concentrated and extracted with ethyl acetate (3 & 5 mL). The 
combined extracts were washed with saturated brine, dried (sodium sulfate), filtered and 
concentrated, yielding a residue which was recrystallized from ethyl acetate and hexane 
to give diethyl 2-acetamido-2-(3-methoxy-5-methylbenzyl)malonate (70) as a white 
solid. 
 
Yield 2.42 g, 74% yield; 
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mp 109.0!110.1 °C; 
 
1H NMR (CDCl3, (): 6.56 (s, 2H, Ar H), 6.38 (s, 1H, Ar H), 6.32 (s, 1H, !NH), 4.26 (q, 
J = 7.2 Hz, 4H, (!OCH2CH3)2), 3.70 (s, 3H, !OCH3), 3.54 (s, 2H, !CCH2), 2.23 (s, 3H, 
!CH3), 1.98 (s, 3H, !(C=O)CH3), and 1.26 (t, J = 7.2 Hz, 6H, (!OCH2CH3)2); 
 
13C NMR (CDCl3, (): 169.0 (!NHC=O), 167.5 (!(C=O)OEt), 159.5 (Ar C3), 139.1 (Ar 
C5), 136.5 (Ar C1), 123.2 (Ar C6), 113.3 (Ar C2), 112.7 (Ar C4), 67.2 (!CNH), 62.6 
(!OCH2), 55.0 (!OCH3), 37.8 (Ar!CH2), 23.0 (!(C=O)CH3), 21.5 (Ar!CH3), and 14.0 
(!CH3); 
 
Mass Spectrum (ESI): m/z 352.4 ([M + H]+) (100%); 
 
Found: C, 61.31; H, 7.17; N, 4.12. C18H25NO6 requires C, 61.53; H, 7.17; N, 3.99%. 
 
 
3-Hydroxy-5-methyl-DL-phenylalanine (71): 
 
 
 
 
3-Hydroxy-5-methyl-DL-phenylalanine (71) was prepared from diethyl 2-acetamido-2-
(3,5-dimethoxybenzyl)malonate (70) by the method used for the hydrolysis of 3,5-
dimethoxyphenylalanine (62).113 A solution of diethyl 2-acetamido-2-(3,5-
dimethoxybenzyl)malonate (70) (2.0 g, 0.0057 mol) in 62% aqueous hydrobromic acid  
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(11.5 mL) and acetic acid (7.0 mL) was heated in a sealed tube at 150 °C for two hours. 
The mixture was diluted with water (10.0 mL), decolorized with charcoal and 
concentrated, affording a residue which was recrystallized from water and ethanol to 
gave 3-hydroxy-5-methyl-DL-phenylalanine (71) as a white solid.  
 
Yield 0.89 g, 80%; 
 
mp 250.0!253.8 °C; 
 
1H NMR (D2O, (): 6.23!6.17 (m, 3H, Ar H), 3.32 (m, 1H, !CH2CH), 2.77-2.43 (m, 2H, 
!CH2CH), and 2.06 (s, 3H, !CH3); 
 
13C NMR (D2O, (): 182.7 (!(C=O)OH), 166.2 (Ar C3), 157.9 (Ar C5), 139.8 (Ar C1), 
117.4 (Ar C6), 116.8 (Ar C4), 116.4 (Ar C2), 57.3 (!CH), 41.0 (!CH2), and 20.4 
(!CH3); 
 
Mass Spectrum (ESI): m/z 196.3 ([M + H]+) (100%); 
 
Found: C, 61.87; H, 6.96; N, 7.26. C10H13NO3 requires C, 61.53; H, 6.71; N, 7.17%. 
 
 
2-Fluoro-4-methoxybenzoyl chloride (78): 
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2-Fluoro-4-methoxybenzoyl chloride (78) was prepared from 2-fluoro-4-
methoxybenzoic acid (77) by the method of Bennett and Niemann.121 A solution of 2-
fluoro-4-methoxybenzoic acid (77) (5.0 g, 0.029 mol) in thionyl chloride (7.0 mL) was 
heated under reflux overnight. The mixture was concentrated, and the resultant residue 
was recrystallized from petroleum to give 2-fluoro-4-methoxybenzoyl chloride (78) as 
colourless crystals. 
 
Yield 5.25g, 95%; 
 
mp 39.9!41.2 °C (lit.121 mp 37!40 °C); 
 
1H NMR (CDCl3, (): 8.05 (m, 1H, Ar H), 6.77 (m, 1H, Ar H), 6.64 (m, 1H, Ar H), and 
3.88 (s, 3H, !OCH3); 
 
The spectral properties of this compound were identical with those previously reported 
for 2-fluoro-4-methoxybenzoyl chloride (78).165 
 
 
2-Fluoro-4-methoxybenzyl alcohol (79): 
 
 
 
 
2-Fluoro-4-methoxybenzyl alcohol (79) was prepared from 2-fluoro-4-methoxybenzoyl 
chloride (78) by the method of Bennett and Niemann.121 To an ice-cooled solution of 2- 
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fluoro-4-methoxybenzoyl chloride (78) (5.0 g, 0.0266 mol) in anhydrous diethyl ether 
(20.0 mL), 0.5 M lithium aluminium hydride in dry diethyl ether was added dropwise 
while the temperature was kept at 0 °C. The mixture was stirred at room temperature for 
20 minutes. Then water (5.0 mL) was added dropwise. The resultant mixture was 
poured onto ice water in 5% sulfuric acid. The ether phase was collected and the 
aqueous phase was extracted with diethyl ether (2 & 10 mL). The combined ether 
extracts were washed with water until neutral, dried (sodium sulphate) and concentrated, 
giving the crude product mixture as light green liquid.  
 
It was shown by 1H NMR to be the major component of the crude product mixture. The 
crude product mixture was used on the next reaction without further purification, as 
described in literature.121 
 
 
2-Fluoro-4-methoxybenzyl chloride (80): 
 
 
 
 
2-Fluoro-4-methoxybenzyl chloride (80) was prepared from 2-fluoro-4-methoxybenzyl 
alcohol (79) by the method of Bennett and Niemann.121 A solution of the crude product 
mixture of 2-fluoro-4-methoxybenzyl alcohol (79) in thionyl chloride (25.0 mL) was 
stirred at room temperature overnight and then warmed at 95 °C for one hour. The 
mixture was concentrated and purified using chromatography from petroleum to give 2-
fluoro-4-methoxybenzyl chloride (80) as a white solid. 
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The total yield of the reactions over two steps, from 2-fluoro-4-methoxybenzoyl 
chloride (78) to 2-fluoro-4-methoxybenzyl alcohol (79), and to 2-fluoro-4-
methoxybenzyl chloride (80) is 3.7 g, 80%. 
 
1H NMR (CDCl3, (): 7.08 (m, 1H, Ar H), 6.47 (m, 1H, Ar H), 6.42 (m, 1H, Ar H), 4.38 
(s, 2H, !CH2Cl), and 3.56 (s, 3H, !OCH3); 
 
Found: C, 54.96; H, 4.61. C8H8ClFO requires C, 55.03; H, 4.62%. 
 
 
Diethyl 2-acetamido-2-(2-fluoro-4-methoxybenzyl)malonate (81): 
 
 
 
 
 
Diethyl 2-acetamido-2-(2-fluoro-4-methoxybenzyl)malonate (81) was prepared from 2-
fluoro-4-methoxybenzyl chloride (80) by the method of Bennett and Niemann.121 To a 
solution of metallic sodium (0.51 g, 0.022 mol) in dry ethanol (40.0 mL), diethyl 
acetaminomalonate (4.78 g, 0.022 mol) was added. The resultant mixture was stirred at 
room temperature for 30 minutes, mixed with 2-fluoro-4-methoxybenzyl chloride (80) 
(3.5 g, 0.02 mol), heated under reflux for four hours, concentrated and extracted with 
ethyl acetate (3 & 10 mL). The combined extracts were washed with saturated brine, 
dried (sodium sulfate), filtered and concentrated, yielding a residue which was  
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recrystallized from ethyl acetate and hexane to give diethyl 2-acetamido-2-(2-fluoro-4-
methoxybenzyl)malonate (81) as a white solid. 
 
Yield  7.83 g, 69%; 
 
mp 117.3!119.4 °C (lit. 120!121.5 °C121 and 122!124 °C123); 
 
1H NMR (CDCl3, (): 6.89 (m, 1H, Ar H), 6.58!6.49 (m, 3H, Ar H and !CNH), 4.28 (m, 
4H, (!OCH2CH3)2), 3.73 (s, 3H, !OCH3), 3.60 (s, 2H, !CCH2), 1.96 (s, 3H, 
!(C=O)CH3), and 1.27 (t, J = 7.2 Hz, 6H, (!OCH2CH3)2); 
 
Found: C, 57.47; H, 6.11; N, 3.88. C17H22O6NF requires C, 57.46; H, 6.24; N, 3.94%. 
 
 
N-acetyl-2-fluoro-4-methoxyphenylalanine (82) 
 
 
 
 
N-acetyl-2-fluoro-4-methoxyphenylalanine (82) was prepared from diethyl 2-
acetamido-2-(2-fluoro-4-methoxybenzyl)malonate (81) by the method of Bennett and 
Niemann.121 A suspension of diethyl 2-acetamido-2-(2-fluoro-4-
methoxybenzyl)malonate (81) (2.0 g, 0.0056 mol) in 2.5 M aqueous sodium hydroxide 
(10.0 mL) was heated under reflux for six hours. Then 5.0 M aqueous hydrochloric acid 
(10.0 mL) was added and the mixture was heated under reflux for additional two hours,  
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affording, after standing at 4 °C overnight, precipitate which was recrystallized from 
ethanol to give N-acetyl-2-fluoro-4-methoxyphenylalanine (82) as colourless crystals. 
 
Yield 1.15 g, 80%; 
 
mp 168.2!171.3 °C (lit.121 mp 169.5!171.5 °C); 
 
1H NMR (D2O, (): 7.13 (m, 1H, Ar H), 6.66 (m, 2H, Ar H), 4.40 (dd, J = 4.8, 4.4 Hz, 
1H, !CH2CH), 3.16 (dd, J = 14.0, 4.4 Hz, 1H, !CHHCH), 2.81 (dd, J=14.0, 8.8 Hz, 
1H, !CHHCH), and 1.87 (s, 3H, !(C=O)CH3); 
 
Found: C, 56.26; H, 5.58; N, 5.34. C12H14O4NF requires C, 56.47; H, 5.53; N, 5.49%.  
 
 
o-Fluoro-DL-tyrosine (83): 
 
 
 
 
o-Fluoro-DL-tyrosine (83) was prepared from N-acetyl-2-fluoro-4-
methoxyphenylalanine (82) by the method used for the preparation of 3,5-
dihydroxylphenylalanine (63) from 3,5-dimethoxy-DL-phenylalanine (62).113 A solution 
of N-acetyl-2-fluoro-4-methoxyphenylalanine (82) (1.0 g, 0.0039 mol) in 62% aqueous 
hydrobromic acid (11.5 mL) and acetic acid (7.0 mL) was heated in a sealed tube at 150 
°C for two hours. The mixture was diluted with water (10.0 mL), decolorized with  
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charcoal and concentrated, affording a residue which was recrystallized from water and 
ethanol to give o-fluoro-DL-tyrosine (83) as a white solid. 
 
Yield 0.5 g, 64%; 
 
mp 265.9!270.4 °C decomp. (lit. 280!285 °C decomp.121 and 293!294 °C decomp.123); 
 
1H NMR (D2O, (): 7.00 (m, 1H, Ar H), 6.44 (m, 2H, Ar H), 3.53 (m, 1H, !CH2CH), 
2.95 (m, 1H, !CHHCH), and 2.79 (m, 1H, !CHHCH); 
 
Found: C, 53.89; H, 5.22; N, 6.83. C9H10O3NF requires C, 54.27; H, 5.06; N, 7.03%. 
 
The spectral properties of this compound were identical with those previously reported 
for o-fluoro-DL-tyrosine (83).166 
 
 
2,4-Dimethoxybenzaldehyde (85): 
 
 
 
 
 
2,4-Dimethoxybenzaldehyde (85) was prepared from 2,4-dihydroxybenzaldehyde (84) 
by the method of Vaya.122 To a solution of 2,4-dihydroxybenzaldehyde (84) (2.0 g, 
0.0145 mol) and cesium carbonate (14.1 g, 0.0435 mol) in dry dimethylformamide  
O
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(200.0 mL), methyl iodide (12.4 g, 0.087 mol) was added dropwise. The resultant 
mixture was heated under reflux for two hours, then cooled and filtered. The filtrate was 
concentrated, redissolved in dichloromethane (60.0 mL), washed with water (3 & 20 
mL), dried (sodium sulphate) and concentrated to yield a residue which was purified 
with chromatography from ethyl acetate and hexane to give 2,4-
dimethoxybenzaldehyde (85) as a white solid. 
 
Yield 2.29g, 95%; 
 
mp 70.2!70.8 °C (lit.116 mp 70!71 °C); 
 
1H NMR (CDCl3, (): 10.25 (s, 1H, !(C=O)H), 7.78 (d, J = 12 Hz, 1H, Ar H), 6.52 (dd, 
J = 12, 2.8 Hz, 1H, Ar H), 6.41 (d, J = 2.8 Hz, 1H, Ar H), 3.86 (s, 3H, !OCH3), and 
3.84 (s, 3H, !OCH3); 
 
The spectral properties of this compound were identical with those previously reported 
for 2,4-dimethoxybenzaldehyde (85).167 
 
 
4-(2,4-Dimethoxybenzyldiene)-2-phenyl-5-oxazolone (86): 
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4-(2,4-Dimethoxybenzyldiene)-2-phenyl-5-oxazolone (86) was prepared from 2,4-
dimethoxybenzaldehyde (85) by the method of Lambooy.116 A suspension of 2,4-
dimethoxybenzaldehyde (85) (2.0 g, 0.012 mol), benzoylaminoethanoic acid (2.59 g, 
0.014 mol) and sodium acetate (1.48 g, 0.018 mol) in dry acetic anhydride (10.0 mL) 
was heated under reflux for one hour, then concentrated to yield a yellow residue which 
was suspended in water (10.0 mL) and permitted to stand overnight. The precipitate was 
recrystallized from ethanol to give 4-(2,4-dimethoxybenzyldiene)-2-phenyl-5-
oxazolone (86) as a yellow solid. 
 
Yield 3.23 g, 87%; 
 
mp 163.1!180.9 °C (lit.116 173!178 °C); 
 
1H NMR (CDCl3, (): 8.9 (d, J = 11.2 Hz, 1H, !C=CH), 8.16 (m, 2H, Ar H), 7.79 (s, 1H, 
Ar H), 7.57 (m, 3H, Ar H), 6.66 (dd, J = 11.2, 3.2 Hz, 1H, Ar H), 6.43 (d, J = 3.2 Hz, 
1H, Ar H), and 3.89 (s, 6H, (!OCH3)2);  
 
The spectral properties of this compound were identical with those previously reported 
for 4-(2,4-dimethoxybenzyldiene)-2-phenyl-5-oxazolone (86).168 
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2-Benzamido-3-(2,4-dimethoxyphenyl)-acrylic acid (87) 
 
 
 
 
 
2-Benzamido-3-(2,4-dimethoxyphenyl)-acrylic acid (87) was prepared from 4-(2,4-
dimethoxybenzyldiene)-2-phenyl-5-oxazolone (86) by the method of Lambooy.116 To a 
solution of 4-(2,4-dimethoxybenzyldiene)-2-phenyl-5-oxazolone (86) (2.0 g, 0.0065 
mol) in ethanol (30.0 mL) that had been heated to 90 °C, 0.5 M aqueous sodium 
hydroxide (17.0 mL) was added dropwise. The mixture was held at 90 °C for two hours, 
then cooled, acidified with 0.5 M aqueous hydrochloric acid and kept at 0 °C overnight, 
affording precipitate which was recrystallized from water and ethanol to give 2-
benzamido-3-(2,4-dimethoxyphenyl)-acrylic acid (87) as colourless needles. 
 
Yield 1.99 g, 94%; 
 
mp 210.3!213.4 °C decomp. (lit.116 229!230 °C); 
 
1H NMR (CD3OD, (): 7.97 (m, 3H, Ar H and !C=CH), 7.68 (d, J = 8.4 Hz, 1H, Ar H), 
7.60!7.52 (m, 3H, Ar H), 6.59 (d, J = 2.0 Hz, 1H, Ar H), 6.51 (dd, J = 8.8, 2.0 Hz, 1H, 
Ar H), 3.89 (s, 3H, !OCH3), and 3.81 (s, 3H, !OCH3). 
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2-Benzamido-3-(2,4-dimethoxyphenyl)-propionic acid (88): 
 
 
 
 
 
2-Benzamido-3-(2,4-dimethoxyphenyl)-propionic acid (88) was prepared from 2-
benzamido-3-(2,4-dimethoxyphenyl)-acrylic acid (87) by the method of Lambooy.116 A 
solution of 2-benzamido-3-(2,4-dimethoxyphenyl)-acrylic acid (87) (1.5 g, 0.0046 mol) 
in 0.3 M aqueous sodium hydroxide (25.0 mL) with palladium on carbon (0.075 g) was 
hydrogenated at 60 p.s.i. at room temperature for two hours. The mixture was filtered 
through celite, acidified and recrystallized from water and acetic acid to give 2-
benzamido-3-(2,4-dimethoxyphenyl)-propionic acid (88) colourless needles.  
 
Yield 1.33 g, 88%; 
 
mp 150.3!164.2 °C (lit.116 169 °C); 
 
1H NMR (CD3OD, (): 7.70 (m, 2H, Ar H), 7.49!7.40 (m, 3H, Ar H), 7.11 (d, J = 8.4 
Hz, 1H, Ar H), 6.47 (d, J = 2.4 Hz, 1H, Ar H), 6.41 (dd, J = 8.4, 2.4 Hz, 1H, Ar H), 
4.71 (m, 1H, !CH2CH), 3.75 (s, 3H, !OCH3), 3.71 (s, 3H, !OCH3), 3.32 (m, 1H, 
!CHHCH), and 3.01 (m, 1H, !CHHCH); 
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2,4-Dihydroxy-DL-phenylalanine (89): 
 
 
 
 
2,4-Dihydroxy-DL-phenylalanine (89) was prepared from 2-benzamido-3-(2,4-
dimethoxyphenyl)-propionic acid (88) by the method of Lambooy.116 A solution of 2-
benzamido-3-(2,4-dimethoxyphenyl)-propionic acid (88) (1.0 g, 0.003 mol) in 62% 
aqueous hydrobromic acid (10.0 mL) and acetic acid (5.0 mL) was heated in a sealed 
tube under nitrogen at 150 °C!160 °C for two hours. The mixture was diluted with 
water (10.0 mL), decolorized with charcoal and concentrated, affording a residue which 
recrystallized from water to give 2,4-dihydroxy-DL-phenylalanine (89) as white solid. 
 
Yield 0.41 g, 68%; 
 
mp 247.3!252.1 °C decomp. (lit.116 255!257 °C decomp.); 
 
1H NMR (CD3OD, (): 6.99 (m, 1H, Ar H), 6.42!6.32 (m, 2H, Ar H), 4.28 (m, 1H, 
!CH2CH), 3.56 (m, 1H, !CHHCH), and 3.03 (m, 1H, !CHHCH). 
  
Found: C, 55.01; H, 5.90; N, 6.91. C9H11NO4 requires C, 54.82; H, 5.62; N, 7.10%. 
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Diethyl 2-acetamido-2-(2-chloro-4-methoxybenzyl)malonate (91): 
 
 
 
 
 
 
Diethyl 2-acetamido-2-(2-chloro-4-methoxybenzyl)malonate (91) was prepared from 2-
chloro-4-methoxybenzyl bromide (90) by the method of McCord.123 To a solution of 
metallic sodium (0.11 g, 0.0047 mol) in dry ethanol (10.0 mL), diethyl 
acetaminomalonate (1.01 g, 0.0047 mol) was added. The resultant mixture was stirred 
at room temperature for 30 minutes, mixed with 2-chloro-4-methoxybenzyl bromide 
(90) (1.0 g, 0.0042 mol), stirred at room temperature for three hours, concentrated and 
extracted with ethyl acetate (3 & 4 mL). The combined extracts were washed with 
saturated brine, dried (sodium sulfate), filtered and concentrated, yielding a residue 
which was recrystallized from ethyl acetate and hexane to give diethyl 2-acetamido-2-
(2-chloro-4-methoxybenzyl)malonate (91) as white solid. 
 
Yield 1.45 g, 92%; 
 
mp 129!131.4 °C (lit.123 mp 128!129 °C); 
 
1H NMR (CDCl3): 6.95 (d, J = 9.2 Hz, 1H, Ar H), 6.85 (d, J = 2.2 Hz, 1H, Ar H), 6.72 
(dd, J = 9.2, 2.2 Hz, 1H, Ar H), 6.50 (s, 1H, !CNH), 4.28 (m, 4H, (!OCH2CH3)2), 3.75  
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(s, 3H, !OCH3), 3.72 (s, 2H, !CCH2), 1.94 (s, 3H, !(C=O)CH3), and 1.29 (m, 6H, 
(!OCH2CH3)2). 
 
 
o-Chloro-DL-tyrosine (92): 
 
 
 
 
o-Chloro-DL-tyrosine (92) was prepared from diethyl 2-acetamido-2-(2-chloro-4-
methoxybenzyl)malonate (91) by the method of McCord.123 A solution of 2-acetamido-
2-(2-chloro-4-methoxybenzyl)malonate (91) (1.0 g, 0.0027 mol) in 62% aqueous 
hydrobromic acid (5.5 mL) and acetic acid (3.0 mL) was heated in a sealed tube at 150 
°C for three hours. The mixture was diluted with water (10.0 mL), decolorized with 
charcoal and concentrated, affording a residue which was recrystallized from water and 
ethanol to give o-chloro-DL-tyrosine (92) as white solid. 
 
Yield 0.39 g, 67%;  
 
mp 251.2!254.7 °C decomp. (lit.123 mp 256!257 °C decomp.); 
 
1H NMR (CD3OD, (): 7.24 (d, J = 10.8 Hz, 1H, Ar H), 6.94 (d, J = 3.2 Hz, 1H, Ar H), 
6.8 (dd, J = 10.8, 3.2 Hz, 1H, Ar H), 4.22 (m, 1H, !CH2CH), 3.44 (m, 1H, !CHHCH), 
and 3.21 (m, 1H, !CHHCH); 
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Found: C, 50.17; H, 4.64; N, 6.44. C9H10ClNO3 requires C, 50.13; H, 4.67; N, 6.5%. 
 
The spectral properties of this compound were identical with those previously reported 
for o-chloro-DL-tyrosine (92).166 
 
 
Diethyl 2-Acetamido-2-(4-methoxy-3-methylbenzyl)malonate (94): 
 
 
 
 
 
 
Diethyl 2-acetamido-2-(4-methoxy-3-methylbenzyl)malonate (94) was prepared from 
3-methyl-4-methoxybenzyl chloride (93) by the method of Wiley.125 A solution of 
metallic sodium (0.15 g, 0.0065 mol) and diethyl acetaminomalonate (1.4 g, 0.0065 
mol) in dry ethanol (10.0 mL) was stirred at room temperature for 30 minutes. To the 
resultant mixture, 3-methyl-4-methoxybenzyl chloride (93) (1.0 g, 0.0059 mol) was 
added dropwise. The mixture was heated at reflux for 1.5 hours, then poured onto ice 
water. The residue oil, which solidified soon after separation, was recrystallized from 
henxane to give diethyl 2-acetamido-2-(4-methoxy-3-methylbenzyl)malonate (94) as 
colourless crystals. 
 
Yield 1.51 g, 73%; 
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mp 110.3!111.9 °C (lit.125 mp 106!107 °C); 
 
1H NMR (CDCl3, (): 6.76!6.53 (m, 3H, Ar H), 4.27 (q, J = 7.2 Hz, 4H, (!OCH2CH3)2), 
3.77 (s, 3H, !OCH3), 3.53 (s, 2H, !CCH2), 2.13 (s, 3H, !CH3), 2.01 (s, 3H, 
!(C=O)CH3), and 1.30 (t, J = 7.2 Hz, 6H, (!OCH2CH3)2); 
 
Found: C, 61.65; H, 7.04; N, 3.98. C18H25NO6 requires C, 61.53; H, 7.27; N, 3.99%. 
 
 
m-Methyl-DL-tyrosine (95): 
 
 
 
 
m-Methyl-DL-tyrosine (95) was prepared from diethyl 2-acetamido-2-(4-methoxy-3-
methylbenzyl)malonate (94) by the method used for 3,5-dihydroxylphenylalanine (63) 
from 3,5-dimethoxyphenylalanine (62), as described in a previous report.113 A solution 
of diethyl 2-acetamido-2-(4-methoxy-3-methylbenzyl)malonate (94) (1.0 g, 0.0028 
mol) in 62% aqueous hydrobromic acid (5.5 mL) and acetic acid (3.0 mL) was heated in 
a sealed tube at 150 °C for three hours. The mixture was diluted with water (10.0 mL), 
decolorized with charcoal and concentrated, affording a residue which was 
recrystallized from water and ethanol to give m-methyl-DL-tyrosine (95) as white solid. 
 
Yield 0.24 g, 43%; 
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mp 282!285.4 °C (lit.125 285 °C decomp.); 
 
1H NMR (D2O, (): 6.89!6.66 (m, 3H, Ar H), 4.11 (m, 1H, !CH2CH), 3.04!2.94 (m, 
2H, !CH2CH), and 1.99 (s, 3H, !CH3). 
 
The spectral properties of this compound were identical with those previously reported 
for m-methyl-DL-tyrosine (95).166 
 
 
4-Methoxy-2-methylbenzyl bromide (97): 
 
 
 
 
4-Methoxy-2-methylbenzyl bromide (97) was prepared from 3,4-dimethylanisole (96) 
by the method of Sabol.127 $,$,$-Trifluorotoluene was used as a substitute for carbon 
tetrachloride as the solvent for benzylic bromination.126 
 
To a solution of 3,4-dimethylanisole (96) (2.0 g, 0.015 mol) and N-bromosuccinimide 
(2.86 g, 0.016 mol) in dry $,$,$-trifluorotoluene (50.0 mL), azobisisobutyronitrile (0.07 
g) was added. The resultant mixture was heated under reflux for 15 minutes, then 
cooled, washed with water (3 & 15 mL), dried (sodium sulphate) and concentrated to 
give a light brown oil. 1H NMR of this crude bromination product mixture showed 4-
methoxy-2-methylbenzyl bromide (97) as the major component. The crude product  
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mixture was used for the following reaction without purification, as described in an 
earlier report.127 
 
 
Diethyl 2-acetamido-2-(4-methoxy-2-methylbenzyl)malonate (98): 
 
 
 
 
 
 
Diethyl 2-acetamido-2-(4-methoxy-2-methylbenzyl)malonate (98) was prepared from 
4-methoxy-2-methylbenzyl bromide (97) by the method of Sabol.127 To a solution of 
diethyl acetaminomalonate (3.5 g, 0.016 mol) and sodium hydride (0.39 g, 0.016 mol) 
in dimethylformamide (20.0 mL), the crude bromination mixture was added. The 
mixture was stirred at room temperature overnight, then diluted with water (10.0 mL) 
and extracted with diethyl ether (3 & 10 mL). The combined ether extracts were dried 
(sodium sulphate) and concentrated, and was recrystallized from dichloromethane and 
hexane to give diethyl 2-acetamido-2-(4-methoxy-2-methylbenzyl)malonate (98) as 
white solid. 
 
The overall yield of the reactions from 3,4-dimethylanisole (96) to 4-methoxy-2-
methylbenzyl bromide (97), and to diethyl 2-acetamido-2-(4-methoxy-2-
methylbenzyl)malonate (98) is 2.1 g, 40%. 
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mp 105.3!106.9 °C (lit.169 mp 102!103 °C); 
 
1H NMR (CDCl3, (): 6.85 (m, 1H, Ar H), 6.65!6.58 (m, 3H, Ar H and !NH), 4.29 (m, 
4H, (!OCH2CH3)2), 3.74 (s, 3H, !OCH3), 3.61 (s, 2H, !CCH2), 2.19 (s, 3H, !CH3), 
2.00 (s, 3H, !(C=O)CH3), and 1.29 (m, 6H, (!OCH2CH3)2). 
 
 
o-Methyl-DL-tyrosine (99): 
 
 
 
 
o-Methyl-DL-tyrosine (99) was prepared from diethyl 2-acetamido-2-(4-methoxy-2-
methylbenzyl)malonate (98) by the method used for the hydrolysis of 3,5-dimethoxyl-
DL-phenylalanine (62).113 A solution of diethyl 2-acetamido-2-(4-methoxy-2-
methylbenzyl)malonate (98) (1.0 g, 0.0032 mol) in 62% aqueous hydrobromic acid (5.5 
mL) and acetic acid (3.0 mL) was heated in a sealed tube at 150 °C for three hours. The 
mixture was diluted with water (10.0 mL), decolorized with charcoal and concentrated, 
affording a residue which was recrystallized from water and ethanol to give o-methyl-
DL-tyrosine (99) as white solid. 
 
Yield 0.44 g, 71%; 
 
mp 246.4!247.1 °C (lit.169 mp 245!249°C); 
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1H NMR (D2O, (): 6.84 (d, J = 8.0 Hz, 1H, Ar H), 6.5 (d, J = 2.4 Hz, 1H, Ar H), 6.45 
(dd, J = 8.0, 2.8 Hz, 1H, Ar H), 3.42 (m, 1H, !CH2CH), 2.9 (m, 1H, !CHHCH), 2.6 
(m, 1H, !CHHCH), and 2.07 (s, 3H, !CH3). 
 
The spectral properties of this compound were identical with those previously reported 
for o-methyl-DL-tyrosine (99).166 
 
 
4-Methoxy-2-nitrobenzyl bromide (102): 
 
 
 
 
4-Methoxy-2-nitrobenzyl bromide (102) was prepared from 4-methyl-3-nitroanisole 
(101) by the method of Katritzky.129 Again $,$,$-trifluorotoluene was used as solvent 
for the bromination of 4-methyl-3-nitroanisole (101).126 
 
To a solution of 4-methyl-3-nitroanisole (101) (2.0 g, 0.012 mol) and N-
bromosuccinimide (2.33 g, 0.013 mol) dry $,$,$-trifluorotoluene (40.0 mL), 
azobisisobutyronitrile (0.06 g) was added. The resultant mixture was refluxed under 
strong illumination using a 400-W General Electric sunlamp for six hours, then cooled 
and filtered. The filtrate was concentrated to yield a light brown oil which was purified 
with chromatography from benzene and hexane to give 4-methoxy-2-nitrobenzyl 
bromide (102) as light yellow crystals. 
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Yield 1.33g, 45%; 
 
mp 64.1!65.2 °C (lit.129 mp 63!64 °C); 
 
1H NMR (CDCl3, (): 7.53 (m, 1H, Ar H), 7.45 (m, 1H, Ar H), 7.13 (m, 1H, Ar H), 4.78 
(s, 2H, !CH2Br), and 3.87 (s, 3H, !OCH3). 
 
The spectral properties of this compound were identical with those previously reported 
for 4-methoxy-2-nitrobenzyl bromide (102).129,170 
 
 
Diethyl 2-acetamido-2-(4-methoxy-2-nitrobenzyl)malonate (103): 
 
 
 
 
 
 
Diethyl 2-acetamido-2-(4-methoxy-2-nitrobenzyl)malonate (103) was prepared from 4-
methoxy-2-nitrobenzyl bromide (102) by the method of McCord.123 To a solution of 
metallic sodium (0.1 g, 0.0045 mol) in dry ethanol (10.0 mL), diethyl 
acetaminomalonate (0.97 g, 0.0045 mol) was added. The resultant mixture was stirred 
at room temperature for 30 minutes, mixed with 4-methoxy-2-nitrobenzyl bromide 
(102) (1.0 g, 0.004 mol), heated under reflux for three hours, then filtered. The filtrate 
was cooled and kept at 0 °C overnight. The precipitate was recrystallized from ethanol  
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to give diethyl 2-acetamido-2-(4-methoxy-2-nitrobenzyl)malonate (103) as white solid. 
 
Yield  1.02 g, 66%; 
 
mp 110.1!111.7 °C (lit.123 mp 108!109 °C); 
 
1H NMR (CDCl3, (): 7.33 (m, 1H, Ar H), 7.14!7.03 (m, 2H, Ar H), 6.45 (broad 
absorption, 1H, !NH), 4.28 (m, 4H, (!OCH2CH3)2), 3.97 (s, 2H, !CCH2), 3.83 (s, 3H, 
!OCH3), 1.95 (s, 3H, !(C=O)CH3), and 1.28 (m, 6H, (!OCH2CH3)2). 
 
Found: C, 53.41; H, 5.78; N, 7.37. C17H22N2O8 requires C, 53.40; H, 5.80; N, 7.33%. 
 
 
o-Nitro-DL-tyrosine (104):  
 
 
 
 
o-Nitro-DL-tyrosine (104) was prepared from diethyl 2-acetamido-2-(4-methoxy-2-
nitrobenzyl)malonate (103) by the method of McCord.123 A solution of diethyl 2-
acetamido-2-(4-methoxy-2-nitrobenzyl)malonate (103) (1.0 g, 0.0026 mol) in 62% 
aqueous hydrobromic acid (5.5 mL) and acetic acid (3.0 mL) was heated in a sealed 
tube at 150 °C for three hours. The mixture was diluted with water (10.0 mL), 
decolorized with charcoal and concentrated, affording a residue which was 
recrystallized from water and ethanol to give o-nitro-DL-tyrosine (104) as white solid.  
104 
HO
NO2
NH2
OH
O
Experimental 
 207 
 
Yield 0.46 g, 77%; 
 
mp 213.3!231.8 °C decomp. (lit.123 mp 225-231 °C decomp.); 
 
1H NMR (CD3OD, (): 7.4 (d, J = 2.8 Hz, 1H, Ar H), 7.27 (d, J = 8.4 Hz, 1H, Ar H), 
7.06 (dd, J = 8.4, 2.8 Hz, 1H, Ar H), 4.19 (m, 1H, !CH2CH), 3.42 (m, 1H, !CHHCH), 
and 3.27 (m, 1H, !CHHCH); 
 
Found: C, 47.66; H, 4.53; N, 12.30. C9H10N2O5 requires C, 47.79; H, 4.46; N, 12.38%.
 !
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Appendix I-A  X-Ray Crystallographic Report for  
Diethyl 3-Hydroxy-5-methoxybenzylacetamidomalonate (70) 
 
Appendix I-B  X-Ray Crystallographic Report for  
3-Hydroxy-5-methylphenylalanine (71) 
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Appendix I-A X-Ray Crystallographic Report for Diethyl 3-Hydroxy-5-
methoxybenzylacetamidomalonate (70) 
 
 
Comment 
 
The crystallographic asymmetric unit consists of a molecule of C18H25NO6 with a Br 
site of ca 0.02 occupancy at one position on the phenyl ring, which suggests co-
crystallization of C18H25NO6 with a small proportion of a C18H24BrNO6 impurity.  
 
The structure also exhibits a small degree of disorder in one of the OCH2CH3 chains.  
 
The space group is noncentrosymmetric but the anomalous dispersion terms are very 
small for all elements in the structure, so the absolute structure of the crystal can not be 
determined in this experiment. Consequently Friedel-pair reflections have been 
averaged and the Flack parameter has not been refined. The space group is not 
enantiomorphic so the compound is present as a racemate within the crystal structure. 
 
 
Experimental 
 
The compound was prepared by ZQW and recrystallized from diethyl ether/n-hexane. 
The sample ID is ZQW2–91. 
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Crystal Data 
 
Empirical formula   C18H24.98Br0.02NO6    
Formula weight   353.01 
Crystal system    Orthorhombic 
Space group     Pna21  
Lattice parameter    a = 9.5734 (2) Å 
b = 20.1742 (4) Å 
c = 9.6910 (2) Å 
V = 1871.68 (7) Å3  
Dx      1.253 Mg m!3 
Cell parameters from 19987 reflections 
!       3!27.5° 
" (Mo K#)     0.14 mm!1 
T       200 K 
Crystal colour, habit    Plate, colourless 
Z value     4 
Crystal dimensions    0.40 & 0.35 & 0.06 mm 
F(000)      754.771  
 
 
Data collection 
 
Diffractometer     Nonius KappaCCD 
Radiation      Mo K# (* = 0.71073 Å) 
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Absorption correction by integration via Gaussian method (Coppens, 1970) 
implemented in maXus (2000) 
Tmin        0.969 
Tmax        0.994  
Number of reflections measured   Total: 24127 
Independent: 2276 
Number of observations (I > 2.0+(I))  2058 
Rint        0.035 
!min        2.9° 
!max        27.5° 
h        !12,12 
 k        !24,26 
l        !11,12 
Scans Graphite monochromator $ and  % with  
CCD 
 
 
Refinement 
 
Refinement on F2    
R[F2 > 2&(F2)]    0.039   
wR(F2)     0.103    
S      1.02 
Number of reflections   2276 
Number of parameters  240 
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Number of restraints   4 
Least-squares matrix   Full 
('/&)max     0.011 
''max      0.17 e Å!3 
''min      !0.21 e Å!3 
Method  Modified Sheldrick w = 1/[+2(F2) + (0.06P)2 + 
0.29P], where P = (max(Fo2,0) + 2Fc2)/3 
Primary atom site location   structure-invariant direct methods 
Hydrogen site location   inferred from neighbouring sites 
H atoms treated by a mixture of independent and constrained refinement 
 
 
Table I-A.1. Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
C1 0.3264 (2) 0.35365 (10) 0.5854 (4) 0.0345  
N2 0.27150 (17) 0.29671 (8) 0.5123 (4) 0.0335  
C3 0.3581 (2) 0.25193 (10) 0.4547 (4) 0.0373  
O4 0.48593 (14) 0.26028 (8) 0.4564 (4) 0.0470  
C5 0.2915 (3) 0.19266 (12) 0.3903 (5) 0.0518  
C6 0.3985 (2) 0.33405 (12) 0.7220 (4) 0.0419  
C7 0.3073 (2) 0.29425 (12) 0.8183 (4) 0.0436  
C8 0.3077 (3) 0.22509 (13) 0.8123 (5) 0.0479  
C9 0.2251 (3) 0.18965 (14) 0.9055 (5) 0.0547  
C10 0.1441 (3) 0.22277 (17) 1.0016 (5) 0.0628  
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Table I-A.1. !Continued 
C11 0.1420 (3) 0.29048 (16) 1.0076 (5) 0.0613  
C12 0.2237 (3) 0.32589 (15) 0.9150 (4) 0.0538  
O13 0.2196 (2) 0.12152 (11) 0.9100 (4) 0.0732  
C14 0.2920 (4) 0.08599 (15) 0.8071 (6) 0.0742  
C15 0.0557 (4) 0.3262 (2) 1.1152 (5) 0.0900  
C16 0.2025 (2) 0.40037 (10) 0.6126 (4) 0.0385  
O17 0.08345 (16) 0.38601 (9) 0.5967 (4) 0.0539  
O18 0.24910 (17) 0.45899 (8) 0.6571 (4) 0.0509  
C19 0.1459 (3) 0.51035 (13) 0.6885 (5) 0.0592  
C20 0.1214 (3) 0.51426 (13) 0.8399 (5) 0.0646  
C21 0.4323 (2) 0.39238 (10) 0.4959 (4) 0.0376  
O22 0.54319 (16) 0.41224 (9) 0.5361 (4) 0.0485  
O23 0.38093 (17) 0.40257 (9) 0.3700 (4) 0.0479  
C24 0.4779 (3) 0.43575 (17) 0.2755 (5) 0.0507 0.883 (6) 
C25 0.4130 (4) 0.43229 (17) 0.1356 (5) 0.0601 0.883 (6) 
Br99 0.209 (2) 0.4161 (9) 0.9593 (19) 0.0800* 0.0203 (10) 
C94 0.428 (3) 0.4534 (9) 0.270 (2) 0.0510* 0.117 (6) 
C95 0.516 (3) 0.4148 (12) 0.171 (3) 0.0600* 0.117 (6) 
H21 0.181 (3) 0.2902 (12) 0.511 (3) 0.0408*  
H51 0.3591 0.1607 0.3658 0.0791*  
H52 0.2286 0.1732 0.4537 0.0783*  
H53 0.2398 0.2051 0.3096 0.0790*  
H61 0.4294 0.3740 0.7676 0.0503*  
H62 0.4794 0.3071 0.6967 0.0498*  
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Table I-A.1. !Continued 
H81 0.3627 0.2024 0.7479 0.0568*  
H101 0.0876 0.1982 1.0643 0.0748*  
H141 0.2858 0.0392 0.8283 0.1113*  
H142 0.3884 0.0988 0.8100 0.1114*  
H143 0.2530 0.0945 0.7174 0.1115*  
H151 0.0220 0.3661 1.0782 0.1364*  
H152 0.1135 0.3351 1.1918 0.1360*  
H153 !0.0188 0.2983 1.1438 0.1365*  
H191 0.1845 0.5521 0.6576 0.0709*  
H192 0.0577 0.5012 0.6419 0.0705*  
H201 0.0513 0.5480 0.8571 0.0949*  
H202 0.2070 0.5276 0.8865 0.0957*  
H203 0.0891 0.4722 0.8748 0.0961*  
H241 0.4905 0.4807 0.3023 0.0609* 0.883 
H242 0.5656 0.4137 0.2755 0.0609* 0.883 
H251 0.4724 0.4533 0.0704 0.0723* 0.883 
H252 0.3251 0.4541 0.1370 0.0723* 0.883 
H253 0.4002 0.3872 0.1103 0.0723* 0.883 
H941 0.4808 0.4870 0.3149 0.0612* 0.117 
H942 0.3504 0.4729 0.2244 0.0612* 0.117 
H951 0.5516 0.4437 0.1024 0.0720* 0.117 
H952 0.5920 0.3952 0.2199 0.0720* 0.117 
H953 0.4616 0.3811 0.1295 0.0720* 0.117 
H121 0.2223 0.3730 0.9180 0.0645* 0.980 
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Table I-A.2. Atomic displacement parameters (Å2) 
 U11 U22 U33 U12 U13 U23 
C1 0.0276 (8) 0.0364 (10) 0.0396 (11) !0.0005 (8) 0.0006 (8) !0.0034 (8) 
N2 0.0236 (7) 0.0353 (8) 0.0415 (9) !0.0001 (6) 0.0029 (7) !0.0037 (7) 
C3 0.0301 (9) 0.0356 (10) 0.0461 (11) !0.0005 (8) 0.0069 (9) 0.0011 (9) 
O4 0.0249 (7) 0.0462 (8) 0.0700 (11) 0.0017 (6) 0.0070 (8) !0.0034 (8) 
C5 0.0387 (12) 0.0439 (13) 0.0729 (17) !0.0044 (9) 0.0126 (12) !0.0162 (12) 
C6 0.0348 (10) 0.0500 (12) 0.0408 (11) 0.0007 (9) !0.0030 (9) !0.0009 (10) 
C7 0.0340 (10) 0.0571 (13) 0.0399 (11) 0.0028 (9) !0.0045 (9) 0.0040 (11) 
C8 0.0407 (11) 0.0590 (14) 0.0441 (12) 0.0024 (10) !0.0021 (10) 0.0043 (11) 
C9 0.0471 (13) 0.0607 (16) 0.0564 (15) !0.0015 (11) !0.0059 (12) 0.0161 (13) 
C10 0.0448 (13) 0.094 (2) 0.0496 (15) !0.0009 (13) 0.0053 (12) 0.0183 (15) 
C11 0.0509 (14) 0.086 (2) 0.0472 (14) 0.0149 (13) 0.0033 (12) 0.0082 (14) 
C12 0.0523 (13) 0.0665 (16) 0.0425 (13) 0.0114 (12) 0.0002 (11) 0.0004 (12) 
O13 0.0748 (13) 0.0653 (12) 0.0795 (15) !0.0035 (11) 0.0034 (12) 0.0213 (12) 
C14 0.0737 (19) 0.0581 (16) 0.091 (2) 0.0038 (14) !0.0076 (19) 0.0097 (18) 
C15 0.076 (2) 0.134 (3) 0.0605 (19) 0.030 (2) 0.0254 (17) 0.006 (2) 
C16 0.0356 (10) 0.0388 (11) 0.0411 (11) 0.0039 (8) 0.0041 (9) !0.0029 (9) 
O17 0.0308 (7) 0.0518 (9) 0.0791 (13) 0.0060 (7) !0.0004 (8) !0.0163 (9) 
O18 0.0431 (8) 0.0414 (8) 0.0681 (11) 0.0040 (7) 0.0019 (8) !0.0141 (8) 
C19 0.0550 (14) 0.0416 (13) 0.081 (2) 0.0114 (11) 0.0009 (14) !0.0113 (13) 
C20 0.0635 (16) 0.0481 (15) 0.082 (2) !0.0003 (12) 0.0182 (16) !0.0167 (15) 
C21 0.0319 (10) 0.0361 (10) 0.0448 (12) !0.0004 (8) 0.0030 (8) !0.0041 (9) 
O22 0.0359 (8) 0.0497 (9) 0.0598 (11) !0.0092 (7) !0.0010 (8) !0.0023 (8) 
O23 0.0452 (9) 0.0532 (10) 0.0454 (9) !0.0112 (7) 0.0014 (8) 0.0071 (7) 
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Table I-A.2. !Continued 
C24 0.0485 (18) 0.0486 (17) 0.0551 (17) !0.0094 (13) 0.0065 (14) 0.0121 (14) 
C25 0.079 (2) 0.0548 (17) 0.0460 (16) !0.0031 (15) 0.0040 (15) 0.0068 (13) 
 
 
Table I-A.3. Geometric parameters (Å, º)  
C1—N2 1.448 (3) C15—H151 0.938 
C1—C6 1.545 (3) C15—H152 0.944 
C1—C16 1.538 (3) C15—H153 0.950 
C1—C21 1.546 (3) C16—O17 1.186 (3) 
N2—C3 1.347 (3) C16—O18 1.336 (3) 
N2—H21 0.88 (3) O18—C19 1.464 (3) 
C3—O4 1.236 (2) C19—C20 1.488 (5) 
C3—C5 1.491 (3) C19—H191 0.967 
C5—H51 0.944 C19—H192 0.975 
C5—H52 0.945 C20—H201 0.970 
C5—H53 0.959 C20—H202 0.973 
C6—C7 1.509 (3) C20—H203 0.965 
C6—H61 0.965 C21—O22 1.199 (3) 
C6—H62 0.977 C21—O23 1.332 (3) 
C7—C8 1.396 (3) O23—C24 1.466 (3) 
C7—C12 1.389 (4) O23—C94 1.479 (16) 
C8—C9 1.398 (4) C24—C25 1.493 (5) 
C8—H81 0.936 C24—H241 0.950 
C9—C10 1.384 (4) C24—H242 0.950 
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Table I-A.3. !Continued 
C9—O13 1.376 (4) C25—H251 0.950 
C10—C11 1.367 (4) C25—H252 0.950 
C10—H101 0.952 C25—H253 0.950 
C11—C12 1.388 (4) Br99—H121 0.968 
C11—C15 1.512 (4) C94—C95 1.496 (17) 
C12—Br99 1.876 (19) C94—H941 0.950 
C12—H121 0.950 C94—H942 0.950 
O13—C14 1.410 (4) C95—H951 0.950 
C14—H141 0.967 C95—H952 0.950 
C14—H142 0.958 C95—H953 0.950 
C14—H143 0.962   
    
Br99---C25i 2.62 (2) O18---C24v 3.558 (4) 
Br99---C95i 3.58 (3) O22---C25v 3.308 (4) 
O4---N2ii 3.015 (2) O22---C5ii 3.482 (4) 
O4---C5ii 3.141 (3) O22---C94v 3.54 (2) 
O4---O17ii 3.381 (3) O22---C14ii 3.546 (6) 
O4---C3ii 3.572 (2) C10---C95iii 3.45 (3) 
O13---C95iii 3.28 (3) C12---C25i 3.530 (5) 
O17---C14iv 3.502 (5) C14---C94vi 3.42 (2) 
O18---C95v 3.40 (3) C19---C95v 3.58 (3) 
    
N2—C1—C6 112.24 (17) C11—C15—H151 109.5 
N2—C1—C16 106.83 (16) C11—C15—H152 108.3 
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Table I-A.3. !Continued 
C6—C1—C16 110.77 (17) H151—C15—H152 109.7 
N2—C1—C21 111.39 (17) C11—C15—H153 109.3 
C6—C1—C21 108.49 (16) H151—C15—H153 111.1 
C16—C1—C21 107.00 (16) H152—C15—H153 109.0 
C1—N2—C3 120.75 (17) C1—C16—O17 124.71 (19) 
C1—N2—H21 119.0 (17) C1—C16—O18 109.87 (17) 
C3—N2—H21 120.1 (17) O17—C16—O18 125.4 (2) 
N2—C3—O4 120.8 (2) C16—O18—C19 117.93 (19) 
N2—C3—C5 116.63 (18) O18—C19—C20 110.4 (3) 
O4—C3—C5 122.6 (2) O18—C19—H191 107.1 
C3—C5—H51 111.1 C20—C19—H191 108.7 
C3—C5—H52 109.5 O18—C19—H192 110.7 
H51—C5—H52 108.5 C20—C19—H192 109.3 
C3—C5—H53 110.6 H191—C19—H192 110.5 
H51—C5—H53 109.1 C19—C20—H201 108.4 
H52—C5—H53 108.1 C19—C20—H202 109.9 
C1—C6—C7 114.05 (17) H201—C20—H202 108.0 
C1—C6—H61 108.4 C19—C20—H203 110.4 
C7—C6—H61 109.8 H201—C20—H203 109.6 
C1—C6—H62 106.3 H202—C20—H203 110.5 
C7—C6—H62 108.5 C1—C21—O22 124.6 (2) 
H61—C6—H62 109.7 C1—C21—O23 110.48 (17) 
C6—C7—C8 120.3 (2) O22—C21—O23 124.9 (2) 
C6—C7—C12 120.4 (2) C21—O23—C24 114.15 (19) 
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Table I-A.3. !Continued 
C8—C7—C12 119.3 (2) C21—O23—C94 126.4 (12) 
C7—C8—C9 118.9 (2) O23—C24—C25 106.4 (2) 
C7—C8—H81 121.2 O23—C24—H241 110.2 
C9—C8—H81 119.9 C25—C24—H241 110.2 
C8—C9—C10 120.3 (3) O23—C24—H242 110.3 
C8—C9—O13 123.6 (3) C25—C24—H242 110.2 
C10—C9—O13 116.0 (3) H241—C24—H242 109.5 
C9—C10—C11 121.3 (3) C24—C25—H251 109.5 
C9—C10—H101 119.8 C24—C25—H252 109.5 
C11—C10—H101 119.0 H251—C25—H252 109.5 
C10—C11—C12 118.6 (3) C24—C25—H253 109.4 
C10—C11—C15 120.8 (3) H251—C25—H253 109.5 
C12—C11—C15 120.5 (3) H252—C25—H253 109.5 
C7—C12—C11 121.7 (3) O23—C94—C95 103.3 (13) 
C7—C12—Br99 130.1 (7) O23—C94—H941 111.0 
C11—C12—Br99 108.0 (7) C95—C94—H941 111.1 
C7—C12—H121 119.2 O23—C94—H942 110.8 
C11—C12—H121 119.2 C95—C94—H942 111.0 
C9—O13—C14 117.8 (2) H941—C94—H942 109.5 
O13—C14—H141 108.3 C94—C95—H951 109.5 
O13—C14—H142 108.4 C94—C95—H952 109.4 
H141—C14—H142 108.4 C94—C95—H953 109.5 
O13—C14—H143 111.0 H951—C95—H952 109.5 
H141—C14—H143 110.0 H951—C95—H953 109.5 
Appendix I 
!232 
 
Table I-A.3. !Continued 
H142—C14—H143 110.7 H952—C95—H953 109.5 
    
Br99—C12—C7—C6 !4.3 (9) C1—C6—C7—C12 !89.8 (4) 
Br99—C12—C7—C8 174.8 (8) C1—C16—O18—C19 179.9 (3) 
Br99—C12—C11—C10 !175.4 (7) C1—C21—O23—C24 !176.7 (2) 
Br99—C12—C11—C15 2.9 (7) C1—C21—O23—C94 160 (1) 
O4—C3—N2—C1 !4.0 (6) C3—N2—C1—C6 !69.0 (4) 
O13—C9—C8—C7 !178.9 (3) C3—N2—C1—C16 169.4 (3) 
O13—C9—C10—C11 179.5 (3) C3—N2—C1—C21 52.9 (4) 
O17—C16—O18—C19 !0.4 (6) C6—C7—C8—C9 178.2 (3) 
O17—C16—C1—N2 11.5 (5) C6—C7—C12—C11 !178.0 (3) 
O17—C16—C1—C6 !111.1 (4) C7—C6—C1—C16 64.3 (3) 
O17—C16—C1—C21 130.9 (4) C7—C6—C1—C21 !178.6 (2) 
O18—C16—C1—N2 !168.8 (3) C7—C8—C9—C10 0.2 (6) 
O18—C16—C1—C6 68.6 (3) C7—C12—C11—C10 !0.5 (5) 
O18—C16—C1—C21 !49.4 (4) C7—C12—C11—C15 177.9 (3) 
O22—C21—O23—C24 5.6 (4) C8—C7—C12—C11 1.1 (5) 
O22—C21—O23—C94 !18 (1) C8—C9—O13—C14 !5.7 (5) 
O22—C21—C1—N2 !134.6 (3) C8—C9—C10—C11 0.3 (6) 
O22—C21—C1—C6 !10.6 (3) C9—C8—C7—C12 !0.9 (5) 
O22—C21—C1—C16 109.0 (3) C9—C10—C11—C12 !0.2 (6) 
O23—C21—C1—N2 47.7 (2) C9—C10—C11—C15 !178.6 (4) 
O23—C21—C1—C6 171.7 (2) C10—C9—O13—C14 175.2 (3) 
O23—C21—C1—C16 !68.8 (3) C16—O18—C19—C20 100.4 (4) 
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Table I-A.3. !Continued 
N2—C1—C6—C7 !55.1 (3) C21—O23—C24—C25 170.4 (2) 
C1—N2—C3—C5 175.9 (3) C21—O23—C94—C95 102 (2) 
C1—C6—C7—C8 91.1 (3)   
Symmetry codes: (i) x, y, z+1; (ii) x+1/2, !y+1/2, z; (iii) x!1/2, !y+1/2, z+1; (iv) x!1/2, !y+1/2, z; (v) 
!x+1, !y+1, z+1/2; (vi) !x+1/2, y!1/2, z+1/2. 
 
 
Table I-A.4. Hydrogen-bond geometry (Å, º)  
D—H---A D—H H---A D---A D—H---A 
N2—H21---O4iv 0.88 (3) 2.19 (3) 3.015 (2) 156 (2) 
Symmetry code: (iv) x!1/2, !y+1/2, z. 
 
 
Computing details  
 
Data collection: COLLECT (Nonius, 2001).; cell refinement: DENZO/SCALEPACK 
(Otwinowski & Minor, 1997); data reduction: DENZO/SCALEPACK (Otwinowski & 
Minor, 1997); program(s) used to solve structure: SIR92 (Altomare et al., 1994); 
program(s) used to refine structure: CRYSTALS (Betteridge et al., 2003); molecular 
graphics: ORTEP-II (Johnson 1976) in TEXSAN (MSC, 1992-1997); software used to 
prepare material for publication: CRYSTALS (Betteridge et al., 2003).  
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Appendix I-B X-Ray Crystallographic Report for 3-Hydroxy-5-methylphenylalanine 
(71) 
 
 
Comment  
 
The crystallographic asymmetric unit consists of one C10H13NO3 molecule and one 
water molecule of crystallization. 
 
The space group is noncentrosymmetric but the absolute structure of the crystal can not 
be determined in this experiment as the anomalous dispersion terms are small for all 
elements that are present. Consequently Friedel-pair reflections have been averaged and 
the Flack parameter has not been refined. 
 
If data were collected on a diffractometer using Cu radiation rather than Mo (e.g. by 
A/Professor Jonathan M. White at the University of Melbourne), then it is possible that 
this would allow the absolute configuration to be established owing to the larger 
anomalous dispersion term for O with this radiation. 
 
 
Experimental 
 
The compound was prepared by ZQW and recrystallized from water/methanol. The 
sample ID is ZQW2–95. 
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Refinement  
 
The H atoms were all located in a difference map, but those attached to carbon atoms 
were repositioned geometrically. The H atoms were initially refined with soft restraints 
on the bond lengths and angles to regularize their geometry (C—H in the range 0.93–
0.98 Å, N—H = 0.86 Å and O—H = 0.82 Å) and with Uiso(H) in the range 1.2–1.5 
times Ueq of the parent atom, after which H atoms attached to C were refined with 
riding constraints and those bonded to N or O which was allowed to refine freely. 
 
The largest peaks in the final difference electron density map are located randomly 
through the structure. 
 
 
Crystal data 
 
Empirical formula  C10H13NO3-H2O 
Formula weight 213.23 
Crystal system  Monoclinic 
Space group  P21 
Lattice parameters  a = 7.3950 (3) Å 
 b = 6.6408 (2) Å 
 c = 10.6716 (4) Å 
 ( = 94.710 (2)° 
 V = 522.30 (3) Å3 
Z value  2 
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Dx  1.356 Mg m!3 
Cell parameters from 15229 reflections  
!  2.6–27.5° 
" (Mo K#)  0.11 mm!1 
T  200 K 
Crystal colour, habit  Plate, colourless 
Crystal dimensions 0.52 & 0.40 & 0.09 mm 
F(000)  228 
 
 
Data collection 
 
Diffractometer    Nonius KappaCCD 
Radiation    Mo K# (* = 0.71073 Å) 
Absorption correction:   by integration via Gaussian method (Coppens, 
1970) implemented in maXus (2000) 
Tmin    0.967  
Tmax    0.991  
Number of reflections measured   Total: 11713 
   Independent: 1305 
Number of observations (I > 2.0+(I))  1246 
Rint    0.052 
!max    27.5° 
!min    2.8° 
h    !9,9 
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k    !8,8 
l    !13,13 
Scans   Graphite monochromator . and / with CCD  
 
 
Refinement 
 
Refinement on F2  
R[F2 > 2+(F2)]    0.033 
wR(F2)    0.090 
S    1.00 
Number of reflections   1305 
Number of parameters   154 
Number of restraint   1 
Least-squares matrix   Full 
 ('/+)max    0.005 
'0max    0.14 e Å!3 
'0min    !0.18 e Å!3 
Method   Modified Sheldrick w = 1/[+2(F2) + ( 0.07P)2 + 
0.06P], where P = (max(Fo2,0) + 2Fc2)/3 
Primary atom site location   Structure-invariant direct methods 
Hydrogen site location    inferred from neighbouring sites 
H atoms treated by a mixture of independent and constrained refinement 
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Table I-B.1. Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2)  
 x y z Uiso*/Ueq 
C1 0.6279 (2) 0.5392 (3) 0.21007 (16) 0.0275 
C2 0.5909 (2) 0.3555 (3) 0.26496 (16) 0.0275 
C3 0.4218 (2) 0.2649 (3) 0.23828 (16) 0.0271 
C4 0.2901 (2) 0.3578 (3) 0.15707 (16) 0.0289 
C5 0.3262 (2) 0.5425 (3) 0.10130 (16) 0.0303 
C6 0.4959 (2) 0.6313 (3) 0.12894 (16) 0.0308 
O7 0.39254 (18) 0.0862 (3) 0.29606 (15) 0.0360 
C8 0.1859 (3) 0.6445 (4) 0.01287 (18) 0.0421 
C9 0.8089 (2) 0.6402 (3) 0.24297 (17) 0.0314 
C10 0.7954 (2) 0.8198 (3) 0.33176 (16) 0.0266 
N11 0.72483 (19) 0.7564 (3) 0.45284 (14) 0.0267 
C12 0.9826 (2) 0.9178 (3) 0.35746 (17) 0.0280 
O13 1.0520 (2) 0.9811 (3) 0.26216 (14) 0.0519 
O14 1.05452 (15) 0.9189 (3) 0.46770 (12) 0.0313 
O15 0.33528 (17) 0.6410 (3) 0.42349 (13) 0.0301 
H21 0.6808 0.2935 0.3206 0.0335* 
H41 0.1693 0.2968 0.1400 0.0349* 
H61 0.5184 0.7602 0.0922 0.0384* 
H71 0.272 (4) 0.055 (5) 0.277 (2) 0.0540* 
H81 0.0807 0.5648 !0.0030 0.0637* 
H82 0.1436 0.7676 0.0510 0.0640* 
H83 0.2278 0.6797 !0.0670 0.0638* 
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Table I-B.1. !Continued 
H91 0.8999 0.5416 0.2819 0.0375* 
H92 0.8560 0.6908 0.1650 0.0388* 
H101 0.7106 0.9196 0.2930 0.0323* 
H111 0.727 (3) 0.863 (5) 0.506 (2) 0.0406* 
H112 0.604 (4) 0.703 (4) 0.446 (2) 0.0400* 
H113 0.800 (4) 0.657 (5) 0.491 (2) 0.0400* 
H151 0.266 (4) 0.725 (5) 0.441 (3) 0.0458* 
H152 0.321 (4) 0.630 (5) 0.348 (3) 0.0463* 
 
 
 
Table I-B.2. Atomic displacement parameters (Å2)  
 U11 U22 U33 U12 U13 U23 
C1 0.0263 (7) 0.0262 (8) 0.0309 (8) !0.0064 (7) 0.0076 (6) !0.0062 (7) 
C2 0.0233 (7) 0.0268 (8) 0.0326 (8) !0.0030 (7) 0.0039 (6) !0.0036 (7) 
C3 0.0258 (7) 0.0245 (8) 0.0318 (8) !0.0060 (7) 0.0070 (6) !0.0042 (7) 
C4 0.0240 (7) 0.0328 (9) 0.0302 (8) !0.0072 (7) 0.0035 (6) !0.0043 (7) 
C5 0.0317 (8) 0.0327 (9) 0.0269 (7) !0.0035 (7) 0.0042 (6) !0.0025 (7) 
C6 0.0338 (8) 0.0284 (8) 0.0307 (8) !0.0095 (7) 0.0060 (6) !0.0006 (8) 
O7 0.0306 (6) 0.0270 (6) 0.0506 (8) !0.0084 (5) 0.0035 (5) 0.0046 (6) 
C8 0.0384 (9) 0.0517 (13) 0.0352 (9) !0.0032 (10) !0.0029 (7) 0.0080 (10) 
C9 0.0243 (7) 0.0302 (9) 0.0403 (9) !0.0061 (7) 0.0066 (6) !0.0041 (8) 
C10 0.0211 (7) 0.0231 (8) 0.0351 (8) !0.0053 (6) !0.0003 (6) 0.0032 (6) 
N11 0.0204 (6) 0.0247 (7) 0.0352 (7) !0.0027 (6) 0.0031 (5) !0.0011 (6) 
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Table I-B.2. !Continued 
C12 0.0220 (7) 0.0232 (8) 0.0383 (9) !0.0055 (6) !0.0010 (6) 0.0021 (7) 
O13 0.0404 (7) 0.0715 (13) 0.0427 (7) !0.0330 (8) !0.0039 (6) 0.0178 (8) 
O14 0.0234 (5) 0.0340 (7) 0.0361 (6) !0.0042 (5) !0.0005 (4) !0.0038 (5) 
O15 0.0278 (6) 0.0306 (7) 0.0323 (6) 0.0043 (5) 0.0041 (5) !0.0013 (6) 
 
 
 
Table I-B.3. Geometric parameters (Å, º)  
C1—C2 1.390 (2) C8—H83 0.959 
C1—C6 1.392 (3) C9—C10 1.531 (3) 
C1—C9 1.512 (2) C9—H91 1.004 
C2—C3 1.397 (2) C9—H92 0.987 
C2—H21 0.948 C10—N11 1.493 (2) 
C3—C4 1.394 (3) C10—C12 1.534 (2) 
C3—O7 1.363 (2) C10—H101 0.981 
C4—C5 1.398 (3) N11—H111 0.91 (3) 
C4—H41 0.984 N11—H112 0.96 (3) 
C5—C6 1.396 (2) N11—H113 0.94 (3) 
C5—C8 1.505 (3) C12—O13 1.249 (2) 
C6—H61 0.962 C12—O14 1.251 (2) 
O7—H71 0.92 (3) O15—H151 0.79 (3) 
C8—H81 0.944 O15—H152 0.80 (3) 
C8—H82 0.976   
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Table I-B.3. !Continued 
O7---O13i 2.610 (2) O14---O14vii 3.4988 (8) 
O7---N11ii 3.097 (2) O14---O14viii 3.4988 (8) 
O7---O15iii 3.296 (3) O14---O15ix 3.519 (2) 
O7---C12i 3.346 (2) O14---C10vii 3.537 (2) 
O7---O14i 3.404 (2) O15---N11ii 2.926 (3) 
O7---C10iii 3.459 (2) O15---N11 2.973 (2) 
O7---O15ii 3.486 (2) O15---C12x 3.221 (2) 
O7---N11iii 3.600 (2) O15---C2 3.249 (2) 
O13---C4iv 3.308 (3) O15---C3 3.280 (3) 
O13---C3iv 3.348 (2) O15---C1 3.337 (2) 
O13---O15v 3.444 (2) O15---C4 3.402 (2) 
O13---C8vi 3.470 (2) O15---C6 3.451 (2) 
O14---O15v 2.846 (2) O15---C5 3.495 (2) 
O14---N11vii 2.860 (2) O15---C10ii 3.566 (2) 
O14---C9vii 3.493 (2) N11---C3ix 3.554 (2) 
    
C2—C1—C6 119.69 (16) H82—C8—H83 107.7 
C2—C1—C9 119.49 (17) C1—C9—C10 112.80 (14) 
C6—C1—C9 120.78 (16) C1—C9—H91 110.9 
C1—C2—C3 119.76 (17) C10—C9—H91 109.1 
C1—C2—H21 119.6 C1—C9—H92 108.8 
C3—C2—H21 120.7 C10—C9—H92 107.6 
C2—C3—C4 120.29 (17) H91—C9—H92 107.4 
C2—C3—O7 117.13 (16) C9—C10—N11 111.16 (14) 
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Table I-B.3. !Continued 
C4—C3—O7 122.57 (15) C9—C10—C12 109.72 (14) 
C3—C4—C5 120.32 (16) N11—C10—C12 109.83 (14) 
C3—C4—H41 120.7 C9—C10—H101 109.7 
C5—C4—H41 119.0 N11—C10—H101 107.4 
C4—C5—C6 118.72 (17) C12—C10—H101 109.0 
C4—C5—C8 121.05 (17) C10—N11—H111 109.4 (17) 
C6—C5—C8 120.23 (18) C10—N11—H112 115.2 (14) 
C5—C6—C1 121.20 (17) H111—N11—H112 108 (2) 
C5—C6—H61 118.2 C10—N11—H113 109.8 (16) 
C1—C6—H61 120.6 H111—N11—H113 107 (2) 
C3—O7—H71 107 (2) H112—N11—H113 107 (2) 
C5—C8—H81 112.1 C10—C12—O13 114.99 (15) 
C5—C8—H82 110.1 C10—C12—O14 118.58 (15) 
H81—C8—H82 104.9 O13—C12—O14 126.34 (16) 
C5—C8—H83 114.2 H151—O15—H152 106 (3) 
H81—C8—H83 107.4   
    
O7—C3—C2—C1 !179.2 (2) C1—C9—C10—C12 !178.3 (1) 
O7—C3—C4—C5 179.2 (2) C2—C1—C6—C5 0.0 (3) 
O13—C12—C10—N11 !178.3 (2) C2—C1—C9—C10 !104.9 (2) 
O13—C12—C10—C9 59.3 (2) C2—C3—C4—C5 0.1 (3) 
O14—C12—C10—N11 5.0 (2) C3—C2—C1—C6 0.0 (3) 
O14—C12—C10—C9 !117.4 (2) C3—C2—C1—C9 177.8 (2) 
N11—C10—C9—C1 60.0 (2) C3—C4—C5—C6 !0.2 (3) 
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Table I-B.3. !Continued 
C1—C2—C3—C4 !0.1 (3) C3—C4—C5—C8 179.7 (2) 
C1—C6—C5—C4 0.1 (3) C5—C6—C1—C9 !177.8 (2) 
C1—C6—C5—C8 !179.7 (2) C6—C1—C9—C10 72.8 (2) 
Symmetry codes: (i) x!1, y!1, z; (ii) !x+1, y!1/2, !z+1; (iii) x, y!1, z; (iv) x+1, y+1, z; (v) x+1, y, z; (vi) 
!x+1, y+1/2, !z; (vii) !x+2, y+1/2, !z+1; (viii) !x+2, y!1/2, !z+1; (ix) !x+1, y+1/2, !z+1; (x) x!1, y, z. 
 
 
Table I-B.4. Hydrogen-bond geometry (Å, º)  
D—H---A D—H H---A D---A D—H---A 
O7—H71---O13i 0.92 (3) 1.69 (3) 2.609 (3) 172 (3) 
N11—H111---O15ix 0.91 (3) 2.06 (3) 2.926 (3) 159 (2) 
N11—H112---O15 0.96 (3) 2.03 (3) 2.973 (3) 170 (2) 
N11—H113---O14viii 0.94 (3) 1.94 (3) 2.860 (3) 167 (2) 
O15—H151---O14x 0.79 (3) 2.06 (3) 2.846 (3) 170 (3) 
Symmetry codes: (i) x!1, y!1, z; (viii) !x+2, y!1/2, !z+1; (ix) !x+1, y+1/2, !z+1; (x) x!1, y, z. 
 
 
Computing details  
 
Data collection: COLLECT (Nonius, 2001).; cell refinement: DENZO/SCALEPACK 
(Otwinowski & Minor, 1997); data reduction: DENZO/SCALEPACK (Otwinowski & 
Minor, 1997); program(s) used to solve structure: SIR92 (Altomare et al., 1994); 
program(s) used to refine structure: CRYSTALS (Betteridge et al., 2003); molecular  
 
Appendix I 
! 246 
 
graphics: ORTEP-II (Johnson 1976) in TEXSAN (MSC, 1992-1997); software used to 
prepare material for publication: CRYSTALS (Betteridge et al., 2003).  
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Unnatural Amino Acids

Appendix II 
! 248 
 
 
 
 
 
 
 
 
 
 
 
Figure II-1. Mass spectral analysis of His6-PpiB synthesised in the presence of m-methylphenylalanine 
(50). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-2. Mass spectral analysis of His6-PpiB synthesised in the presence of m-chlorophenylalanine 
(53). 
Mass reconstruction of  +TOF MS: 0.079 to 0.639 min from Sample 5 (ZQW  3-Me) of 17_11_11 ZQW.w... Max. 4.5e4 cps.
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Mass reconstruction of  +TOF MS: 0.048 to 0.283 min from Sample 9 (ZQW 3-Cl) of 11_11_11 ZQW.wiff... Max. 3.8e4 cps.
1.94e4 1.96e4 1.98e4 2.00e4 2.02e4 2.04e4
Mass, Da
0.0
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
2.6e4
2.8e4
3.0e4
3.2e4
3.4e4
3.6e4
3.8e4
In
te
n
s
ity
, C
o
u
n
ts
19663.7357
19691.3323
19630.7861
19731.1374
19756.7158
19596.5160 19797.7516
19825.2123
19968.413719938.4354 19998.595619561.5305 20412.309220158.768019534.1967
Appendix II 
!249 
 
 
 
 
 
 
 
 
 
 
 
Figure II-3. Mass spectral analysis of His6-PpiB synthesised in the presence of o-fluorophenylalanine 
(36). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-4. Mass spectral analysis of His6-PpiB synthesised in the presence of m-fluorophenylalanine 
(37). 
Mass reconstruction of  +TOF MS: 0.047 to 0.481 min from Sample 1 (ZQmF) of 121214ZQW.wiff Agilen... Max. 2.2e4 cps.
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Mass reconstruction of  +TOF MS: 0.078 to 0.530 min from Sample 3 (ZQ 3-F Phe) of 20_04_12 ZQ Sa... Max. 1.5e5 cps.
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Figure II-5. Mass spectral analysis of His6-PpiB synthesised in the presence of p-fluorophenylalanine 
(38). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-6. Mass spectral analysis of His6-PpiB synthesised in the presence of 3,5-difluorophenylalanine 
(58). 
Mass reconstruction of  +TOF MS: 0.070 to 0.359 min from Sample 4 (ZQ 4-F Phe) of 20_04_12 ZQ Sa... Max. 2.8e5 cps.
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Mass reconstruction of  +TOF MS: 0.081 to 0.569 min from Sample 13 (ZQ 3,5-Di F) of 20_04_12 ZQ Sa... Max. 8.4e4 cps.
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Figure II-7. Mass spectral analysis of His6-PpiB synthesised in the presence of 3,5-
dihydroxyphenylalanine (63). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-8. Mass spectral analysis of His6-PpiB synthesised in the presence of 3-hydroxy-5-
methylphenylalanine (71). 
Mass reconstruction of  +TOF MS: 0.063 to 0.244 min from Sample 19 (ZQW D) of 28_09_12 Tom Mant... Max. 1.8e5 cps.
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Mass reconstruction of  +TOF MS: 0.160 to 1.608 min from Sample 3 (ZQOHMe2) of 121214ZQW.wiff A... Max. 646.5 cps.
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Figure II-9. Mass spectral analysis of His6-PpiB synthesised in the presence of 0.2 mM phenylalanine 
(20) and 2.0 mM o-fluorophenylalanine (36). 
 
 
 
Figure II-10. Mass spectral analysis of His6- 
 
 
 
 
 
 
 
 
 
 
PpiB synthesised in the presence of 0.2 mM phenylalanine (20) and 2.0 mM m-fluorophenylalanine (37). 
 
Mass reconstruction of  +TOF MS: 0.094 to 0.384 min from Sample 4 (ZQ 2F + Phe) of 17_08_12 HK Sa... Max. 1.2e5 cps.
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5.00e4
6.00e4
7.00e4
8.00e4
9.00e4
1.00e5
1.10e5
1.20e5
1.24e5
In
te
n
s
it
y
, 
C
o
u
n
ts
19268.5227
19286.4485
19243.9652
19259.5518
19223.5372 19304.1379
19356.5371
19377.4806
19386.7402
19441.2649
19206.2961 19487.256919148.6762 19510.9113 19666.1458 19858.975619752.0913 19893.3151
Mass reconstruction of  +TOF MS: 0.111 to 0.347 min from Sample 5 (ZQ 3F + Phe) of 17_08_12 HK Sa... Max. 2.6e5 cps.
1.90e4 1.91e4 1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4 2.00e4
Mass, Da
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
In
te
n
s
it
y
, 
C
o
u
n
ts
19302.3245
19275.6638
19258.6905
19319.9595
19240.4079
19221.7385
19390.1132
19420.8389
19437.9569
19455.9139
19519.0519 19545.272219154.418019177.5598 19748.9157 19857.470319124.9867 19892.6027
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Figure II-11. Mass spectral analysis of His6-PpiB synthesised in the presence of 0.2 mM phenylalanine 
(20) and 2.0 mM p-fluorophenylalanine (38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-12. Mass spectral analysis of His6-PpiB synthesised in the presence of 3,4-
dihydroxyphenylalanine (14). 
Mass reconstruction of  +TOF MS: 0.053 to 0.433 min from Sample 2 (ZQW 1) of 10062014ZQW.wiff Ag... Max. 4.7e5 cps.
1.92e4 1.94e4 1.96e4 1.98e4 2.00e4 2.02e4
Mass, Da
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
4.7e5
In
te
n
s
ity
, C
o
u
n
ts
19296.6105
19317.8113
19338.1395
19279.4918
19357.1730
19268.0956
19380.2830 19432.6351
19454.6401
19502.121719251.6860 19641.691519665.1134 19770.2921 20075.805120054.951119220.2882
Mass reconstruction of  +TOF MS: 0.089 to 0.396 min from Sample 2 (ZQ 4F + Phe) of 17_08_12 HK Sa... Max. 1.7e5 cps.
1.90e4 1.91e4 1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4 2.00e4
Mass, Da
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
1.5e5
1.6e5
1.7e5
In
te
n
s
it
y
, 
C
o
u
n
ts
19339.6197
19312.8003
19295.3906
19357.4642
19302.9544
19277.7510
19374.4674
19389.566519259.3565
19428.0000
19241.1543 19457.2441
19496.1391
19510.1069
19223.3969 19546.2644 19594.189519180.0437 19750.7536 19944.015919787.3606
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Figure II-13. Mass spectral analysis of His6-PpiB synthesised in the presence of 2,4-
dihydroxyphenylalanine (89). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-14. Mass spectral analysis of His6-PpiB synthesised in the presence of m-chlorotyrosine (40). 
Mass reconstruction of  +TOF MS: 0.139 to 0.971 min from Sample 2 (ZQ 2-OH Tyr) of 24_8_12 HK ZQ ... Max. 3.3e4 cps.
1.91e4 1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4
Mass, Da
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
2.6e4
2.8e4
3.0e4
3.2e4
In
te
n
s
ity
, C
o
u
n
ts
19299.2787
19271.6839
19281.8766
19320.6793
19254.7251 19341.2640
19364.1660 19478.0944
19389.6242
19496.2937 19518.561419223.3564 19606.2756 19680.8779 19852.709319166.2000
Mass reconstruction of  +TOF MS: 0.042 to 0.205 min from Sample 4 (ZQW 5) of 190313 ZQW.wiff Agil... Max. 1.6e5 cps.
1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4 2.00e4 2.01e4
Mass, Da
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
1.5e5
1.6e5
In
te
n
s
ity
, C
o
u
n
ts
19352.5642
19324.3950
19376.1433
19395.6395
19418.9037
19441.885119461.2683
19290.2323
19507.0464
19551.6722
19640.287819728.845419814.356519220.9453 19958.637819255.3559 20117.9615
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Figure II-15. Mass spectral analysis of His6-PpiB synthesised in the presence of o-chlorotyrosine (92). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-16. Mass spectral analysis of His6-PpiB synthesised in the presence of m-methyltyrosine (95). 
Mass reconstruction of  +TOF MS: 0.091 to 0.308 min from Sample 3 (ZQ 2-Cl Tyr) of 11_05_12 ZQW M... Max. 6.5e5 cps.
1.90e4 1.92e4 1.94e4 1.96e4 1.98e4 2.00e4 2.02e4
Mass, Da
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.5e5
In
te
n
s
ity
, C
o
u
n
ts
19353.0747
19325.3117
19381.1561
19291.0182
19418.8383 19459.1056 19658.689419221.2631 19958.835719191.6829 20260.929220209.123218877.9498
Mass reconstruction of  +TOF MS: 0.085 to 0.664 min from Sample 8 (ZQW 3-Me Tyr) of 3_9_12 ZQW ... Max. 1.2e4 cps.
1.90e4 1.91e4 1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4 2.00e4
Mass, Da
1000.00
2000.00
3000.00
4000.00
5000.00
6000.00
7000.00
8000.00
9000.00
1.00e4
1.10e4
1.20e4
In
te
n
s
ity
, C
o
u
n
ts
19293.4712
19279.4472
19265.7004
19319.7124
19338.770819251.3659
19358.1317 19430.0110
19598.754019448.2848
19223.9024 19557.1779 19619.223119509.7201 19724.2607 19864.943119154.6911
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Figure II-17. Mass spectral analysis of His6-PpiB synthesised in the presence of o-methyltyrosine (99). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-18. Mass spectral analysis of His6-PpiB synthesised in the presence of o-nitrotyrosine (104). 
Mass reconstruction of  +TOF MS: 0.078 to 0.313 min from Sample 4 (ZQ 2-Me Tyr) of 11_05_12 ZQW ... Max. 6.4e5 cps.
1.90e4 1.92e4 1.94e4 1.96e4 1.98e4 2.00e4 2.02e4
Mass, Da
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.4e5
In
te
n
s
ity
, C
o
u
n
ts
19291.9320
19264.2846
19316.555819276.3700
19249.5294
19597.5454
19398.840619235.226519158.4385 19896.1860 20283.646620063.078219640.284618944.1939
Mass reconstruction of  +TOF MS: 0.076 to 0.474 min from Sample 9 (ZQW 2-NO2 Tyr) of 3_9_12 ZQW... Max. 1.1e4 cps.
1.90e4 1.91e4 1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4 2.00e4
Mass, Da
500.00
1000.00
1500.00
2000.00
2500.00
3000.00
3500.00
4000.00
4500.00
5000.00
5500.00
6000.00
6500.00
7000.00
7500.00
8000.00
8500.00
9000.00
9500.00
1.00e4
1.05e4
1.10e4
In
te
n
s
ity
, C
o
u
n
ts
19386.3081
19341.4331
19691.5871
19296.3359
19408.5609
19430.3058
19646.692419363.5767
19477.0189
19452.5880 19714.779819251.1523
19497.3200 19672.003219319.0053 19665.7903 19755.9002
19274.5340 19577.5266 19611.5797 19854.846219840.283619070.6673
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Figure II-19. Mass spectral analysis of His6-PpiB synthesised in the presence of 0.2 mM tyrosine (12) 
and 2.0 mM o-fluorotyrosine (83). 
Mass reconstruction of  +TOF MS: 0.067 to 0.266 min from Sample 23 (zqw C8) of 16_10_12 ZQW.wiff ... Max. 6.6e4 cps.
1.90e4 1.92e4 1.94e4 1.96e4 1.98e4 2.00e4 2.02e4
Mass, Da
5000.0
1.0e4
1.5e4
2.0e4
2.5e4
3.0e4
3.5e4
4.0e4
4.5e4
5.0e4
5.5e4
6.0e4
6.5e4
In
te
n
s
ity
, C
o
u
n
ts
19267.8355
19248.9024
19287.3652
19309.5824
19332.5710
19221.5534
19377.9841
19421.3836
19443.5242
19508.788219533.8633
19670.9947 19863.0551 20284.793920155.8600
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Figure III-1. ITC of 5.0 mM m-fluorotyrosine (39) with 0.05 mM E. coli TyrRS. 
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Figure III-2. ITC of 5.0 mM o-fluorotyrosine (83) with 0.05 mM E. coli TyrRS. 
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Figure III-3. ITC of 5.0 mM 2,4-dihydroxyphenylalanine (89) with 0.05 mM E. coli TyrRS. 
 
 
 
 
 
 
 
 
 
Appendix III 
!261 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-4. ITC of 5.0 mM o-chlorotyrosine (92) with 0.05 mM E. coli TyrRS. 
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Figure III-5. ITC of 5.0 mM o-methyltyrosine (99) with 0.05 mM E. coli TyrRS. 
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Figure III-6. ITC of 5.0 mM m-fluorotyrosine (39) with 0.05 mM human TyrRS. 
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Figure III-7. ITC of 7.0 mM m-fluorotyrosine (39) with 0.15 mM human TyrRS. 
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Figure III-8. ITC of 5.0 mM o-fluorotyrosine (83) with 0.05 mM human TyrRS. 
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Figure III-9. ITC of 5.0 mM 2,4-dihydroxyphenylalanine (89) with 0.05 mM human TyrRS. 
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Figure III-10. ITC of 10.0 mM 2,4-dihydroxyphenylalanine (89) with 0.1 mM human TyrRS. 
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Figure III-11. ITC of 10.0 mM o-chlorotyrosine (92) with 0.1 mM human TyrRS. 
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Figure III-12. ITC of 10.0 mM o-methyltyrosine (99) with 0.1 mM human TyrRS. 
 
